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Abstract 
Polycystic ovary syndrome (PCOS) is characterised by hyperandrogenism 
and insulin resistance. Granulosa cells in PCOS demonstrate impaired 
insulin-induced glucose uptake and lactate accumulation, suggesting a post 
receptor, signalling pathway-specific impairment of insulin action. 
Gonadotrophins are also important in the regulation of glucose metabolism by 
of granulosa cells.  
The first objective of this project was to use KK1 cells an immortalised mouse 
granulosa cell line, to characterise insulin, androgen and FSH signalling as 
well as glucose metabolism. Cell lysates were subjected to western 
immunoblotting for key proteins in the insulin signalling pathways. Glucose 
metabolism of KK1 cells was also measured. Surprisingly, androgen alone 
stimulated glucose uptake and lactate production and augmented insulin-
induced glucose metabolism. This suggests that the insulin resistance 
observed in granulosa cells from women with PCOS is not a direct effect of 
exposure to androgen. 
The main part of the thesis was examination of insulin action on human 
primary ovarian granulosa-lutein (GL) cells to investigate the mechanism of 
insulin resistance in PCOS. Insulin and FSH signalling in GL cells from 
women with anovulatory PCOS (anovPCO, n=11) was compared to that in GL 
cells from ovulatory women with (ovPCO, n=8) and without polycystic ovaries 
(controls n=12). Primary GL cells were incubated with insulin or FSH and 
analysed for glucose metabolism and progesterone production. Cell lysates 
were prepared for identification of signalling pathways, using western 
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immunoblotting. 
The results confirmed selective impairment of glucose metabolism in cells 
from anovulatory PCOS. No significant impairment of insulin stimulated PI3K 
signalling was observed. However there was a reduction of p42/44ERK 
phosphorylation in the ovulatory PCOS group compared to controls. The 
significance of this finding with respect to impaired glucose metabolism in 
granulosa cells remains to be determined. We also showed FSH induced 
glucose metabolism, but without clear evidence of activation of the PI3-kinase 
pathway. 
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1.1 Polycystic ovary syndrome (PCOS) 
PCOS is the commonest endocrine disorder of women, affecting 5-10% of the 
population. It is a heterogeneous syndrome, but classical features include 
anovulation (irregular menstrual cycles) and symptoms of androgen excess 
such as hirsutism, acne and alopecia. Biochemically it is common to see high 
levels of LH with normal FSH levels and high androgen levels. PCOS is also 
associated with metabolic abnormalities, in particular insulin resistance and 
hyperinsulinaemia, which carry a higher risk developing type 2 diabetes (1-7). 
Controversy surrounds the definition of PCOS. The NIH criteria (1990) identify 
androgen excess and ovarian dysfunction in the absence of other causes, 
which may present with symptoms similar to PCOS, no mention is made of 
ovarian phenotype in this classification. Under the 2003 Rotterdam criteria 
however two of the following three criteria are required for the diagnosis of 
PCOS: clinical or biochemical hyperandrogenism, polycystic ovaries on 
ultrasonography, and menstrual irregularities (8). One of the main aims 
behind the revised Rotterdam criteria is to highlight and accommodate the 
increasing evidence that the spectrum of biochemical and clinical features of 
women with polycystic ovary syndrome is very wide, wider than that allowed 
by the NIH criteria. This classification has the advantage of highlighting the 
heterogeneity of the disorder.  
One of the main controversies of the Rotterdam criteria is the inclusion of 2 
subgroups of patients, those with polycystic ovaries on imaging and irregular 
periods, and those with polycystic ovaries and hyperandrogenism, women 
who would not on the NIH criteria be recognised as having PCOS.  
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However, ‘The Androgen Excess Society’ guidelines (2006) emphasise that 
androgen excess is the foundation of PCOS (9) and indeed, elevated serum 
levels of serum testosterone are the most consistent biochemical feature of 
PCOS.  
Insulin resistance is also central to the nature of polycystic ovary syndrome. 
Insulin sensitivity varies with the PCOS phenotype (10), it is most prevalent in 
women with anovulation and hyperandrogenism (11). Overall insulin 
resistance and compensatory high insulin levels affect 65-70% of women with 
PCOS (12-14). Many studies have shown that both lean and obese women 
with PCOS have insulin resistance (3). High levels of insulin increase 
androgen levels, and acts synergistically with gonadotrophins to augment 
steroidogenesis (15-17). Insulin in combination with LH also prematurely 
enhances follicle arrest at earlier stages than normal, contributing to 
anovulation.  
1.2 Developmental origin of PCOS and its evolution during 
childhood 
PCOS is thought to be a genetic disorder that is heavily influenced by 
environmental factors, such as diet (18, 19). The fact that PCOS presents in 
adolescence, suggests that the origins of the disease occur much earlier than 
this, most probably in fetal life. Studies done in female Rhesus monkeys 
which were exposed to high concentrations of testosterone in utero, develop 
as adults many of the features of women with PCOS, such as high LH levels, 
ovarian hyperandrogenism, anovulation in relation to increased body weight, 
and insulin resistance (20, 21). This suggests that the PCOS phenotype could 
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be a direct result of androgen exposure, which could programme the fetal 
hypothalamic-pituitary-ovarian axis in utero and may predispose to insulin 
resistance (figure 1.1). 
In the case of the Rhesus monkey model of PCOS, it is important to note that 
the doses of androgen that were used were high enough to exceed two 
normally very efficient physiological barriers: firstly, placental aromatase, 
which converts excess androgen to oestrogens, and secondly, high circulating 
sex hormone binding globulin (SHBG) which binds testosterone and prevents 
placental transfer. It is therefore unlikely that, in pregnant women with PCOS, 
any excess maternal androgen would be able to cross the placenta in 
significant amounts (22). So “vertical transmission” of PCOS from mother to 
fetus probably does not occur. It is therefore suggested that the source of 
excess androgen is the fetal ovary (and/or adrenal) which may either be 
actively secreting excess androgen in utero or, perhaps more plausibly, be 
genetically predisposed to produce high ovarian androgen levels at the time of 
activation of the hypothalamic-pituitary-ovarian axis in infancy or at puberty 
(23). If the adrenal is contributing to excess androgen in PCOS, the normal 
burst of androgen secretion at adrenarche may be advanced or enhanced and 
there is indeed evidence for links between premature adrenarche, premature 
pubarche and the appearance of PCOS in adolescence (24).  
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Figure 1.1:  Adapted and revised from Abbott, Dumesic and Franks (23) and Franks 
McCarthy and Hardy (25). It is proposed that the ovary is genetically predisposed to androgen 
hypersecretion at the activation of the HPO (hypothalamo-pituitary-ovarian) axis, which 
occurs transiently in infancy and in a more sustained fashion at puberty. Higher androgen 
levels programme the HP axis to produce increased LH and amplify the physiological insulin 
resistance of puberty. High LH and insulin levels act synergistically to increase androgen 
levels further and may contribute to the mechanism of anovulation (26). 
 
 
Normal pubertal development is characterized by activation of the 
hypothalamic-pituitary-ovarian axis and is associated with physiological 
changes in insulin sensitivity. In girls with a predisposition to PCOS, these 
changes are exaggerated, for example by higher than normal levels of LH 
and, significantly, by hyperinsulinemia that is further amplified by obesity. 
1.3  Genes and PCOS 
The aetiology of PCOS is unknown but heritability studies suggest a strong 
genetic susceptibility (27). Familial clustering has been noted (19) and also 
greater concordance of symptoms is seen in monozygotic twins compared to 
dizygotic twins (28). Studying complex diseases such as PCOS and diabetes 
is difficult due to their likely genetic heterogeneity (29). However, recently two 
genes have been highlighted as important. 
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It is known that common variants in a 47kb region of the first intron of the fat 
mass and obesity associated gene FTO, influences susceptibility to type 2 
diabetes, via a substantial effect on BMI and fat mass (30). Barber et al. 
showed a significant link between the FTO genotype and PCOS status in a 
UK case control analysis (31). The association was most evident in obese 
PCOS patients. The FTO gene predisposes to common obesity and also an 
altered susceptibility to PCOS, suggesting a mechanistic link between them, 
which is most likely mediated by fat mass. 
Using linkage disequilibrium an association has been found between a 
dinucleotide repeat marker D19S884, closely linked to the insulin receptor 
gene on chromosome 19p13.2 and PCOS. This maps to intron 55 of fibrillin 3 
(FBN3). Moreover this locus is associated with metabolic features of the 
syndrome in reproductive age women and their brothers (32). The function of 
FBN3 is not clear but fibrillins are TGF" binding proteins, and growth factors 
in the TGF" family have been implicated in early follicle development and 
theca formation in the ovary (33).   
The candidate gene approach is time consuming and has been quite ‘hit and 
miss’ and genome wide association studies similar to that undertaken for 
Type II diabetes (34) may be a more successful method of identifying other 
candidate genes. 
1.4 Normal human ovarian cycle  
Women are born with multiple primordial follicles, which can stay in an 
arrested state for up to 50 years. Regular recruitment of primordial follicles to 
growing follicles begins at puberty. A few follicles recommence growth each 
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day. A primordial follicle that has commenced growth passes through three 
stages of development, a primary or pre-antral follicle, secondary or antral 
follicle and finally a pre-ovulatory follicle. Throughout the cycle this trickle of 
growing follicles of various stages grow without gonadotrophic support, and 
do not secrete significant amounts of steroid hormones. Antral follicles are 
doomed to atresia unless rescued by FSH. At the beginning of the menstrual 
cycle, roughly 10 small antral follicles undergo a few days of rapid growth until 
they reach 10mm by the mid follicular phase. One (or occasionally) two of 
these rescued follicles survives and grows to become the dominant antral 
follicle and produces high levels of serum oestradiol (35, 36), which 
suppresses FSH secretion thus reducing blood levels (37). This suppression 
of FSH does not affect the dominant follicle, as it has plentiful FSH receptors. 
Evidence from the rat suggests that both oestradiol and FSH play an 
important part in acquiring LH receptors (38), and only that follicle in which 
granulosa cells contain the LH receptor can respond to the mid cycle LH 
surge.  
The LH surge stimulates ovulation and the successful ovulatory follicle then 
converts into the corpus luteum and secretes progesterone and oestradiol 
until luteolysis 14 days later. LH and FSH levels are at their lowest during this 
phase of the cycle due to negative feedback from the high oestradiol and 
progesterone levels (37), and this suppresses further development of small 
antral follicles (figure 1.2).  
After luteal regression the secretion of FSH and LH begin again to rise and 
further maturation of antral follicles will begin again at this stage.  
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Figure 1.2: Graphs showing the cyclical hormonal changes and follicular growth of the 
human ovarian menstrual cycle. Adapted from Baird 1983 (37) 
 
1.4.1 Androgen and oestrogen production in the follicle 
In women, androgen is the main steroid made by thecal cells, and aromatase 
activity is highest in granulosa cells (39). It is generally assumed that 
interaction occurs between the two cell types in the follicle with LH stimulating 
androgen production from the thecal cells, which is then used by the 
granulosa cells to produce oestrogen, this is known as the two-cell two-
gonadotrophin concept (figure 1.3). There is strong evidence that mixing the 
two cell types in vitro enhances oestrogen synthesis (40) and in vivo the use 
of testosterone antiserum infusion into the ovarian artery of the sheep ovary 
bearing the dominant follicle, inhibited oestradiol production by 50% (41). 
These experiments support the idea that androgen precursors leave the theca 
cells before being aromatised to oestrogens by the granulosa cells; this is the 
basis of the two-cell two-gonadotrophin concept. This is thought to be a two 
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way process however. A reduction of androgen production has been seen 
from thecal tissue culture after granulosa cell removal (42, 43) and also LH 
stimulated androgen production from culture rat theca was greater after FSH 
pre-treatment. Chang et al. have shown that in PCOS patients androgen 
production is enhanced by intravenous FSH administration which supports a 
granulosa-theca cell paracrine interaction (44). 
 
Figure 1.3: Two-cell two-gonadotrophin concept 
1.5  Abnormal antral follicle development in PCOS 
In women with polycystic ovaries, numerous arrested antral follicles are seen 
with a maximum diameter of 5-10mm (figure 1.4). Despite follicle arrest, 
granulosa cells from a subset of follicles in anovulatory women with polycystic 
ovaries hypersecrete oestradiol (45, 46), have increased aromatase activity 
and progesterone production compared to size matched follicles from normal 
or polycystic ovaries from ovulatory women (45, 47).  
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Figure 1.4: Ultrasound appearance of a polycystic ovary (48) 
 
This appears to reflect a state of advanced maturation of medium sized antral 
follicles. Steroidogenesis by thecal cells is also abnormal with an increase in 
testosterone and androstenedione (49), this is seen in women with both 
ovulatory and anovulatory PCOS (50). PCOS is characterised by 
hypersecretion of LH and FSH levels that are below the normal early follicular 
phase concentrations. This is likely to be a reflection of the slightly elevated 
levels of oestradiol (compared to the normal early follicular phase), which lead 
to suppression of FSH. It may also be partly due to a persistently rapid GnRH 
pulse frequency of one pulse an hour. This favours pituitary production of LH 
over FSH, (51-53), which produces the high LH/FSH ratio seen in PCOS 
(figure 1.5) (54) . The elevated LH level stimulates the theca to produce high 
androgen levels and low FSH levels impair aromatisation of androgen to 
oestrogen. The addition of FSH in vitro or in vivo increases oestradiol levels 
and in vivo helps normal follicle development to resume (55).  
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Figure 1.5: Neuroendocrine control of androgen production, adapted from Blank et al. 
2008 (54) 
 
LH also triggers terminal differentiation and follicle growth arrest in the normal 
mature preovulatory follicle (56). In normal ovulatory follicles the dominant 
follicle only responds to LH when it is about 10mm in diameter. In follicles 
from women with anovulatory PCOS the response to LH occurs 
inappropriately in a proportion of smaller follicles. 
However many patients with PCOS have normal LH levels (57), in these 
patients elevated serum concentrations of insulin may contribute to follicle 
arrest. In human granulosa cells of both normal and polycystic ovaries insulin 
in the absence of gonadotrophins stimulates oestradiol and progesterone 
production, and has been shown to augment LH induced steroidogenesis in 
granulosa cells (58). Therefore either high LH levels or amplification of LH 
action by insulin may cause follicle arrest (figure 1.6) (59). 
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Figure 1.6:  Arrest of follicle growth in PCOS, Franks et al. 2000 (59) 
 
1.6. Classic insulin action in target tissues 
The insulin signalling pathway is illustrated in figure 1.7. The insulin receptor 
(IR) has two extracellular ! and two transmembrane " subunits that have 
protein tyrosine kinase activity. Insulin binding activates an 
autophosphorylation between the two " subunits, activating its receptor 
tyrosine kinase activity, which then phosphorylates insulin receptor substrate 
1 (IRS1) at several tyrosine kinase residues. Phosphoinositide 3 kinase 
(PI3K) consists of a regulatory subunit p85 and a catalytic subunit p110, the 
SH2 domain of the p85 interacts with the phospho-tyrosine residues on the 
IRS1. Through this interaction PI3K is recruited to the plasma membrane and 
then converts phosphadtidylinositol 4,5 bisphosphate (PIP2) to 
phosphadtidylinositol 3,4,5 trisphosphate (PIP3).   
The serine threonine kinase Akt (otherwise known as protein kinase B, PKB) 
plays a pivotal role in the metabolic actions of insulin. Akt is necessary for 
insulin action as has been shown by studies utilizing Akt2 knockout mice (60) 
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and by ablation of Akt action, using small interfering RNA (siRNA) (61).  Akt 
has a PH domain which binds PIP3 but this interaction alone does not activate 
it. In order to activate it, phosphorylation at 2 sites, Thr308 and Ser 473 must 
occur. PDK1 catalyses the phosphorylation and activation of Akt only in the 
presence of lipid vesicles containing PIP3, which implies Akt activation is PIP3 
dependent. Both Akt and PDK1 have PH domains, which bind the PIP3. 
When Akt binds PIP3 it undergoes a conformational change, exposing the 
Thr308 binding site to PDK1. The mammalian target of rapamycin (mTOR) is 
the protein kinase that activates Ser 473. It is usually bound to a regulatory 
unit called the rapamycin insensitive companion of mTOR (RICTOR), together 
the mTOR-RICTOR complex is known as mTORC2. The exact mechanism by 
which insulin activates mTORC2 is unknown. 
Glycogen synthase kinase 3 (GSK3) inactivates glycogen synthase by 
phosphorylating serine residues. Insulin activated Akt therefore inactivates 
GSK3. Insulin activated Akt/PKB also has functions other than glycogen 
synthase activation, such as activating GLUT4 translocation (62). 
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Figure 1.7: Insulin signalling, Adapted from Cohen et al. 2006 (62) 
 
1.6.1   Insulin receptor substrate proteins 
There are 4 insulin receptor substrates (IRS) proteins. Although these 
proteins are highly homologous they appear to provide a complimentary role 
to each other in insulin/IGF-1 signalling. IRS-1 knockout mice develop insulin 
resistance in peripheral tissues and impaired glucose tolerance (63, 64). IRS-
2 knockout mice exhibit insulin resistance in both peripheral tissues and the 
liver, and also cause defective growth of islet cells in the pancreas. The 
combination of multi-factorial insulin resistance and decreased "-cell mass 
leads to type 2 diabetes (65). The roles of IRS 3 and 4 are less clear in 
cultured cells. 
1.6.2  Glucose uptake; the role of GLUT4 
In 1980 it was reported that in rat adipocytes, insulin triggered the movement 
of a ‘sugar transporter’ from an intracellular store to the cell membrane (66). 
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This transporter was later characterised as the glucose transporter 4 
(GLUT4).  Tissues such as the brain have a high glucose need and have 
glucose transporters that are constitutively located at the cell membrane 
(GLUT1-3). Mammalian tissues such as muscle and fat, are able to respond 
to stimuli such as exercise or food absorption, by up-regulating glucose 
transport by 10-40 fold within minutes using GLUT4. 
GLUT4 has been found and extensively studied in insulin responsive tissues 
such as muscle and adipose tissue. One drawback of using these tissues to 
resolve the exact positioning and movement of GLUT4, has been that the 
cytoplasm in these cells is compressed by either myofibrils, or fat droplets, 
causing poor visualisation. Little work has been done on investigating GLUT4 
expression in granulosa cells. 
Abnormally low GLUT4 expression has been shown in adipocytes from 
subjects with PCOS (67) and skeletal muscle from type 2 diabetics (68). 
GLUT4 expression is mostly restricted to insulin sensitive tissues such as 
skeletal muscle, cardiac muscle and adipose, however it has been found in 
the granulosa cells of sheep (69) and mice (70).  
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1.6.3  MAPK signalling 
The activation of the PI3K signalling pathway by insulin stimulates the 
metabolic functions of insulin, such as glucose uptake and glycogen 
synthesis. However there is a divergence of the insulin signalling pathway 
following activation of the insulin receptor. The insulin receptor once activated 
can bind SHC (a mammalian adaptor protein) and activate the MAPK 
signalling pathway, which activates certain mitogenic actions of insulin such 
as cell metabolism, growth, differentiation and steroidogenesis (figure 1.8). 
Insulin resistance in PCOS appears to be selective affecting metabolic but not 
mitogenic activity of insulin (71, 72). In insulin resistant states when 
pancreatic " cells are continuing to compensate, insulin levels rise 
overcoming insulin resistance and maintaining glucose levels. However the 
hyperinsulinaemia can lead to an overstimulation of mitogenic actions. This 
selective insulin resistance may explain how insulin acting through the insulin 
receptor can stimulate the overproduction of androgen from thecal cells in 
women with PCOS, despite resistance to the effect of insulin on glucose 
metabolism (15, 73). 
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Figure 1.8:  Principal signalling pathways activated by the insulin receptor, Drawn by 
K.Hardy 
 
Mitogen activated protein kinase (MAPK) pathways are involved in cell 
proliferation, growth, differentiation and apoptosis. These functions are closely 
related to energy levels of the cells and a signal network between ERK and 5’ 
adenosine monophosphate-activated protein kinase (AMPK) has emerged as 
a key regulator. 
There are five major groups of MAP Kinases, extracellular signal-regulated 
kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 MAPK and ERK 5. 
ERK 1 and 2, were cloned in 1991 by Boulton et al. (74). ERK 1 and 2 are 
very similar and activated by insulin, cytokines, growth factors such as insulin 
like growth factor 1 (IGF-1) and epidermal growth factor (EGF) acting via 
receptor tyrosine kinases (RTKs), and hormones acting via the G-protein 
linked receptors such as LH and FSH. Both ERK 1 and 2 are inactive when 
not phosphorylated, and require dual phosphorylation for activation at a 
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threonine and a tyrosine residue. Phosphorylation is likely to result in a 
conformational change, which allows substrate to bind (75) 
Each MAPK pathway contains a three tiered kinase cascade comprising of a 
MAP kinase kinase kinase (MAPKKK, MAP3K, MEKK or Raf), which 
phosphorylates a MAP kinase kinase (MAPKK, MAP2K, MEK), which in turn 
phosphorylates the MAPK. MEK1 activates p44 through phosphorylation of 
Thr202/Tyr 204 and MEK2 activates p42 through phosphorylation of Thr 
185/Tyr 187. Deactivation in vitro occurs via phosphatases. 
Insulin acts via the insulin receptor a tyrosine kinase receptor. Subsequent 
autophosphorylaton of the cytoplasmic tails of the receptor on tyrosine leads 
to tyrosine phosphorylation of SHC. SHC then recruits GRB2-SOS complex 
(growth factor receptor bound protein 2- Son of Sevenless protein) to the cell 
membrane. SOS can then catalyse an exchange of the GDP bound to Ras (a 
GTPase) for a GTP. Ras then recruits serine/threonine kinase Raf to the cell 
membrane, which becomes activated and phosphorylates MEK. 
There is some cross talk between the MAPK and PI3K signalling pathways. It 
has been shown that activated Ras can interact directly with the catalytic unit 
of PI3K and cause its activation (76) (77). PI3K can also activate ERK via Rac 
(a GTPase) and p21-Activated Kinase (PAK). Rac and cell division cycle-42 
(CDC42) can synergize with Raf to promote Raf and subsequent ERK 
activation. It has also been shown that Wortmannin, a PI3K inhibitor can also 
block the MAP Kinase cascade (78). 
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A role for MAPK in glucose transport 
MAP kinase is capable of phosphorylating an impressive array of target 
proteins in vitro, many of which have a regulatory role and are known to be 
phosphorylated in response to insulin. For example, GSK-3 ! and " are 
phosphorylated and inactivated by two protein kinases ribosomal protein S6, 
the 90kDa S6 (also known as 90rsk or MAPKAP-K1) (79) and 70KDa S6 
which lie downstream of MAPK (80, 81). 
But this only gives us circumstantial evidence in favour of a role for MAPK in 
insulin action. Studies ablating MAPK activity using truly specific inhibitors or 
mRNA targeting have been hampered by the presence of multiple related 
MAPK isoforms (82). 
1.6.4 FOXO proteins 
The FOXO proteins are a family of transcription factors, highly conserved from 
C elegans, and Drosophilla to man (83). In the nucleus, FOXO proteins are 
transcription factors that act to activate or repress certain target genes, by 
direct binding of the forkhead domain to DNA (84). This is usually in a tissue 
specific manner. Various deletion studies have highlighted the importance of 
certain FOXO proteins. FOXO-3a -/- mice exhibit a distinct phenotype of 
global follicular activation followed by early death of functional ovarian 
follicles, and therefore premature ovarian failure (85). Complete deletion of 
FOXO1 in mice is lethal to embryos (86).  
FOXO1 expression, in granulosa cells in vivo, is hormonally induced by FSH 
and oestradiol and down regulated in response to LH during luteinization. In 
cultured granulosa cells, FSH and IGF-I rapidly phosphorylate FOXO1 via 
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activation of the PI3K pathway, leading to its exclusion from the nucleus. 
FOXO1 acts as a co-repressor. Insulin and IGF1 acting via the PI3K pathway, 
phosphoryate FOXO1 and relieve this inhibition (87). The phosphorylated 
FOXO1 is inactive, its DNA binding affinity is reduced and it is expelled from 
the nucleus (88) 
In cultured granulosa cells FSH also rapidly down-regulates the expression of 
the FOXO1 gene. Therefore FSH and LH in vivo act to suppress the functions 
and expression of FOXO1 (89). Recent studies indicate that FOXO1 is a 
negative regulator of FSH-mediated proliferation and differentiation (90). 
Thus, in granulosa cells there appears to be an FSH receptor FOXO1 
regulatory loop (91). 
1.7   Glucose metabolism 
Anaerobic metabolism 
Early anaerobic metabolic steps can convert monosaccharides, via pyruvate 
to acetyl coA. Under anaerobic conditions, pyruvate is converted to lactate by 
the enzyme lactate dehydrogenase (LDH), and the lactate is transported out 
of the cell into the circulation. The conversion of pyruvate to lactate, under 
anaerobic conditions, provides the cell with a mechanism for the oxidation of 
NADH (produced during glycolysis) to NAD+, which occurs during the LDH, 
catalyzed reaction. This reduction is required since NAD+ is a necessary 
substrate for G3PDH (glyceraldehyde-3-phosphate dehydrogenase) an 
enzyme within the glycolysis pathway (figure 1.9). 
As there is no reverse reaction of pyruvate to phosphenolpyruvate, the 
pyruvate must first be converted to oxaloacetate, which can then be converted 
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to glucose by gluconeogenesis.  
Aerobic Metabolism 
Alternatively glucose is converted by glycolysis to pyruvate and then to acetyl 
CoA, which enters the citric acid, also known as the tricarboxylic acid (TCA) 
cycle where it can be converted to triglycerides or amino acids. The TCA 
cycle is a central metabolic pathway that completes the oxidative degradation 
of fatty acids, amino acids and monosaccharides. The TCA cycle has two 
main purposes, to increase the cells ATP producing potential, and to provide 
the cell with a variety of precursors, which can be used to build molecules.  
Aerobic glycolysis has the advantage of generating substantially more ATP 
per mole of glucose oxidized than anaerobic glycolysis, but it is 100 times 
slower. Anaerobic metabolism is therefore particularly useful when anabolic 
reactions are not needed, but the generation of as much ATP as possible in 
the shortest time frame is needed, for example muscle cells during exercise.  
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Figure 1.9:  An overview of carbohydrate metabolism and the TCA cycle.  
 
1.7.1  Granulosa cell glucose metabolism 
Glucose metabolism by granulosa cells is important in providing substrates for 
the developing oocyte (92). The average glucose concentration of follicular 
fluid is 3.3mM, compared to a plasma glucose of about 5mM (93). The follicle 
is a relatively oxygen depleted environment, lactate concentrations in human 
serum range between 1.5-2mM (94), considerably lower than the average 
lactate level in follicular fluid of 6.1mM (93), which suggests lactate is 
produced locally in the follicle and secreted into follicular fluid. This is 
supported by the fact that gonadotrophins are known to stimulate glucose 
consumption and lactate production by cumulus cells (95). FSH also induces 
cumulus cell-enclosed mouse oocyte expression of the glycolytic enzyme 
hexokinase (96). Follicular fluid levels of pyruvate from women undergoing 
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IVF are in the order of 0.3mM, which is higher than the average plasma 
pyruvate of 0.08mM (93). Isolated mouse cumulus cells (97) have been 
shown to produce pyruvate from glucose which may explain this 3-5 fold rise. 
Most studies concur that mouse ovarian follicles produce large amounts of 
lactate during growth and development and prefer a predominantly glycolytic 
mode of energy production to sustain growth and steroidogenesis. The 
glycolytic rate is stimulated by gonadotrophins. The amount of lactate 
produced suggests that ovarian follicles behave like solid tumours, 
predominantly metabolising glucose via glycolysis (98). This is supported by 
the observation that when oxidative phosphorylation is prevented using a TCA 
cycle inhibitor, follicles are still able to undergo normal development and 
steroidogenesis (99). 
1.8   Insulin resistance 
1.8.1  Endogenous insulin resistance 
In addition to tyrosine phosphorylation both the insulin receptor and IRS 
proteins undergo serine phosphorylation, which can reduce signalling by 
attenuating insulin induced tyrosine phosphorylation (100). These inhibitory 
phosphorylations provide negative feedback to insulin signalling and provide a 
mechanism for other signalling pathways to have an effect on insulin 
resistance. Several kinases have been implicated in this process including 
GSK-3, PKC mTOR and Akt (101). 
Insulin receptor tyrosine phosphorylation can also be attenuated by protein 
tyrosine phosphatases (PTP). One in particular, cytoplasmic phosphatase 
PTP1B, has been shown to be interesting. Knockout of PTP1B leads to an 
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increase in tyrosine phosphorylation of insulin receptor and IRS protein in 
muscle together with improved insulin sensitivity (102).   
1.8.2  Causes of insulin resistance 
Insulin resistance is characterised by defects at many levels, decreases in 
receptor concentration and kinase activity, glucose transporter translocation 
and concentration, and phosphorylation of IRS-1 and PI3K activity (103). 
MAPK activity is not reduced in Type 2 Diabetes, and it has been suggested 
that this may provide a mechanism for some of the detrimental effects of 
chronic high insulin levels on cell growth in vessels (104, 105). Studies in 
bovine vascular smooth muscle cells have shown a three fold mitogenic 
response to insulin via the MAPK pathway (106). Activation of MAPK leads to 
the proliferation and migration of vascular smooth muscle cells contributing to 
atherosclerosis (107, 108). 
Genetic factors can profoundly affect insulin sensitivity. Targeted gene 
deletions have helped provide some insight into the complexity of these 
mechanisms. For example although knock outs of the insulin receptor (109), 
Akt2 (60) and IRS-2 cause diabetes (60, 65, 110), knockout of IRS-1 (63, 64), 
p85 regulatory subunit of PI3K (111) and GLUT4 (112) do not.  
1.8.3  The role of adipose in insulin sensitivity 
Fatty Acids and Adipokines 
Circulating free fatty acids are elevated in insulin resistance states and are 
thought to contribute to insulin resistance in diabetes by interfering with 
glucose uptake, glycogen synthesis and glucose oxidation (113). They are 
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also thought to be involved in attenuating the response to IRS1 
phosphorylation to insulin (114). 
The fat cell produces hormones known as adipokines, examples of which 
include tumour necrosis factor ! (TNF-!), leptin and adiponectin. TNF-! has 
been shown to produce serine phosphorylation of IRS-1 (100) and inhibition of 
TNF-! significantly improves insulin resistance (115). Severe leptin deficiency 
has been characterised by insulin resistance states. Genome wide scanning 
has shown a susceptibility locus for type 2 diabetes at chromosome 3q27 in 
the region of the adiponectin gene. Insulin resistance in lipoatrophic mice was 
completely reversed by replacement of adiponectin together with leptin. 
Treatment with either leptin or adiponectin alone produced only partial 
reversal (116). 
1.8.4  Insulin resistance in PCOS 
It has become clear over the last 25 years that polycystic ovary syndrome is 
an important metabolic disorder. In 1980 Burghen et al. reported that obese 
women with PCOS had significantly elevated basal and post glucose load 
insulin levels compared to weight matched control women, suggesting women 
with PCOS were resistant to insulin (117). Insulin mediated glucose uptake is 
decreased by 35-40% compared to age and weight matched control women 
(3, 118). Subsequent studies determined that high insulin levels are 
characteristic of women with PCOS, independent of obesity (10). Many 
studies have shown that both lean and obese women with PCOS have insulin 
resistance (3).  
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Insulin resistance is an inability of a known quantity of exogenous or 
endogenous insulin to increase glucose uptake and utilisation as much as it 
does in the normal population. The main consequences are a reduced ability 
of insulin to suppress hepatic gluconeogenesis and stimulate peripheral 
glucose uptake. It would be expected that circulating glucose levels would rise 
as a consequence, however provided " cell function of the pancreas is 
adequate, insulin secretion increases to overcome this insulin resistance and 
glucose levels are normalized. Compensatory high insulin levels are therefore 
the hallmark of insulin resistance. When this compensatory mechanism fails 
type 2 diabetes occurs. However glucose stimulated insulin release is also 
inappropriately low in women with PCOS suggesting there are further defects 
in pancreatic " cell function (118). Women with PCOS have a 3-4 times 
greater risk of developing type 2 diabetes (119, 120).  
Although common insulin resistance it is not a universal feature of all women 
with PCOS. Interestingly insulin resistance is most prevalent in women with 
PCOS who have both androgen excess and anovulation (i.e NIH criteria), 
independent of polycystic ovaries. Whereas weight matched women with 
ovulatory cycles, who are equally hyperandrogenaemic have normal insulin 
sensitivity and serum insulin concentrations (figure 1.10). 
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Figure 1.10: Insulin sensitivity in BMI-matched groups of women with oligomenorrhoea and 
PCOS (anov.PCOS, n=53), or in hirsute women with polycystic ovaries and regular cycles 
(ov.PCO n=19), compared with values in BMI-matched normal controls (control, n=31). The 2 
groups of women with PCO were equally hyperandrogenemic. Only the group with PCO and 
oligomenorrhea were insulin resistant (p<0.01 compared with controls). Values shown are 
means + SEM. Data from Robinson et al, 1993 (11). 
 
 
Rotterdam phenotypes of polycystic ovaries and hyperandrogenism with 
ovulatory cycles or polycystic ovaries with normal androgen levels and 
anovulation have milder metabolic dysfunction. Whereas women with 
polycystic ovary phenotype and regular cycles are metabolically normal 
although may have subtle hormonal abnormalities (12, 121). 
Insulin resistance has been implicated in the mechanism of anovulation seen 
in PCOS patients. Insulin in combination with LH prematurely enhances 
follicle arrest at earlier stages than normal, contributing to anovulation. 
Therapies that lower insulin levels such as insulin sensitising drugs and 
weight loss significantly improve menstrual cyclicity, fertility, and 
hyperandrogenism, in both lean and obese patients, which suggests insulin 
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resistance plays an important role in the aetiology of anovulation in PCOS 
(122) (123). 
Paradoxically, insulin greatly augments the action of LH on steroidogenesis 
(58), thus implying that some actions of insulin on the ovary in PCOS (notably 
on steroidogenesis and growth/differentiation pathways) are maintained in the 
face of peripheral insulin resistance. This could result in an enhancement of 
oestradiol and progesterone production from granulosa cells, causing the 
suppression of follicle stimulating hormone (FSH) and premature arrest of 
follicular growth (59).  However as indicated below, the metabolic actions of 
insulin in granulosa cells appear to be impaired. 
1.8.5  Mechanism of insulin resistance in PCOS 
The exact mechanism of reduced insulin sensitivity in PCOS is unknown. 
Potential areas of disturbance in the insulin signalling pathway are highlighted 
below in Table 1, adapted from Diamanti-Kandarakis et al. 2006 (124). This 
table highlights the variability of defects found in different tissues and also the 
many areas where information is unknown. 
 
 
 
 
 
 
 
Chapter 1 
 49 
 
 
Adipocytes in 
vitro 
Fibroblasts 
in vitro 
Skeletal 
muscle in vivo 
Skeletal muscle in 
vitro 
Insulin stimulated 
glucose uptake 
!(125) ? !(126) Normal (127) 
Number and affinity 
of IRs 
Normal(125, 
128, 129) 
Normal 
(130, 131) 
Normal (126) Normal (127) 
IR basal 
phosphorylation 
Normal (128) " in 50% 
(130) 
? Normal (127) 
IR insulin-dependent 
phosphorylation 
! (125) ! in 50% 
(130) 
? Normal (127) 
IRS-1 expression ! or normal 
(132) 
Normal 
(131) 
Normal (126) " (127) 
IRS-1 Tyr 
phosphorylation 
!(132, 133) ? ? ? 
IRS-2 expression Normal(134) ? " (126) Normal (127) 
IRS-2 Tyr 
phosphorylation 
!(134) ? ? ? 
GLUT4 !(67) ? ? Normal (127) 
GLUT1 ? ? ? " (127) 
IRS-1 associated 
PI3K 
? Normal 
(131) 
! Insulin 
stimulated 
(134) 
!insulin stimulated 
after adjustment 
(127) 
IRS-2 associated 
PI3K 
? ? ? ! (baseline and 
insulin stimulated) 
(127) 
Insulin stimulated 
glycogen synthesis 
? ! or normal 
(131) 
? ? 
AKT ? Normal (7) ? ? 
GSK-3 ? ! (7) ? ? 
Table 1: Defects in molecular pathways of different tissues in PCOS. Adapted from Diamanti-
Kandarakis et al. 2006 (124). Abbreviations: (?) = not determined; upward and downward 
arrows indicate increased and decreased levels respectively.  
 
Abnormalities of the insulin receptor itself are rare causes of PCOS and the 
majority of evidence points to a post-receptor defect in insulin signalling 
pathways (3, 7, 127).  It is likely that the signalling defect in insulin resistance 
seen in PCOS is located proximally in the pathway, involving serine 
phosphorylation of the insulin receptor (IR) and/or insulin receptor substrates 
1and 2 (IRS1/2) (3, 127). Isolated skin fibroblasts of about 50% of women with 
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PCOS who had insulin resistance documented by euglycaemic clamp studies, 
have constitutively active serine phosphorylation of the insulin receptor that 
inhibits insulin-stimulated tyrosine phosphorylation and therefore normal 
signalling (130) . 
In skeletal muscle cultures from obese women with PCOS, IRS-1 protein 
abundance was found to be significantly increased, associated with 
decreased activity of PI3K (127). Phosphorylation of IRS-1 Ser312 (equivalent 
to Ser307 in rat) was increased in PCOS, but despite these defects, cultured 
myotubules showed normal insulin responsiveness. No differences in IR 
tyrosine phosphorylation were seen between women with PCOS and controls. 
Thus, in contrast to skin fibroblasts, the defects in skeletal muscle seen in vivo 
are not reproduced in culture, suggesting that the in vivo environment is the 
major determinant of muscle insulin resistance in PCOS. However certain 
defects in insulin signalling persist (127). Serine phosphorylation of IRS1 
inhibits its tyrosine phosphorylation and therefore its ability to recruit PI3K 
(135). Another feature of insulin target tissues in women with PCOS is that 
expression of the insulin-dependent glucose transporter GLUT4 is abnormally 
low. This has been shown in adipocytes from subjects with PCOS (67) as well 
as in skeletal muscle from type 2 diabetics (68). 
Little work has been done looking into insulin action in granulosa cells. 
Erickson et al. have shown however that granulosa cells from women with 
and without PCOS show no differences in oestrogen and progesterone 
production in response to insulin, suggesting that granulosa cells remain 
insulin responsive despite peripheral insulin resistance (136). Franks et al. 
have confirmed the preserved steroidogenic response to insulin, but have also 
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shown paradoxically a resistance to insulin mediated glucose metabolism in 
granulosa-lutein cells from women with anovulatory PCOS (71) (figure 1.11). 
The preservation of steroidogenesis and the impairment of glucose 
metabolism suggests that there is a post-receptor insulin signalling 
abnormality affecting glucose uptake and metabolism (71).  
 
Figure 1.11:  Lactate production and progesterone production by cultured granulosa-lutein 
cells after 48h of incubation in response to insulin (1-1000ng/ml) in women with normal 
ovaries (open squares), with ovulatory PCO (open diamonds) and with anovulatory PCO 
(filled circles). Adapted from Rice et al. 2005 (71)  
 
Experimental data from cultured granulosa cells do not support the idea that 
signalling pathways such as PI3K and MAPK control the steroidogenic activity 
of insulin as in other insulin target tissues (137, 138). The mechanism of 
insulin induced steroidogenesis has been attributed to its direct effect on 
components of the steroidogenic pathway as described in section 1.10. 
1.9 Gonadotrophin action on glucose metabolism in granulosa 
cells 
Gonadotrophins are also thought to be involved in energy metabolism during 
follicle development. Hillier et al. showed granulosa cells respond to 
gondotrophins by increasing lactate production (95). Gonadotrophins are also 
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believed to enhance the activity of the p38 MAPK (139), ERK (140), and PI3K 
(141) pathways, the latter being involved in metabolism and uptake (70, 142). 
PKA selective inhibitors, inhibit the activation of these signalling pathways and 
target genes, suggesting a PKA dependent mechanism of PI3K and ERK 
activation (140, 143). 
FSH has been shown to have important effects on glucose metabolism. FSH 
significantly increased oocyte maturation and produced a 2-3 fold increase in 
glucose uptake and lactate production by cumulus oocyte complexes in which 
the enclosed oocyte completed maturation (70). In this study, the PI3-kinase 
inhibitor LY294002 inhibited FSH stimulated glucose uptake, and GLUT4 
glucose transporter was found in granulosa cells suggesting that FSH 
increased glucose uptake by PI3-kinase-mediated translocation of GLUT4 to 
the granulosa cell membrane  (figure 1.12) (70). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12:  Insulin and gonadotrophin action on PI3K and MAPK signalling (K Hardy) 
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Rice et al. used granulosa-lutein cells from women with anovulatory PCOS, 
ovulatory PCOS, and a control group of women and looked into the effects of 
insulin (1-1000ng/ml) and LH (1-5ng/ml) on carbohydrate metabolism and 
progesterone production. Cells from the anovulatory PCO subjects were 
significantly less responsive to insulin in lactate production than those from 
both of the other two groups. LH addition however resulted in a dose-
dependent increase in glucose uptake, lactate and progesterone production in 
each group (figure 1.13) (71).  
Figure 1.13: Lactate and progesterone production by cultured granulosa-lutein cells after 48h 
of incubation in response to LH (1-5ng/ml) in women with normal ovaries (open squares), with 
ovulatory PCO (open diamonds) and with anovulatory PCO (filled circles) (71). LH-stimulated 
progesterone production (P=0.012, ANOVA b) Adapted from Rice et al. 2005 (71) 
 
1.9.1  Protein Kinase A Signalling 
The response of granulosa cells to LH and FSH is mainly mediated by cyclic 
adenosine monophosphate/ protein kinase A (cAMP/PKA) signalling (figure 
1.14). LH binds the LH receptor and FSH binds the FSH receptor both of 
which are transmembrane receptors. On binding the gonadotrophins both 
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receptors stimulate the Gs protein (144). GDP bound to the !Gs subunit is 
exchanged for GTP and the !Gs-GTP subunit breaks off and binds with 
adenylate cyclase. This generates cAMP, which then binds the regulatory 
units of PKA. The complex then dissociates into 2 catalytic subunits and a 
regulatory subunit. The catalytic subunit then phosphorylates cAMP response 
binding proteins (CREM and CREB), which bind upsteam DNA regulatory 
elements called cAMP response elements. Genes such as those encoding the 
LH receptor and P450 aromatase are regulated by this method. 
 
Figure 1.14: Illustration of FSH and LH signalling via the PKA pathway 
 
1.10  Androgen production in normal women and in PCOS 
The major androgens in women are dehydroepiandrosterone sulphate 
(DHEAS) a unique product of the adrenal zona reticularis (AZR); 
dehydroepiandrosterone (DHEA), androstenedione (A) and testosterone (T) 
which are all secreted by both the adrenal zona reticularis and ovarian thecal 
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cells and finally dihydrotestosterone (DHT) which is primarily a product of 
peripheral testosterone production. Androgen synthesis occurs in both the 
adrenal and ovary. The first three hormones described above are considered 
as pro-androgens, requiring conversion to testosterone in order to exert an 
effect.  The regulation of androgen secretion requires ACTH action on the 
adrenal gland, and LH action on the ovary. The liver, adipose and skin have 
3"HSD and 17"HSD, together with aromatase, which allow conversion of 
androgen to oestrogen (figure 1.15) 
Androgen biosynthesis is modulated by two critical P450 enzymes, P450 side 
chain cleavage (P450scc) which catalyses cholesterol side chain cleavage, 
and P450c17, which catalyzes 17 hydroxylation and 17-20 bond cleavage 
necessary to make DHEA from pregnenolone and androstenedione from 
progesterone. The other two very important enzymes are 3" hydroxysteroid 
dehydrogenase (3"HSD) which catalyses pregnenolone to progesterone and 
17" hydroxysteroid dehydrogenase (17"HSD) which catalyses 
androstenedione to testosterone (145).  
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Figure 1.15:  The steroidogenic pathway leading to production of testosterone which can 
be further metabolised to DHT or to oestradiol. 
 
The fundamental abnormality in women with PCOS is the overproduction of 
androgen by the ovary, particularly testosterone by the thecal cells. These 
cells over express various proteins including LH receptors, insulin receptors, 
steroidogenic acute regulatory protein (StAR), P450scc and 3"HSD, and 
P450c17; all these molecules are involved in steroidogenesis (figure 1.15). 
1.10.1 Effect of gonadotrophins and insulin on androgen 
production 
The basis for overproduction has been attributed to constitutive increase in 
theca cell responsiveness to gonadotrophins, in association with the higher 
pituitary LH levels often seen in women with PCOS. Hyperandrogenaemic 
women with PCOS have been shown to have excess 17-OHP production in 
response to GnRH agonist compared to women without PCOS suggesting a 
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general increase in activity of the androgen biosynthetic pathway (146). This 
is supported by in vitro work showing cultured thecal cells from PCOS patients 
produced far greater androgen levels both basally and when exposed to LH, 
than theca from normal women (50).  
1.10.2 Effect of insulin on androgen production 
Insulin has a critical role in regulating androgen levels (figure 1.1). Insulin acts 
to increase androgen levels directly and indirectly.  Insulin has been shown to 
act directly via its’ own receptor at physiological concentrations in cultured 
thecal cells from women with PCOS to increase androgen production (15).  
So insulin alone can increase androstenedione production, but also 
importantly insulin and LH together can increase androgen biosynthesis 
further (16). In women with PCOS, high levels of LH and insulin act 
synergistically to raise androgen levels (17). 
Insulin can also act indirectly to increase androgen levels by reduction of 
hepatic production of sex hormone binding globulin (SHBG) levels, thereby 
raising free androgen levels (147). The effects of insulin on androgen are 
summarised in Table 2 adapted from Diamanti-Kandarakis et al. 2006. 
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Effects Tissue References 
"Amplitude of LH secretion Pituitary (148, 149) 
!SHBG secretion Liver (150) 
!IGFBP-1 Liver (151, 152) 
"Testosterone production Theca cells (153) 
"17!! hydroxylase Theca cells (16, 153, 
154) 
"3"-HSD Theca and/or granulosa cells (155, 156) 
"Progesterone production Theca and/or granulosa cells (157) 
"P450 activity Granulosa cells (158, 159) 
"Oestradiol production Granulosa cells (157) 
"cAMP and or StAR biosynthesis Granulosa cells (160) 
"LDL receptor Granulosa cells (161) 
Table 2: Effects of insulin on hyperandrogenaemia in PCOS, upward and downward arrows 
indicate increased and decreased levels respectively. Adapted from Diamanti-Kandarakis et 
al. 2006 (124). 
 
1.10.3 Non-ovarian sources of excess androgen production 
Enzyme dysregulation in the adrenal, ovary, liver and peripheral tissues seem 
to contribute to hyperandrogenaemia in PCOS. Ovarian thecal cells from 
PCOS ovaries in vitro demonstrate persistent overexpression of enzymes in 
the steridogenic pathway, with resulting excess androgen production (162).  
In 25% of adults with PCOS there is increased adrenal responsiveness to 
ACTH, with an accelerated production of DHEA-S and androstenedione (163, 
164). This could be due to increased P450c17! activity, which is the rate-
limiting enzyme in androgen production in both the adrenal gland and the 
ovary. In addition androgen action may be enhanced by 5! reductase activity 
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in peripheral tissue such as adipose tissue and the liver, which will increase 
the production of dihydrotestosterone (DHT) from testosterone (T) (165) 
(figure 1.15). DHT has a higher affinity than testosterone for the androgen 
receptor and can not be converted to oestradiol. 
1.11  Androgen action 
1.11.1 Classical androgen receptor signalling 
Knowledge of the mode of action of steroid receptors has been extended in 
recent years. In addition to classical nuclear action, acting as transcription 
factors, they can also regulate cell signalling phosphorylation and exert 
actions that are initiated at the cell membrane, and often induce rapid 
responses. During classical nuclear action, T normally passively diffuses 
across the cell membrane where it can be converted to DHT by the enzyme 
5!-reductase. Both DHT and T are able to bind the androgen receptor (AR), 
which is found in its unbound state in the cytoplasm attached to heat shock 
proteins and cytoskeletal proteins. On binding, a conformational change 
occurs which dissociates these proteins and allows binding to co-regulator 
proteins, such as importin-!. This promotes AR stability and thereafter nuclear 
translocation and activity (166) (figure 1.16).  
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Figure 1.16: Illustration of the classical androgen receptor (AR) cycle and the non-
genomic effects of androgen; NTD (N-terminal transactivation domain), DBD (DNA-binding 
domain). (1) Conversion of testosterone to DHT via 5!-reductase; (2) DHT moves into the 
cytoplasm and binds AR; (3) Ligand binding to AR induces AR conformational change, 
proteins such as heat shock proteins (HSPs) dissociate and others such as importin-! and 
androgen receptor-associated protein-70 (ARA70) are recruited to help stabilise AR and 
promote AR nuclear translocation; (4) AR dimerises in the nucleus. Other co-activators bind 
to AR in the nucleus, the AR-DBD then facilitates nucleic acid binding at androgen response 
elements (ARE) which promote recruitment of co-activators resulting in chromatin remodeling, 
and subsequent gene transcription (not shown) (5) Non-ligand-bound AR is shuttled back to 
the cytoplasm and re-cycled. (6) DHT diffuses through the cytoplasmic membrane and 
interacts directly with AR where it can exert a 'non-genomic effect' with kinases, Adapted from 
Bennett et al, 2009 (166) and from Gronemeyer et al. 2004 (167).  
 
1.11.2 Non classical androgen receptor signalling 
It is only recently that non-classical or non-genomic, rapid (seconds to 
minutes), membrane initiated testosterone actions have received attention, 
and has now been seen in reproductive tissues (sertoli cells, oocytes), 
immune tissues, cardiovascular system and musculoskeletal system. There is 
evidence for both cytoplasmic AR and novel, membrane bound AR in this non 
classical action (168). The AR has been shown to interact directly with the 
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p85 regulatory subunit of PI3K in mouse vas deferens and stimulate Akt 
phosphorylation, this was then abolished using the AR antagonist 
bicalutamide (169). Early suggestions were that the rapid effects of 
testosterone were via aromatisation to oestrogen, and oestrogen receptor 
(ER) signalling. Compelling evidence for the rapid effects of oestrogen on 
PI3K and MAPK signalling now exist (170, 171), however this has proven not 
to be the case using aromatase inhibition and ER inhibition. 
1.11.3 Membrane bound androgen receptor 
It is now been demonstrated that a proportion of ‘classical’ ARs in certain cells 
such as sertoli cells and also breast cancer cells localise to the plasma 
membrane. Treatment with testosterone conjugated to bovine serum albumin 
(T-BSA), a membrane impermeable analogue, mimics the actions of 
testosterone and exerts specific effects in both sertoli cells and breast cancer 
cells, indicating plasma membrane action (172, 173). After testosterone 
stimulation AR is thought to associate with and activate tyrosine kinase, Src 
kinase which subsequently activates the MAPK pathway via the EGF receptor 
(figure 1.17) (168).  
It is possible that the AR may also activate Akt via the EGFR.  Recently 
Hammes and Levin introduced the theory of signalling complexes to explain 
steroid/growth factor interactions. This accepts the co-existence at the plasma 
membrane of androgen receptor, oestrogen receptor, G coupled protein, 
growth factor receptors (EGFR, IGFR), and tyrosine kinases (src/ras) and 
linker proteins such as MNAR (modulator of genomic activity of ER). AR may 
utilise MNAR as a scaffold in its interactions with growth factors. The close 
proximity of these molecules in a strict spatially defined area promotes 
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protein-protein interactions, which may then activate signalling pathways such 
as PI3K and MAPK (174).  
 
Figure 1.17: Classical ARs activate EGFR in response to ligand by signalling via src and 
MNAR. (PRB=progesterone receptor B, MNAR=modulator of genomic activity of ER). 
Adapted from Hammes et al. 2007 (174). 
 
Another possible mechanism of Akt activation by androgen could be via lipid 
rafts. In LnCaP cells androgen has been seen to bind to membrane bound 
androgen receptor (mAR) which then interacts with and activates Akt via lipid 
raft membranes, independently of PI3K (175) (figure 1.18). 
PI3K activation and Akt phosphorylation by insulin like growth factor 1 (IGF-1) 
is also involved in both AR serine phosphorylation and translocation into the 
nucleus of skeletal muscle cells, which leads to an increase in AR target gene 
expression (skeletal !-actin) (176). 
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Figure: 1.18: Model illustrating diversification of signals originating from AR at lipid raft 
membranes, in LNCaP prostate cancer cells. Adapted from Cinar et al. 2007 (175) 
 
The role of androgen in male reproduction and prostate cancer has been well 
defined and many of the studies described above have been in the male 
reproductive system. However little is known about the direct involvement of 
androgens and the AR in females. Recently a global androgen receptor knock 
out (ARKO) mouse was created and mature females were found to have 
premature ovarian failure (177). Further to this granulosa cell (GC) specific 
and oocyte specific ARKO mice have now been created. Granulosa cell 
specific ARKO mice were shown to have atretic follicles, premature ovarian 
failure and were sub-fertile whereas oocyte specific ARKO had normal fertility 
and ovarian morphology. This data suggests that the AR in granulosa cells 
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promotes preantral follicle growth and prevents follicle atresia, and is 
therefore essential for normal fertility (178). 
1.11.4 Effect of androgen on insulin sensitivity 
Excess androgen production is a pathophysiological feature of PCOS and 
exposure to exogenous testosterone in vivo has been associated with 
development of insulin resistance in rats and human females (179-181). 
However the mechanism by which hyperandrogenism reduces insulin 
sensitivity is unknown. In adolescents with PCOS, the risk of developing the 
metabolic syndrome increases as bioavailable testosterone levels rise, and 
this phenomenon is independent of obesity (182).  
1.11.5 Androgens and insulin resistance 
It is thought that high androgen levels and insulin resistance are linked. Insulin 
resistance is most prevalent in women with PCOS who have both androgen 
excess and anovulation (figure 1.10). Clinically administration of testosterone 
to female patients undergoing transformation to the male gender has been 
shown to induce insulin resistance (183). Administration of anabolic steroids 
such as methandrostenolone, which acts via the androgen receptor, have also 
been shown to induce insulin resistance in young athletes (184). Other 
evidence supporting the adverse effect of sex hormones on insulin sensitivity, 
comes from children reaching puberty, who have been found using 
euglycaemic clamp studies to have a reduction in insulin stimulated glucose 
metabolism (185). 
In vitro, intravenous testosterone administration in rats has been shown to 
produce a polycystic ovarian phenotype, associated with low/normal glucose 
Chapter 1 
 65 
and high insulin blood levels (186).  Also male rhesus monkeys that have 
been pre-natally androgenised, have been shown to have diminished insulin 
sensitivity (187). Corbould et al. investigated the action of androgen on pre-
adipocytes from healthy women treated with testosterone or anti-androgens 
for 48h. Maximal insulin stimulated glucose uptake (insulin 10nM) was 
impaired in the cells treated with testosterone 10nmol/L and 100nmol/L. This 
defect was attenuated by co-incubation with anti-androgens. However, 
testosterone treatment did not alter phosphorylation of IRS-1, AKT or MAPK 
(188). 
1.11.6 Insulin signalling activates androgen signalling 
There is also some evidence of a link between insulin and androgen 
signalling. Liganded AR recruits a protein known as forkhead transcription 
factor (FOXO-1/FKHR) to the AR promoter area where it interferes with AR-
DNA interactions. FOXO1 acts as a co-repressor of AR. Insulin and insulin 
like growth factor 1 (IGF1) abolish this occupancy, and relieve this inhibiton 
(87). PI3K signalling which is activated by both insulin and IGF1 
phosphorylates FOXO1. The phosphorylated FOXO1 is inactive and expelled 
from the nucleus (88).  
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1.12  Aim 
The overall aim of this project was to investigate the mechanism of insulin 
resistance in polycystic ovary syndrome in granulosa lutein cells. KK1 cells, 
an immortalised luteinizing mouse granulosa tumour cell line, expressing well 
characterised gonadotrophin receptors and steroidogenic enzymes were used 
initially to investigate the effects of androgen and its’ interaction with insulin on 
glucose metabolism and PI3K and MAPK signalling (189). Investigating 
insulin and androgen action in granulosa cells provided a good model for 
comparison of insulin action in women with PCOS. 
FSH has been shown to have important effects on glucose metabolism. FSH 
significantly increased oocyte maturation and produced a 2-3 fold increase in 
glucose uptake and lactate production by cumulus oocyte complexes in which 
the enclosed oocyte completed maturation (70). Gonadotrophins are thought 
to be involved in energy metabolism during follicle development. Hillier et al. 
showed granulosa cells respond to gonadotrophins by increasing lactate 
production (95). The signalling pathways involved in insulin action, androgen 
action and insulin/androgen interaction in mouse granulosa cells were then 
compared with those mediating FSH stimulated glucose metabolism and 
steroidogenesis in KK1 cells. 
Insulin and FSH action in human primary granulosa lutein cells from women 
with normal ovaries (control), those with endogenous androgen excess i.e 
women with polycystic ovary syndrome who continue to ovulate (ovPCO) and 
those who have irregular or anovulation (anov PCO) was then compared. The 
time and dose dependent effects of insulin and FSH action on glucose uptake, 
lactate accumulation and progesterone production were characterised. Insulin 
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and FSH action on key phospho-proteins in the PI3K and MAPK signalling 
pathways was also assessed.  
Several studies have shown an effect of FSH on steroidogenesis in human 
primary granulosa lutein cells taken from normal women undergoing IVF (190-
193). However this is the first study in primary human granulosa lutein cells to 
look at gonadotrophin effects on downstream signalling pathways involved in 
glucose metabolism. Previous work in luteinized GL cells has looked at the 
effect of LH but not of FSH.  
 
 
 
 
Chapter 2 
 68 
 
 
 
 
 
 
Chapter 2 
Effects of insulin and androgen on glucose metabolic pathways in 
an immortalised mouse granulosa cell line (KK1) 
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2.1 Introduction 
Polycystic ovary syndrome (PCOS) is characterised by hyperandrogenism 
and insulin resistance. Insulin resistance is central to the nature of polycystic 
ovary syndrome and varies with the PCOS phenotype (10), it is most 
prevalent in women with anovulation and hyperandrogenism (11). Patients 
with PCOS have reduced insulin sensitivity and a 3-7 times greater risk of 
developing Type II Diabetes (119, 120). High levels of insulin increase 
androgen levels, and acts synergistically with gonadotrophins to augment 
steroidogenesis (15-17). Insulin in combination with LH also prematurely 
enhances follicle arrest at earlier stages than normal, contributing to 
anovulation.  
Little is known about the mechanism of insulin resistance in PCOS particularly 
in relation to action in the ovary. Given that high androgen levels and insulin 
resistance are often found together in PCOS, we decided to assess the 
impact of androgen on insulin stimulated glucose metabolism and also its 
effect on insulin signalling. This has not been previously studied in granulosa 
cells. In previous studies, we demonstrated that the effect of insulin on 
glucose metabolism in granulosa-lutein cells from women with anovulatory 
PCOS is attenuated while its steroidogenic response is preserved (71). 
Glucose metabolism is needed for normal oocyte maturation and function (70) 
and this defect may contribute to infertility seen in PCOS patients. The 
preservation of steroidogenesis and the impairment of glucose metabolism 
suggests that there is a post-receptor insulin signalling abnormality affecting 
glucose uptake and metabolism (71).  
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Excess androgen production is a pathophysiological feature of PCOS and 
exposure to exogenous testosterone in vivo has been associated with 
development of insulin resistance in rats and human females (179-181). 
However the mechanism by which hyperandrogenism reduces insulin 
sensitivity is unknown. In adolescents with PCOS, the risk of developing the 
metabolic syndrome increases as bioavailable testosterone levels rise, and 
this phenomenon is independent of obesity (182).  
The fundamental abnormality in women with PCOS is the overproduction of 
androgen by the ovary, particularly testosterone by the thecal cells. These 
cells over express various proteins including LH receptors, insulin receptors, 
steroidogenic acute regulatory protein (StAR), P450 side chain cleavage 
(P450scc) and 3-"-hydroxysteroid dehydrogenase (HSD), cytochrome 
P450c17 and all these molecules are involved in steroidogenesis (figure 
1.15). Enzyme dysregulation in the adrenal, ovary, liver and peripheral tissues 
contribute to hyperandrogenaemia in PCOS as described in section 1.10.3. 
Insulin also has a critical role in regulating androgen levels. Insulin acts to 
increase androgen levels directly and indirectly. The effects of insulin on 
androgen are summarised in table 2, section 1.10.2 (124). 
It is thought that high androgen levels and insulin resistance are linked. Insulin 
resistance is most prevalent in women with PCOS who have both androgen 
excess and anovulation (figure 1.10). Clinically, administration of testosterone 
to female patients undergoing transformation to the male gender has been 
shown to induce insulin resistance (183). Administration of anabolic steroids 
such as methandrostenolone, which acts via the androgen receptor, have also 
been shown to induce insulin resistance in young athletes (184). Other 
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evidence supporting the effect of sex hormones on insulin sensitivity, comes 
from children reaching puberty, who have been found using euglycaemic 
clamp studies to have a reduction in insulin stimulated glucose metabolism 
(185). 
In vitro, testosterone injection into rats has been shown to produce a 
polycystic ovarian phenotype, associated with a low/normal glucose and high 
insulin blood levels (186).  Also male rhesus monkeys that have been pre-
natally androgenised, have been shown to have diminished insulin sensitivity 
(187). Corbould et al. investigated the action of androgen on pre-adipocytes 
from healthy women treated with testosterone or anti-androgens for 48h. 
Maximal insulin stimulated glucose uptake (insulin 10nM) was impaired in the 
cells treated with testosterone 10nmol/L and 100nmol/L. This defect was 
attenuated by co-incubation with anti-androgens. However, testosterone 
treatment did not alter phosphorylation of IRS-1, Akt or MAPK (188). 
In addition to classical nuclear action of steroid receptors, acting as 
transcription factors, androgen receptors can also regulate cell signalling 
phosphorylation and exert actions that are initiated at the cell membrane, and 
are often rapid responses (non genomic) (figure 1.16 and 1.17). This is 
described in greater detail in section 1.11. 
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2.2  Aims 
The objective of this study was to explore the effects of androgen and its 
interaction with insulin on glucose metabolism and phosphoinositide 3 kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) signalling in granulosa 
cells. KK1 cells are an immortalised luteinizing mouse granulosa tumour cell 
line, expressing well characterised gonadotrophin receptors and steroidogenic 
enzymes (189). Investigating insulin and androgen action in granulosa cells 
provides a good model for comparison of insulin action in women with PCOS. 
 
Specific Aims were: 
1. to establish a mouse granulosa cell line to examine the effects of 
insulin on glucose uptake and metabolism 
2. to explore the effect of insulin on the glucose transporter GLUT4 
3. to define the signalling pathways involved and to investigate the effect 
of androgen, in vitro, on insulin mediated glucose metabolism 
4. to explore the effect of androgen alone on signalling pathways or 
glucose metabolism 
5. to compare the signalling pathways involved in insulin action, androgen 
action and insulin/androgen interaction in mouse granulosa cells with 
those mediating gonadotrophin stimulated glucose metabolism and 
steroidogenesis. 
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2.3   Materials and Methods 
2.3.1  KK1 cell line    
KK1 cells are an immortalised luteinized mouse granulosa tumour cell line, 
expressing well characterised gonadotrophin receptors and steroidogenic 
enzymes (189). We have used these cells to explore the actions of insulin and 
androgens on Akt, phosphorylated Akt, as well as glucose uptake and 
metabolism in KK1 cells. 
The KK1 cell line (kindly donated by Prof Ilpo Huhtaniemi) was established 
from transgenic mice. This was achieved by introducing a gene construct 
containing a 6 kilobase fragment of mouse inhibin ! subunit promoter with 
simian virus 40 T-antigens into one cell stage embryos. Mouse inhibin !-
subunit promoter, is a tissue specific promoter, therefore producing transgenic 
mice expressing the SV40 T-antigen driven by the mouse inhibin !-subunit 
will allow only specific cell types to undergo transformation. This resulted in 
the development of tumorous ovaries in female mice. Permanent ovarian cell 
lines were established by growing cells from explant cultures of these ovaries 
and then allowing them to grow in monolayers in culture. Subculture 28 gave 
the strongest cAMP and steroidogenic responses so became further 
characterised to become the KK1 cell line. This cell line is a good model for 
granulosa cells as they use the cAMP/ adenylate pathway to produce 
progesterone.  
2.3.2  Reviving KK1 cells from frozen stock 
Cells were revived from frozen cell stocks.  The vial was warmed in the hand 
to 37°C and added to 5mls DMEM-F12 with phenol red (Invitrogen 31330-
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038) supplemented with 1% penicillin and streptomycin (Sigma P0781) and 
10% heat inactivated foetal bovine serum (FBS) (Invitrogen 10108-165) in a 
15ml centrifuge tube. This tube was then centrifuged at 200g for 5 minutes 
using a Centra CL3 (Thermo IEC) centrifuge. The supernatant was discarded 
leaving a pellet of cells. This step is to ensure the removal of 
dimethylsulfoxide (DMSO) which was used in the freezing media to prevent 
the formation of ice crystals which otherwise lyse cells during thawing. 5mls of 
serum-supplemented medium was then added to the KK1 cell pellet and the 
centrifuge tube was then vortexed. Following this the cells were added to 
75cm tissue culture flasks (TPP), and topped up with 20mls of serum 
supplemented media. The passage number of the cells and the date was 
noted and recorded on the flasks. 
2.3.3  Cell culture and splitting cells 
All culture dishes (Nunc, VWR) and flasks (TPP, Helena Biosciences) were 
suitable for tissue culture and all serological plugged pipettes were purchased 
from Costar. All experiments were carried out in a Class II flow cabinet and 
cells were grown at 37°C in 5% CO2. KK1 cells were grown in Dulbeco’s 
Modified Medium (DMEM-F12) supplemented with 10% heat inactivated 
Foetal Calf Serum (FCS), 50 U/ml penicillin/streptomycin (Invitrogen, Gibco) 
and 200 "M glutamine (Invitrogen, Gibco).  Cells were passaged thrice weekly 
by incubating with 5 ml of 0.25% trypsin/EDTA mix (T3924, Sigma) for 3 
minutes. The cells were re-suspended in 5 ml of DMEM-F12 supplemented 
with 10% heat inactivated FCS, 50 U/ml penicillin/streptomycin (Invitrogen, 
Gibco) and 200 "M glutamine (Invitrogen, Gibco) and plated to the required 
density.  
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2.3.4  Freezing KK1 cells after culture 
Cells were grown in T75 flasks until confluent. Adherent cells were incubated 
with 5 ml of 0.25% trypsin. The trypsin was then inactivated; by adding 5ml of 
DMEM-F12 with 10% heat inactivated fetal bovine serum (FBS). The cells 
were spun down in a centrifuge tube and resuspended in freezing mixture 
(standard media + 10% DMSO + 10% FBS). Cells were then aliquoted into 
special freezing vials and transferred to a Mr Frosty (freezing container 
providing 1°C/min cooling rate required for successful cell cryopreservation). 
This was then placed in the -80°C freezer. 
2.3.5  Cell counting 
Cells were counted using disposable haemocytometers (Hycor Biomed) using 
a light microscope (Olympus CK2).  The values were converted into cell 
density based on the volume of the counting chamber.  The experiments were 
repeated 2-3 times to overcome the fact that cell culture experiments can 
produce variable results on different occasions. For each experiment the KK1 
cells were plated in triplicate.  
2.3.6  KK1 cell culture, protein isolation and expression 
For protein expression experiments, cells were cultured in 6 well plates at a 
density of 1.4 x 106 cells/well, in 3mls of serum-supplemented medium 199. 
For glucose uptake and metabolism, cells were plated in 96 well plates at a 
density of 2 x 104 viable cells/well in 200µl of serum-supplemented medium 
199. For each experiment the KK1 cells were plated in triplicate. To those 
KK1 cells being exposed to androgen, Dihydrotestosterone (DHT) (Sigma) 
was added at this stage. The DHT was dissolved in ethanol (appendix 3), and 
Chapter 2 
 76 
the ethanol was tested to ensure it had no effects at the concentrations used. 
After 24 hours incubation at 37°C in 5% CO2, the medium was removed and 
cells washed thoroughly with PBS. They were then incubated in serum free 
DMEM-F12 +/- 10nM DHT (appendix 3) for 24 hours. Insulin (dissolved in 
acidified H2O) was added for various amounts of time at various doses 
(appendix 3). Cells were lysed in 100 µl ice cold RIPA buffer directly on the 
plate (appendix 2), with 10 µl protease inhibitors (appendix 2), 10 µl aprotinin 
(MP Biochemicals) and 10 µl sodium orthovanadate.  Using a cell scraper, the 
lysates were transferred into eppendorfs and pelleted at 13000 x g in a 
microfuge for 5 minutes at 4 °C and pellets were discarded and the 
supernatant collected.   30 µl Laemlli lysis buffer (appendix 2) was added to 
each western blotting lysate.  Samples were stored at -20 °C. The wells of the 
gel were each loaded with 2-3 µl standard loading buffer and then 15 µl 
supernatant was loaded on a Bis-Tris NuPAGE pre cast polyacrylamide gel 
(Invitrogen) or a self cast gel (appendix 2). 5µl of a pre stained standard 
ladder was also loaded (Invitrogen). The experimental protocol is summarised 
in figure 2.1. 
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Figure 2.1: Flow diagram of experimental protocol for KK1 experiments 
 
2.3.7  Primary human granulosa cells: Patients 
Granulosa cells were obtained, with informed, written consent, at the time of 
egg collection for IVF at Hammersmith Hospital from 31 women described 
further in Chapter 4, section 4.3.1: 12 with normal ovaries (control), 8 with 
ovulatory PCOS (ov PCO) and 11 with anovulatory PCOS (anov PCO). These 
granulosa cells are isolated from the fluid that is collected from eggs in the 
ovary for IVF and are usually thrown away. Described in more detail in section 
4.3 of Chapter 4. In this Chapter, two control patients were used to continue 
the work done in KK1 cells on androgen pre-incubation and insulin addition. 
Chapter 2 
 78 
2.3.8  Human granulosa lutein cell collection, preparation and 
culture 
All procedures were carried out under sterile conditions in a fume hood using 
aseptic tissue culture techniques. To enable removal of serum and reduce 
follicular fluid volume, samples were centrifuged at 200g for 5 minutes using a 
Centra CL3 (Thermo IEC) centrifuge. After discarding the clear follicular fluid 
supernatant, the pellets were then transferred into one 50mL centrifuge tube. 
If the volume of flush was too large, the pellets were centrifuged again and the 
process above repeated. The supernatant was then discarded and the cell 
solution volume was made up to 8mL with PBS.  
In order to separate off any remaining red blood cells (RBCs) the follicular 
fluid mixture was gently layered over a percoll gradient. An autoclaved glass 
pipette was filled with cells and pipetted into 15mL centrifuge tubes containing 
8mL pre-prepared shaken Percoll solution (8.9mL of Percoll [GE Healthcare], 
1mL 10xM199, 100mL NaHCO3 7.5%, 10mL M199 [all from Invitrogen]). The 
45% Percoll solution was filtered before use and shaken to produce bubbles, 
which provided a gentle surface for the cells to land on. The tubes were then 
centrifuged at 400g for 20-30min to isolate the granulosa-lutein cells; red 
blood cells separated off and sunk to the bottom of the tube. If the cell mixture 
was seen to be particularly bloody a greater number of test tubes of percoll 
gradients were used.  
Granulosa lutein cells were then aspirated from the Percoll/PBS interface with 
an autoclaved glass pipette and washed twice, using serum supplemented 
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M199. Cell number and viability were determined using a Trypan Blue 
exclusion test (Sigma). Cell separation protocol summarised in figure 4.1. 
For the glucose, lactate and progesterone assays, 20 x 104 cells were plated 
into 96 well plates, and supplemented with 200µl serum supplemented 
medium 199 with or without DHT 10nM. Each experimental condition was 
repeated in triplicate. Cells were placed centrally and surrounding wells filled 
with sterile PBS to avoid evaporation. After 24h incubation at 37°C in 5% CO2, 
serum containing medium was removed and the cells washed with PBS. They 
were then incubated for a further 24h with 200µL serum free Medium 199 with 
or without 100ng/ml of Insulin (Sigma) and DHT 10nM.  
For the protein expression results, 50 x 104 cells were added to 24 well plates 
and each well was supplemented with 1mL serum supplemented media +/- 
DHT 10nM. After 24h incubation at 37°C in 5% CO2, the medium was 
removed and cells washed with PBS. They were then incubated for a further 
24h with 1mL serum free Medium 199 +/-10nM DHT.  The cells were the 
incubated with or without 100ng/ml of Insulin (Sigma) for 15, 30 or 60 minutes. 
Cells were then harvested in RIPA buffer, with aprotinin (MP Biochemicals, 
Cambridge, UK), protease inhibitors and sodium orthovanadate (Sigma). The 
samples were then centrifuged at 12000xg for 5 minutes at 4°C and 
supernatant collected. Laemmli sample suffer was added, and 20 µl loaded on 
a Bis-Tris NuPAGE pre cast polyacrylamide gel (Invitrogen). 5µl of a pre 
stained standard ladder was also loaded (Invitrogen) (see figure 4.2). 
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2.3.9  Western Blotting 
Gels were run using a wet-blotting system, X cell Surelock Mini-Cell system. 
The gels were then transferred using a semi-dry transfer system. 
Polyvinylidene fluoride (PVDF) membrane (Thermo Scientific), was cut to the 
size of the gel and soaked in ethanol or methanol for membrane activation. 
Alternatively nitrocellulose membrane (Whatman) was used, which did not 
require prior activation. The transfer sandwich was then assembled in the 
following way: transfer sponge, followed by two sheets of Whatman 
chromatography paper, the PVDF membrane, the gel, a further two sheets of 
Whatman paper and finally another transfer sponge. The whole sandwich of 
layers was soaked in a dish filled with transfer buffer (appendix 2) and a roller 
was rolled over the sandwich to remove trapped air. The apparatus was 
closed into the transfer machine and proteins were then transferred for 3.5h at 
200mA.          
2.3.10 Immunoblot analysis 
The membrane was first stained with ponceau to check protein transfer, and 
equal loading. The membrane was blocked with 5% skimmed milk and 1% 
100mM sodium orthovanadate in 10% diluted 10x TBST buffer solution (Tris 
Buffered Saline with Tween) (blocking solution) for 15min at room 
temperature. Primary antibodies (appendix 1) were diluted in blocking solution 
and incubated with membranes overnight at 4°C. Blots were washed and 
incubated with the appropriate secondary antibody (appendix 1), for 1 hour at 
room temperature.  
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Signal was developed using ECL western blotting detection kit, and blots were 
then exposed to Kodak blue sensitive film.  For the detection of total Akt and 
MAPK protein, membranes were stripped using stripping buffer (Thermo 
scientific) before re-probing. The following polyclonal antibodies were all 
obtained from New England biolabs (UK) LTD, Akt Ab, phospho-Akt (Ser473) 
Ab, phospho-Fox01 (Thr24)/Fox03a (Thr32), p42/44 phospho MAPK, p42/44 
MAPK (appendix 1). 
No quantitative analysis was performed as it was difficult on some occasions 
to scan, view and quantify the total protein blots with this method. 
2.3.11 Measurement of lactate production and glucose uptake 
Individual 3-µl aliquots of culture medium from the experimental and control 
incubation drops were collected using a 10µl pipette and diluted 1:200 for 
glucose analysis an 1:400 for lactate analysis, with a mixture of 5µM lactate 
and 2µM pyruvate solution. All samples were stored at -70oC until analysis 
with the COBAS bioanalyser. 
Glucose and lactate assay 
The depletion of glucose and the production of lactate by the granulosa cells 
were measured by analyzing the difference between substrate concentrations 
in the control and treatment wells as described previously (194). The assays 
were based on the conversion of substrate to product with the reduction of 
NAD+ (lactate assay) or NADP+ (glucose assay) (195). NADH and NADPH are 
highly fluorescent; hence the amount of fluorescence emitted is proportional 
to the amount of substrate in the sample. The fluorescence of the reactions 
was quantified using a COBAS Bio centrifugal autoanalyser  (Roche Products, 
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Welwyn Garden City, UK) fitted with a fluorescence immunoassay (FIA) 
option. Reactions were carried out at 25oC. Light of a particular excitation 
wavelength (340nm) passed through the reaction mix in multiple cuvettes 
resulting in emission of secondary light. This is detected by a photomultiplier 
and signals were measured by photometer, and compared to a standard 
curve produced from 3 glucose or lactate standards (appendix 4). All 
chemicals were obtained from Roche (Welwyn Garden City, UK) unless 
otherwise stated. Cobas bioanalyser settings are set out in appendix 4. These 
programmes are based on those described by Stappenbeck et al. (196) and 
Harrison et al. (194, 197). 
Glucose assay 
Diluted media (1:200, 70µl) was automatically sampled and added to 200µl 
buffer containing 24ml Tris Buffer (0.1mM working concentration), 4.8ml 
MgCl2 Buffer (0.1mM), 500µl NATP (NADP 1.8mM and ATP 4.0mM). 
Hexokinase/glucose-6-phosphate dehydrogenase (40mM) diluted 1:80 with 
distilled water was added before fluorometric measurement. 
Hexokinase:  Glucose  + ATP #  Glucose 6- phosphate + ADP 
G6PDH:  Glucose- 6 phosphate + NADP+ # 6-phosphogluconate + NADPH + H 
Lactate assay 
Diluted medium (1:400, 40µl) was automatically sampled and added to 200µl 
buffer containing 0.54M Glycine (Sigma), 0.2M hydrazine sulphate (Sigma), 
2.7nM EDTA (BDH). 0.54M sodium hydroxide (NaOH) and 0.6mM 
nicotinamide adenine dinucleotide (NAD). 20µl of lactate dehydrogenase 
(LDH) diluted 1:10 distilled water was added before fluorometric 
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measurement. The increase in fluorescence due to the formation of NADH is 
proportional to the amount of lactate consumed. 
LDH:  Lactate  + NAD+# Pyruvate + NADH + H+ 
2.3.12     Immunocytochemistry (ICC) 
KK1 cells were plated onto a 24 well plate with a coverslip at the base of each 
well, at a density of 1 x 105 cells per well. The cells were fixed with 4% 
paraformaldehyde (Sigma) for 20 minutes at room temperature and then 
washed off 4 times with PBS. The cell membranes were then permeabilised 
with 0.1% Triton. This was also washed 4 times with PBS. Each sample was 
blocked in the appropriate blocking serum for 20 minutes (20% goat serum 
was made up using 1ml of inactivated goat serum, 0.2g bovine serum albumin 
(BSA) and 4ml PBS). The primary antibody was diluted in 20% goat serum 
and samples were incubated overnight at 4o C (appendix 1). The two primary 
antibodies used were, rabbit anti-GLUT4 antibody (Santa Cruz, California, 
USA) and rabbit anti-androgen receptor antibody (Fitzgerald: 20-RAR012, 
Acton, MA, USA). Some slides were incubated with rabbit immunoglobulin 
(IgG) (100µg/ml) in PBS. One well was incubated in blocking solution alone 
with no primary antibody, thus acting as a negative control. 
Each well was then rinsed three times with PBS before addition of biotinylated 
goat anti-rabbit IgG secondary antibody 1:200, for 30 min, then washed three 
times in PBS followed by application of peroxidase-conjugated avidin-biotin 
complex (Vector) for 30 minutes. 
The well was then washed three times, followed by application of 
diaminobenzidine (DAB) (Zymed) for 10 minutes, after which the reaction was 
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terminated with distilled water. Haematoxylin was added for 30 seconds and 
then thoroughly washed off with water. The coverslips were then removed 
from the 24 well trays and mounted onto glass slides using Faramount (Dako, 
Glostrup, Denmark). 
2.3.13 Transfection of KK1 cells with HA-GLUT4-GFP 
2.3.13.1 Plasmid construction  
HA-GLUT4-GFP was made from HA-tagged (Haemagglutinin tagged) human 
GLUT4 gene, pHA-GLUT4 vector (198) with enhanced GFP at the GLUT4 
terminus in the GFP expression vector pQBI25 (Quatum Biotechnologies, 
Montreal, Canada) in two steps. The HindIII and KpnI restriction sites were 
initially inserted into the pQBI25 plasmid upstream of the GFP gene. The HA-
GLUT4 sequence without the STOP codon was then inserted in between 
these restriction sites to yield pHA-GLUT4-GFP (199). 
The KK1 cells were then transfected with an HA-GLUT4-GFP plasmid in order 
to assess sub-cellular trafficking (199) (kindly donated by J Tavare). The dual 
tagging of GFP and HA was created to aid differentiation of cell membrane 
and cytoplasm clearly in fat cells, but we have only used the GFP visualisation 
in the KK1 cells.  
2.3.13.2 Elution of plasmid and transformation of DH5!  cells 
with plasmid DNA 
The HA-GLUT4-GFP plasmid was posted to our department on a piece of 
whatmann paper. This paper was soaked in distilled water overnight. To 
precipitate the DNA, 2µl of glycogen was then added together with 30µl 3M 
sodium acetate and 3x volume of 200C 100% ethanol. This mixture was then 
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kept on ice for 1 hour followed by centrifuge for 30 minutes at 40C.  1mL 80% 
ethanol was then added. The supernatant was removed and the remaining 
pellet was left to air dry for 3 minutes. 20µl distilled water was then added, 
and left for 15 minutes on ice. After a quick spin to collect all the drops 
together, DNA was measured using a nanodrop machine. 
Competent DH5 ! cells (Invitrogen) were transformed with 1-10ng of plasmid 
DNA. DNA was added to 100"l of cells and the tubes were placed on ice for 
45 minutes before being heat shocked for 90 seconds at 37°C. Cells were 
transferred to tubes containing 1 ml of 2 x TY and shaken for 30 minutes at 
37°C. Following this 100 "l of each culture was plated onto TY agar plates 
containing 100"g/ml ampicillin and incubated at 37°C overnight in an inverted 
position.  
The following day many colonies were seen on the agar plate. A tip was 
touched to an isolated large colony taking care not to touch the satellite 
colonies, and placed in a breathable test tube containing 2mls of TY and 
ampicillin at a concentration of 1:1000 (2"l). This test tube was then placed on 
a shaker at 250rpm at 37°C overnight. The samples were then decanted into 
an eppendorf and spun for 30 seconds. The supernatant was removed and 
the QIAprep spin miniprep kit and protocol used on the pellet to amplify and 
purify up the plasmid DNA (Qiagen, West Sussex, UK). 
2.3.13.3 Transient transfection  
In preparation for these studies the KK1 cells were initially transfected with 
GFP alone, using a CMV promoter. During the optimisation process a GFP 
plasmid with H1 promoter was used, but the cells did not transfect well with 
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this.  Different transfection methods were also tried such as calcium chloride 
and HBS, but the lipofectamine method worked best. 
The cells were grown to 80% confluence and the growth media was changed 
to DMEM/F12 with glutamine 1%, and 10% FBS, but no antibiotic.  Cells were 
transfected with lipofectamine lipid based transfection reagent as per 
manufacturers protocol (Invitrogen).  Briefly, for transfection of plasmid DNA 
into a 6 well plate, 10 µl of lipofectamine was mixed with 240ul Opti-Mem I 
reduced serum media (Invitrogen) and in a separate tube, 240 µl of Opti-Mem 
I was mixed with 4 µg of plasmid. Each tube was mixed gently alone, and 
incubated for 5 minutes at room temperature.  The two mixtures were then 
combined, mixed gently and incubated at room temperature for 20 minutes.  
The mixture was added to cells drop wise and incubated for 24-48 hours.   
2.3.14 Live imaging using confocal microscopy 
For live confocal microscopy, KK1 cells were plated at a density of 5 x 105 
viable cells in 2ml of serum-supplemented DMEM-F12 (without phenol red or 
antibiotic) and incubated at 37°C in 5% CO2. The KK1 cells were grown in a 
35mm glass bottomed culture dish (Mat Tek Corporation, MA, USA), which 
combined the standard size 35mm disposable plastic petri dish with optical 
quality glass, providing high quality, high resolution microscopic images. The 
cells were grown to 80% confluence and were transiently transfected 24-48 
hours in advance of the live confocal imaging (section 2.3.13.3). Prior to 
imaging, the KK1 cells were washed thoroughly with PBS and the medium 
was switched to serum free DMEM-F12 (without phenol red) for 24 hours.  
The cells were imaged without insulin for 10 minutes and then imaged for 10 
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minutes after insulin 100ng/ml addition with images taken at 10-second 
intervals. Fluorescence was observed using an SP5 confocal microscope. To 
excite GFP, the 488nm line of the argon laser was used at 10% laser energy. 
Each experimental condition was repeated in triplicate and the best examples 
are shown in figures 2.7 and 2.8. 
2.3.15 Statistical analysis 
Statistical analyses were performed using InStat 3.0a for Macintosh Graph 
Pad, San Diego, CA. Graphs were produced using GraphPad Prism Version 
5.0. The experiments were repeated 2-3 times to overcome the fact that cell 
culture experiments can produce variable results on different occasions 
However the statistics were calculated using one experiment in which the 
cells were plated in triplicate. Non parametric analysis was performed 
throughout as we were unable to calculate the normal distribution using three 
values.  
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2.4  Results of KK1 cells 
2.4.1  Effect of insulin on KK1 cells 
2.4.1.1 Glucose uptake and lactate production 
The uptake of glucose and the production of lactate was measured at 0, 15, 
30, 60 minutes and 4, 24 and 48 hours after addition of 100ng/ml insulin. 
Dose response experiments were performed with 10ng/ml, 100ng/ml, and 
1000ng/ml insulin, and glucose uptake and lactate production increased as 
the doses increased (data not shown). This particular insulin dose (100ng/ml) 
was chosen as although slightly supra-physiological it produced clear results. 
No significant changes were seen in glucose or lactate concentrations until 
after 48h in culture (Kruskal-Wallis non parametric anova, figure 2.2).   
The effects of insulin were compared to those of incubation with medium 
alone. Control KK1 cells that had not been exposed to insulin, showed no 
change in glucose or lactate concentration at 48h.  However a significant 
difference in glucose uptake was seen after 48h of insulin exposure compared 
to 48h of no insulin (p=<0.05, Mann Whitney). A significant difference in both 
glucose uptake and lactate production was also seen at 48h of insulin 
100ng/ml incubation when compared to time zero (p=<0.05, Kruskal-Wallis, 
figure 2.3).  
The experiment was repeated three times, however the statistics were 
calculated using one experiment in which the cells were plated in triplicate. 
Non parametric analysis was performed throughout it was not possible to 
calculate normal distribution using three values.  
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Figure 2.2:  (a) Glucose uptake into KK1 cells after addition of insulin 100ng/ml. (b) 
Lactate production from KK1 cells after addition of insulin 100ng/ml. There were no significant 
changes in glucose or lactate levels until 48 hours. P values calculated using Kruskal-Wallis, 
non parametric anova. Results are of one representative experiment, cells plated in triplicate. 
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Figure 2.3:   (a) Shows glucose depletion from the media, a significant difference was 
seen in glucose uptake after 48h of insulin exposure compared to 48h of no insulin (p=<0.05, 
Mann Whitney). (b) Lactate production after the addition of 100ng/ml insulin (grey bars) 
compared to KK1 cells with no insulin addition (control/green). A significant difference in 
lactate production was seen at 48h of insulin 100ng/ml incubation when compared to time 
zero (p=<0.05, Kruskal Wallis). No significant differences were seen when comparing 48h of 
insulin exposure vs 48hrs of no insulin exposure. Results are of one representative 
experiment, cells plated in triplicate. 
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Addition of a PI3K inhibitor LY294002 (LY) to the KK1 cells inhibited glucose 
uptake and lactate production. Using Kruskal-Wallis (non parametric one way 
anova) a significant reduction in lactate production was seen at both 24h and 
48h of insulin exposure when compared to 24h (p=0.01) and 48h (p=<0.001) 
respectively of exposure to insulin after LY294002 25 µM pre-treatment (figure 
2.4). No significant differences were seen in glucose uptake.  
The experiment was repeated twice, however the statistics were calculated 
using one experiment in which the cells were plated in triplicate. Non 
parametric analysis was performed throughout as we were unable to calculate 
the normal distribution using three values.  
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Figure 2.4:  Effect of PI3K inhibitor LY 294002; (a) Although glucose uptake was reduced 
after 48h of insulin 100ng/ml addition in the presence of 1h pre-incubation with PI3K inhibitor 
LY294002 25µM; no significant difference was seen (Kruskal-Wallis) (b) A significant 
reduction in lactate production was seen after 24h and 48h respectively of exposure to insulin 
after LY 294002 25 µM pre-treatment (Kruskal-Wallis). Results are of one representative 
experiment, cells plated in triplicate. 
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A second PI3K inhibitor wortmannin was used. One hour of either 
Wortmannin 1µmol  (p=<0.001, Kruskal-Wallis) or LY294002 25µM 
(p=<0.001, Kruskal-Wallis) pre-incubation resulted in a significant reduction in 
lactate production in response to insulin 100ng/ml, although LY294002 
produced a significantly greater inhibition than wortmannin (p<0.001, Kruskal-
Wallis)  (figure 2.5). The experiment was repeated twice, however the 
statistics were calculated using one experiment in which the cells were plated 
in triplicate. Non parametric analysis was performed throughout as we were 
unable to calculate the normal distribution using three values.  
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Figure 2.5: (a) Glucose uptake (b) lactate production in KK1 cells in response to two PI3K 
inhibitors LY and Wortmannin. Lactate production is significantly reduced in the presence of 
both wortmannin 1µmol (p=<0.001) and LY 25 µM (p=<0.001) after 48h of insulin 100ng/ml 
addition, compared to insulin treatment alone for 48h.  The presence of 1h pre-incubation with 
PI3K inhibitor LY294002 25µM produced a significantly greater inhibition of lactate production 
from the medium than wortmannin 1µmol (p=<0.001). Calculated using Kruskal Wallis. 
Results are of one representative experiment, cells plated in triplicate. 
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2.4.1.2 GLUT4 expression 
GLUT4 expression was then explored in the KK1 cells. GLUT4 was shown to 
increase expression in response to insulin 100ng/ml (figure 2.6 b,c) but not 
forskolin 10µmol (figure 2.6 d).   
The KK1 cells were then transfected with an HA-GLUT4-GFP plasmid in order 
to assess sub-cellular trafficking (199) (kindly donated by J Tavare). The dual 
tagging of GFP and HA was created to aid differentiation of cell membrane 
and cytoplasm clearly in fat cells, but we only used GFP visualisation in the 
KK1 cells.  
Initially the cells were exposed to insulin and then mounted on slides and 
fluorescence imaging was used to analyse GLUT4 distribution prior to insulin 
addition. However it was not easy to monitor GLUT4 using this method (data 
not shown). Therefore live confocal imaging was used to visualise the GLUT4 
response to insulin 100ng/ml as shown in figures 2.7 and 2.8. GLUT4 was 
seen to move toward the cell membrane after 5 minutes of insulin addition.   
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Figure 2.6:  Immunocytochemistry: KK1 cells, GLUT4  (a) GLUT4 immuno-staining 
(primary antibody dilution 1:200) (b, c) GLUT4 immuno-staining (1:400 dilution) addition of 
insulin 100ng/ml for 1h showed GLUT4 up-regulation to the membrane (d) GLUT4 immuno-
staining (1:400 dilution) addition of forskolin 10µmol for 1hr showed some background GLUT4 
expression which was comparable to the control (a). 
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 a.  
  
b.  
 
Figure 2.7: Live confocal imaging: HA-GLUT4-GFP transfected cells (a) GFP-GLUT4 
transfected KK1 cell (b) GFP-GLUT4 transfected KK1 cell 5 minutes after insulin 100ng/ml 
addition, showed movement of GLUT4 towards the surface of the cell membrane.  
 
a.     b.   
 
Figure 2.8: Live confocal imaging: (a) GFP-GLUT4 transfected KK1 cell, 2 minutes after 
insulin 100ng/ml addition, note green tubular structure extending from cell, highlighted with an 
arrow (b) GFP-GLUT4 transfected KK1 cell, 5 minutes after insulin 100ng/ml addition, showed 
movement of GLUT4 expression and further green tubules, highlighted with an arrow. 
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2.4.1.3 Akt phosphorylation 
The KK1 cells showed phosphorylation of Akt within 5 minutes of insulin 
100ng/ml exposure. The expression of phosphorylated Akt increased with 
time and peaks at 60 minutes. Total Akt levels were used as a loading control 
and were unchanged throughout (figure 2.9). The blots of KK1 cell 
experiments were all imaged using ECL and exposed using Kodak blue 
sensitive film. No quantitative analysis was performed, as it was difficult on 
some occasions to scan, view and quantify the total protein blots with this 
method. 
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Figure 2.9: Immunoblot; Time course of insulin 100ng/ml action on Akt phosphorylation. 
Western blot showing phosphorylated Akt, which was activated by 5 minutes and maximally 
stimulated at 1 hour. The membrane was stripped and re-probed for Akt as a loading control. 
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As the concentration of insulin changed from 10-1000ng/ml the amount of Akt 
phosphorylation also increased (figure 2.10). Some constitutive activation of 
Akt phosphorylation was seen at time zero. 
  10                       100                  1000                       Insulin 100ng/ml                     
   0   15   30   60   0   15  30  60    0   15  30   60        mins 
     Phosphorylated Akt
   Akt 
 
Figure 2.10: Immunoblot; Dose effect of insulin action on Akt phosphorylation. 
Phosphorylated Akt expression was shown to increase stepwise as insulin concentrations rise 
from 10-1000ng/ml. 
 
Pre-incubation of PI3K inhibitor LY294002 (25µM) for 1 hour prior to insulin 
100ng/ml addition, inhibited Akt phosphorylation (figure 2.11).  
 
    Insulin (100ng/mL)     LY (25µM) + Insulin (100ng/mL) 
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Figure 2.11:  Immunoblot; Effect of inhibition of PI3K on expression of phosphorylated Akt 
in KK1 cells. Akt phosphorylation was reduced with 1h LY294002 25µM pre-treatment. 
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2.4.1.4 MAPK phosphorylation 
ERK also shows a time dependent rise in phosphorylation in response to 
insulin, but does not increase greatly with higher insulin concentrations (figure 
2.12). 
 
   10                    100                  1000                       
   0   15  30  60  0   15  30  60   0  15  30  60 
 
 
 
Figure 2.12: Immunoblot; Effect of insulin on MAPK. p42-44 ERK (MAPK) was 
phosphorylated in response to insulin (10-100ng/ml) and peaked at 15 minutes. There was no 
rise in expression with higher insulin concentrations. 
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2.4.2  Effect of androgen in KK1 cells 
2.4.2.1 Immuno-cytochemistry 
Expression of androgen receptors was confirmed in KK1 cells using 
immunocytochemistry (figure 2.13).  
 
 
Figure 2.13:  Immunocytochemistry: Expression of androgen receptor in KK1 cells: KK1 cells 
passage 10. Immuno-stained for IgG (control) and androgen receptor (primary antibody 1:50 
dilution) 
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2.4.2.2 Glucose and Lactate 
KK1 cells were then exposed to Dihydrotestosterone (DHT) 10nM alone. DHT 
10nM alone produced a significant rise in lactate production (p=<0.0019, 
Kruskal-Wallis) and significant glucose uptake at 48h (p=<0.01, Kruskal-Wallis 
[KW]) compared to no treatment at 48h. Although this response was slightly 
attenuated by the anti-androgen Flutamide 1µmol, this result was not 
significant (figure 2.14).  
Figure 2.14: Effect of DHT 10nM alone on glucose metabolism in KK1 cells: DHT 10nM alone 
produced an increase in lactate production (p<0.0019 KW) and glucose depletion (p<0.01 
KW) from the media compared to no substrate addition at 48h.  This response was partially 
attenuated by the presence of Flutamide 1µmol. Results are of one representative 
experiment, cells plated in triplicate. 
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Pre-incubation of KK1 cells with DHT 10nM followed by insulin 100ng/ml 
exposure, lead to a significantly higher depletion of glucose from media 
(p=<0.001, Kruskal-Wallis), and a significantly higher lactate production at 48h 
(p=<0.01, Kruskal-Wallis) than those cells not pre-incubated in androgen 
(figure 2.15). 
Figure 2.15: Glucose uptake from the media and lactate production in KK1 cells exposed to 
both insulin and androgen. Pre-incubation of KK1 cells with DHT 10nM followed by insulin 
100ng/ml exposure, lead to a significantly higher depletion of glucose from media (p=<0.001), 
and a significantly higher lactate production at 48h (p=<0.01) than those cells not pre-
incubated in androgen. Kruskal-Wallis, one way anova was used for statistics. Results are of 
one representative experiment, cells plated in triplicate. 
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2.4.2.3 PI3K and MAPK Signalling 
KK1 cells were then exposed to Dihydrotestosterone (DHT) 10nM alone and 
response of Akt phosphorylation and ERK phosphrylation monitored over 
time. KK1 cells were cultured in the absence of treatment and in the presence 
of DHT (10nM). Samples were collected at 5, 10, 15, 30 and 60 minutes and 
the phosphorylation of Akt and ERK was investigated (figure 2.16).  
 
   DHT 10nM 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Immunoblot, action of DHT 10nM alone in KK1 cells. KK1 cells, in the presence 
of DHT 10nM alone, phosphorylated Akt and ERK within 5 minutes, with a maximal 
stimulation at 15 minutes. 
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Insulin induced Akt phosphorylation was enhanced by 48h DHT 10nM pre–
incubation (figure 2.17). This was also shown to be the case with longer 
periods of androgen exposure; 106h (figure 2.18) and 14 days (figure 2.17). 
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Figure 2.17: Immunoblot; effects of varying time lengths of androgen pre-exposure. Shows 
insulin induced Akt and ERK phosphorylation was enhanced in response to both short term 
(48hrs) and long term (14 days) androgen pre-incubation. 
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Figure 2.18: Pre-incubation with androgen for 106h, followed by insulin addition 
a. Western blot showing the response of phosphorylated Akt and ERK to insulin (10-
1000ng/ml) alone. The blot below shows total Akt and ERK used as a loading control. 
b. Increased expression of phosphorylated Akt and ERK after 106hrs of DHT 10nM pre-
incubation, followed by addition of insulin (10-1000ng/ml). The blot below shows total Akt and 
ERK as a loading control. 
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Pre-incubation with increasing doses of DHT (1,10, and 25ng/ml), did not 
clearly produce an increase in the amount of phosphorylated Akt (figure 2.19). 
ERK phosphorylation also did not appear to increase with DHT 
concentrations. DHT 50ng/ml pre-incubation caused KK1 cell death.  
 
   Insulin 100ng/mL  +DHT 1nM                     +DHT 10nM          +DHT 25nM 
   0    15    30   60     0   15    30   60               0   15    30   60     0    15   30   60    
   
       
 
Figure 2.19: Immunoblot showing DHT dose response. As the concentration of DHT used to 
pre-incubate the cells increases from 1nM to 25nM, the amount of phosphorylated Akt also 
rises. This is most evident at 30 and 60 minutes. ERK phosphorylation does not appear to 
increase with DHT concentrations. 
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2.4.2.4 Effect of androgen on human primary granulosa cells 
In order to establish whether the results seen in the KK1 cells were limited 
only to this cell line, the experiments were repeated using human granulosa-
lutein (GL) cells from two control patients with no evidence of PCOS. The 
results of these experiments mirrored those of the KK1 cells. DHT exposure 
for 48h enhanced insulin induced glucose uptake from the media and lactate 
production (figure 2.20) in primary human granulosa cells from 2 control 
patients (i.e without polycystic ovary syndrome, undergoing IVF for tubal 
infertility or sperm motility problems).  
 
 
Figure 2.20: Human granulosa lutein cells from two control patients: Patient 1 and 2, glucose 
uptake and lactate production. A greater depletion of glucose from the media and lactate 
production was seen in the granulosa cells that have been exposed to 10nM DHT for 48hours 
before the addition of insulin 100ng/ml in both patients. This change was seen maximally at 
48hours of insulin incubation and reached significance in the glucose uptake of Patient 1 but 
not Patient 2. 
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DHT pre-incubation also enhanced insulin induced phosphorylation of Akt in 
primary human GL cells from control patient 1, this is not so easy to see in 
control patient 2 [figure 2.21 (a) and (b)].  
 
 
    Insulin 100ng/ml            +DHT10nM 48hrs 
    0       15     30     60        0    15    30    60           (mins) 
 
 
 
 
 
Figure 2.21 (a) Human granulosa lutein cells from control patient, immunoblot: Patient 1, 
Effect of androgen on insulin action in control human granulosa cells. Western Blot showing 
increased phosphorylated Akt when cells from control women were pre-incubated for 48hours 
in DHT 10nM prior to the addition of insulin 100ng/ml. 
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Figure 2.21 (b): Human granulosa cells from control patient, immunoblot: Patient 2, Western 
Blot showing increased phosphorylated Akt when cells from patient 2 were pre-incubated for 
48hrs in DHT 10nM prior to the addition of insulin. 
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2.5  Discussion 
2.5.1  Effect of insulin in KK1 cells 
As in other insulin sensitive tissues such as adipose (188) and skeletal 
muscles (200) Akt and ERK phosphorylation in KK1 granulosa cells 
responded to insulin in a dose and concentration dependent manner.  
Using LY294002 and wortmannin, we have shown PI3K inhibition leads to 
impaired glucose uptake and metabolism, this was associated with 
impairment of insulin stimulated Akt phosphorylation, with no effect on insulin 
stimulated MAPK phosphorylation. This suggested that the PI3K pathway is 
important in glucose metabolism in KK1 cells. This is supported by studies in 
primary porcine granulosa cells that have also shown that wortmannin 
prevents insulin induced Akt phosphorylation and glucose uptake (201). This 
study used mRNA expression to show that the induction of insulin resistance 
using wortmannin, led to a reduction in GLUT4 mRNA and an increase in 
MAPK mRNA. 
We have also shown that GLUT4 was up-regulated to the cell membrane in 
response to insulin using immunocytochemistry. Live confocal imaging has 
allowed visualisation in real time of how GLUT4 constantly cycles from an 
intracellular compartment up to the cell surface and back down again within a 
few minutes of insulin exposure. 
2.5.2  Effect of insulin and androgen 
The most significant finding in this study was that exposure to androgen in 
vitro both in the short [48-106h] and long term [14 days] enhanced rather than 
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inhibited insulin-stimulated phosphorylation of Akt as well as glucose uptake 
and metabolism. This was reproduced in primary human granulosa cells.  
Interestingly, DHT alone also augmented Akt and ERK phosphorylation. 
Uptake of glucose from the media and production of lactate was highest in 
response to DHT (10nM) compared to both treatment with insulin 100ng/ml, 
and intrinsic glucose uptake and lactate production with no stimulation. 
Flutamide (1µmol), an androgen receptor antagonist, partially attenuated this 
response, thus supporting the effect of DHT alone. It also suggested that this 
response is stimulated via the AR, which we have demonstrated in KK1 cells 
using immunocytochemistry. This effect of insulin and androgen augmentation 
on glucose metabolism and Akt phosphorylation was also seen in two 
experiments done using primary human granulosa cells from ‘control’ women 
without polycystic ovary syndrome. 
Rather than the expected inhibition of insulin-stimulated glucose uptake and 
lactate production, this augmentation by androgens is a surprising result. The 
results suggest that the insulin resistance observed in granulosa cells from 
women with PCOS (71), can not be explained by direct exposure to androgen. 
The actions of DHT are particularly interesting as although testosterone can 
be aromatised to oestradiol by the enzyme aromatase, DHT, which is an 
irreversible end product of 5 !-reductase action on testosterone, can not. 
Our results correlate well with some recent work done in skeletal muscle. It 
has been shown that T and DHEA activate glucose metabolism-related 
signalling in skeletal muscle. The addition of T or DHEA to cultured primary 
rat skeletal muscle cells increased GLUT4 protein expression, 
phosphorylation of Akt and protein kinase C-$/% and also increased activity of 
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hexokinase and phosphofructokinase which are important glycolytic enzymes 
(202). It has also been shown in osteoblasts that testosterone accelerates Akt 
phosphorylation via the PI3K pathway, and that this effect is abolished using a 
PI3K inhibitor (203). 
However our results contrast with work done in adipocytes. Corbould et al. 
investigated the action of androgen on pre-adipocytes from healthy women 
treated with testosterone or anti-androgens for 48h. Maximal insulin 
stimulated glucose uptake (insulin 10nM) was impaired in the cells treated 
with testosterone 10nmol/L and 100nmol/L. This defect was attenuated by co-
incubation with anti-androgens. However testosterone treatment did not alter 
phosphorylation of insulin receptor substrate-1, Akt or MAPK. It did however 
impair atypical protein kinase C (PKC) isoform $ phosphorylation (188). PKC 
is activated by PI3K and PDK, and has been shown to be important in glucose 
metabolism (204). These different results may be due to tissue specific 
differences in insulin action on glucose metabolism, this has previously been 
reported in PCOS (131). 
Work done by Depi Bessi an MSc student in our laboratory using quantitative 
polymerase chain reaction, has shown that insulin up-regulates androgen 
receptor (AR) expression in passage number ten KK1 cells after 24h of 
treatment (unpublished). This result is consistent with findings in skeletal 
muscle cells which revealed that the insulin-like growth factor-I is able to 
induce AR gene expression (176). Preliminary data, using relative luciferase 
activity measurements in HeLa cells after co-incubation with androgen and 
insulin showed that insulin potentiates the effect of androgens by inducing AR 
gene expression (Patel et al., Endocrine Society annual conference, 2010, 
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abstract P1-350). Other evidence for cross talk between androgen signalling 
systems and growth factor/tyrosine kinase pathways comes from a study by 
Reinikainen et al. 1996, again in this experiment HeLa cells were co-
transfected with androgen receptor expression vector, and exposure to EGF 
and IGF1 increased AR dependent transactivation by 1.5 to 2.5 fold (205). 
Insulin like growth factor 1 (IGF-1) activates both AR serine phosphorylation 
and AR translocation into the nucleus of skeletal muscle cells, via PI3K and 
Akt phosphorylation. An increase in AR target gene expression (skeletal !-
actin) was also seen, suggesting that rapid non-genomic signalling may lead 
to an increase in gene transcription and translocation (176). One other 
mechanism of interaction between androgen and insulin could be via 
Forkhead transcription factor (FOXO-1 or FKHR). Liganded AR recruits 
FOXO1 to the AR promoter area, where it interferes with AR-DNA 
interactions. It acts as a co-repressor of AR. Insulin and insulin like growth 
factor 1 (IGF1) abolish this occupancy, and relieve this inhibiton (87). PI3K 
signalling which is activated by both insulin and IGF1 phosphorylates FOXO1. 
The phosphorylated FOXO1 is inactive and expelled from the nucleus (88). 
In some western blots a constitutive activation of protein phosphorylation, 
especially of Akt, is seen in KK1 cells. One explanation could be that KK1 
cells were created using Simian Virus 40 (SV40) T-antigen transgene and it 
has been reported that this T-antigen can bind to IRS1 and therefore activate 
Akt (206, 207).  
One anomaly noted was that glucose uptake from the media and lactate 
production, were only detected at 24-48h of exposure to substrates such as 
insulin although phosphorylation of Akt and ERK and also movement of 
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GLUT4 were seen within minutes. It was postulated that the COBAS machine 
was insensitive to small amounts of glucose uptake, and if time had permitted 
it was thought that the use of a second method to measure glucose uptake 
such as measurement of the uptake of radiolabelled glucose from the media 
would have been a sensitive method of monitoring small amounts of glucose 
taken up rapidly by KK1 cells. 
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3.1  Introduction 
3.1.1  Two cell two gonadotrophin concept  
In women, androgen is the main steroid made by thecal cells, and aromatase 
activity is highest in granulosa cells (39). It is generally assumed that 
interaction occurs between the two cell types in the follicle with LH stimulating 
androgen production from the thecal cells, which is then used by the 
granulosa cells to produce oestrogen, this is known as the two-cell two-
gonadotrophin concept (figure 1.3).  
3.1.2  Gonadotrophin signalling in the ovary 
The response of granulosa cells to LH and FSH is mainly mediated by cyclic 
adenosine monophosphate/ protein kinase A (cAMP/PKA) signalling. LH 
binds the LH receptor and FSH binds the FSH receptor both of which are 
transmembrane receptors. On binding the gonadotrophins both receptors 
stimulate the Gs protein (144). GDP bound to the !Gs subunit is exchanged 
for GTP and the !Gs-GTP subunit breaks off and binds with adenylate 
cyclase. This generates cAMP, which then binds the regulatory units of PKA. 
The complex then dissociates into 2 catalytic subunits and a regulatory 
subunit. The catalytic subunit then phosphorylates cAMP response binding 
proteins (CREM and CREB), which bind upsteam DNA regulatory elements 
called cAMP response elements. Genes such as those encoding the LH 
receptor and P450 aromatase are regulated by this method (figure 3.1). 
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Figure 3.1: PKA signalling. FSH binds to its receptor, causing Gs! subunit dissociation. 
Together with GTP, this complex directly activates adenylate cyclase (AC), leading to cAMP 
synthesis. PKA is activated by cAMP, which causes the dissociation of the catalytic subunit 
(C) from the regulatory subunit (R). The catalytic site can activate proteins by 
phosphorylation. cAMP production also leads to an intracellular rise of Ca2+. In the nucleus 
the catalytic subunit of the PKA phosphorylates (P) and activates transcription factors such as 
CREB and CREM, which then bind to CREs (cAMP response elements) preceding certain 
genes. Finally mRNA synthesis of primary response genes of FSH begins. Adapted from 
Simoni et al. 1997 (208). 
 
3.1.3  Gonadotrophin activation of other signalling pathways 
LH and FSH are classically believed to act via the PKA pathway, but there is 
evidence that other pathways such as the PKB and MAPK pathway are also 
stimulated by gonadotrophins (209, 210), illustrated in figure 3.2. Cyclic AMP 
(3#,5# cyclic adenosine monophosphate) is a second messenger and induces 
physiological responses such as growth and gene expression. These effects 
have been attributed to the binding of cAMP to cAMP-dependent protein 
kinase A (PKA).   However cyclic AMP may act to control diverse cellular 
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signalling pathways. A family of cAMP-binding proteins that exhibit both 
cAMP-binding and guanine nucleotide exchange factor (GEF) domains has 
been seen. These cAMP-regulated GEFs (cAMP-GEFs) bind cAMP and 
selectively activate the Ras superfamily guanine nucleotide binding protein 
Rap1A in a cAMP-dependent but PKA-independent manner (211, 212). 
cAMP-GEFI has been shown to regulate the activity of Rap1, which can 
activate B-Raf kinase, leading to activation of the ERK pathway.  
These cAMP-GEFs, by activation of Rap-1 and possibly other GTPases, are 
potential activators of PI3-K, a known target of Ras (213). Thus, cAMP may 
regulate specific members of the PKB and MAPK pathways by PKA-
independent as well as PKA-dependent mechanisms (214). 
FSH also activates serum and glucocorticoid inducible kinase (SgK), a 
member of the serine threonine protein kinase family. It is also a downstream 
target of PI3K in addition to PDK (215). 
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Figure 3.2:  Follicle-stimulating hormone (FSH) and insulin/insulin-like growth factor-1 
(IGF-1) signalling pathways operate in granulosa cells. FSH/LH and IGF-1 stimulate the 
proliferation and differentiation of granulosa cells. Common downstream targets of FSH and 
IGF-1 in granulosa cells include components of the PI3-kinase cascade that lead to the 
phosphorylation of protein kinase B (PKB) and serum and glucocorticoid-induced kinase 
(Sgk) as well as the transcription factor, Forkhead (FKHR), which is selectively expressed at 
high levels in granulosa cells of growing follicles. Adapted from Richards et al. 2002 (216). 
 
Gonadotrophins are also believed to enhance the activity of the p38 MAPK 
(139), and ERK pathways (140), as well as the PI3K (141) pathway, both 
pathways being involved in glucose metabolism and uptake (70, 142). PKA 
selective inhibitors inhibit the activation of these signalling pathways and 
target genes, suggesting a PKA dependent mechanism of PI3K and ERK 
activation (140, 143). The FSH mediated increase in cAMP has also resulted 
in up-regulation of the PI3K pathway (141, 214). Other evidence that FSH 
activates the PI3K pathway includes the fact that a PI3-kinase inhibitor 
LY294002 significantly decreases FSH stimulated glucose uptake in mouse 
cumulus oocyte complexes (70). 
Chapter 3 
 119 
3.1.4  Role of gonadotrophins in energy metabolism 
Oocytes depend primarily on energy metabolites derived from granulosa cells 
to allow growth and protein synthesis (92, 217, 218). Most studies concur that 
mouse ovarian follicles produce large amounts of lactate during growth and 
development and prefer a predominantly glycolytic mode of energy production 
to sustain growth and steroidogenesis. The rate of glycolysis is controlled by 
gonadotrophins. The amount of lactate produced suggests that ovarian 
follicles behave like solid tumours, predominantly metabolising glucose via 
glycolysis (98). This is supported by the observation that when oxidative 
phosphorylation is prevented using a TCA cycle inhibitor, follicles are still able 
to undergo normal development and steroidogenesis (99). 
The average glucose concentration of follicular fluid is 3.29mM, compared to 
a plasma glucose concentration of about 5mM (93). Human serum lactate 
concentrations range between 1.5-2mM (94), considerably lower than the 
average lactate level in follicular fluid of 6.12mM (93), which suggests lactate 
is produced locally in the follicle and secreted into follicular fluid. This is 
supported by the fact that gonadotrophins are known to stimulate glucose 
consumption and lactate production by cumulus cells (95). FSH also induces 
cumulus cell-enclosed mouse oocyte expression of the glycolytic enzyme 
hexokinase (96).  
In human granulosa-lutein cells, LH has been shown to have a dose 
dependent effect on lactate production in both women with normal and 
polycystic ovaries as shown in Figure 1.12 (71). 
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3.2  Aim 
Studies from Chapter 2 have shown the effect of insulin and androgen on 
PI3K and MAPK pathway activation, as well as glucose metabolism in KK1 
cells.  
The effects of FSH on glucose metabolism and activation of the PI3K and 
MAPK pathways (and the interaction with androgen) was studied using KK1 
cells transfected with the FSH receptor. 
 
Specific aims were: 
1. to explore the effect of FSH on glucose uptake and metabolism   
2. to define the signalling pathways involved and to investigate the effect 
of androgen, on FSH mediated signalling 
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3.3   Materials and Methods 
3.3.1  Transfection of KK1 cells with the FSH receptor 
KK1 cells are generally poorly responsive to gonadotrophins. FSH receptor 
expression is typically maintained for up to 10 passages while LH receptor 
expression is typically maintained up to 20 passages (189). However, if the 
FSH receptor is transfected into KK1 cells, it can become a suitable granulosa 
cell line to demonstrate the effects of FSH and androgen on glucose 
metabolism of granulosa cells. 
A vial of frozen KK1 cells, which had previously been stably transfected with a 
plasmid expressing human FSH receptor (FSH-R) using the lipofection 
method, was used for the FSH induction experiments. The construction of the 
wild type human FSH-R expression plasmids is described by Aittomaki et al. 
1995, and Gromoli et al. 1992 (219, 220). FSH receptor plasmid transfection 
was achieved with a total of 6µg of expression plasmid with 0.6µg of 
neomycin resistance plasmid pPGKneobpA. After transfection, resistant 
colonies were picked, expanded and screened for FSH receptor mRNA (221). 
The lipofectamine transfection method is described in section 2.3.13.3.  
3.3.2  Cell culture and splitting cells 
Cells were revived from frozen cell stocks as described in section 2.3.2. All 
culture dishes (Nunc, VWR) and flasks (TPP, Helena Biosciences) were 
suitable for tissue culture and all serological plugged pipettes were purchased 
from Costar. All experiments were carried out in a Class II flow cabinet and 
cells were grown at 37°C in 5% CO2. KK1 cells were grown in Dulbeco’s 
modified medium (DMEM-F12) supplemented with 10% heat inactivated foetal 
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calf serum (FCS), 50 U/ml penicillin/streptomycin (Invitrogen, Gibco) and 200 
"M glutamine (Invitrogen, Gibco).  Cells were passaged thrice weekly by 
incubating with 5 ml of 0.25% trypsin/EDTA mix (T3924, Sigma) for 3 minutes. 
The cells were re-suspended in 5 ml of DMEM-F12 supplemented with 10% 
heat inactivated FCS, 50 U/ml penicillin/streptomycin (Invitrogen, Gibco) and 
200 "M glutamine (Invitrogen, Gibco) and plated to the required density. Cells 
were grown in T75 flasks until confluent and some were frozen down as 
described in section 2.3.4.  
3.3.3  Cell counting 
Cells were counted using disposable haemocytometers (Hycor Biomed) using 
a light microscope (Olympus CK2). The experiments were repeated 2-3 times 
to overcome the fact that cell culture experiments can produce variable results 
on different occasions. For each experiment the KK1 cells were plated in 
triplicate.  
3.3.4  Cell culture, protein isolation and expression 
For protein expression experiments, cells were cultured in 6 well plates at a 
density of 1.4 x 106 cells/well, in 3mls of serum-supplemented medium 199. 
For glucose uptake and metabolism, cells were plated in 96 well plates at a 
density of 2 x 104 viable cells/well in 200µl of serum-supplemented medium 
199. For each experiment, the KK1 cells were plated in triplicate. To those 
KK1 cells being exposed to androgen, Dihydrotestosterone (DHT) was added 
at this stage. The DHT was dissolved in ethanol (appendix 3), and the ethanol 
was tested to ensure it had no effects at the concentrations used. After 24 
hours incubation at 37°C in 5% CO2, the medium was removed and cells 
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washed thoroughly with PBS. They were then incubated in serum free DMEM-
F12 +/- 10nM DHT (appendix 3). FSH 20ng/ml (dissolved in PBS +0.1% 
bovine serum albumin) was added for various amounts of time (appendix 3). 
Cells were lysed in 100 µl ice cold RIPA buffer directly on the plate, with 10 µl 
protease inhibitors, 10 µl aprotinin (MP Biochemicals) and 10 µl sodium 
orthovanadate.  Using a cell scraper, the lysates were transferred into 
eppendorfs and pelleted at 13 000 x g in a microfuge for 5 minutes at 4 °C 
and pellets were discarded and the supernatant collected.   30 µl Laemlli lysis 
buffer (see appendix 2) was added to each western blotting lysate.  Samples 
were stored at -20 °C. The wells of the gel were each loaded with 2-3 µl 
standard loading buffer and then 15 µl supernatant was loaded on a Bis-Tris 
NuPAGE pre cast polyacrylamide gel (Invitrogen) or a self cast gel (appendix 
2). 5µl of a pre stained standard ladder was also loaded (Invitrogen).  
3.3.5  Western Blotting 
Gels were run using a wet-blotting system, X cell Surelock Mini-Cell system. 
The gels were then transferred using a semi-dry transfer system. 
Polyvinylidene fluoride (PVDF) membrane (Thermo Scientific), was cut to the 
size of the gel and soaked in ethanol or methanol for membrane activation. 
Alternatively nitrocellulose membrane (Whatman) was used, which did not 
require prior activation. The transfer sandwich was then assembled in the 
following way: transfer sponge, followed by two sheets of whatman 
chromatography paper, the PVDF membrane, the gel, a further two sheets of 
whatman and finally another transfer sponge. The whole sandwich of layers 
was soaked in a dish filled with transfer buffer and a roller was rolled over the 
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sandwich to remove trapped air. The apparatus was closed into the transfer 
machine and proteins were then transferred for 3.5h at 200mA.          
3.3.6  Immunoblot analysis 
The membrane was first stained with ponceau to check protein transfer, and 
equal loading. This was then washed off with water. The membrane was 
blocked with 5% skimmed milk and 1% 100mM sodium orthovanadate in 10% 
diluted 10x TBST buffer solution (Tris Buffered Saline with Tween) (blocking 
solution) for 15min at room temperature. Primary antibodies (appendix 1) 
were diluted in blocking solution and incubated with membranes overnight at 
4°C. Blots were washed and incubated with the appropriate secondary 
antibody (appendix 1), for 1 hour at room temperature.  
Signal was developed using ECL western blotting detection kit, and blots were 
then exposed to Kodak blue sensitive film.  For the detection of total AKT and 
MAPK protein, membranes were stripped before re-probing. The following 
polyclonal antibodies were all obtained from New England biolabs (UK) LTD, 
Akt Ab, phospho-Akt (Ser473) Ab, phospho-Fox01 (Thr24)/Fox03a (Thr32), 
p42/44 phospho MAPK, p42/44 MAPK. 
3.3.7  Measurement of lactate production and glucose uptake 
Individual 3-µl aliquots of culture medium from the experimental and control 
incubation drops were collected using a 10µl pipette and diluted 1:200 for 
glucose analysis an 1:400 for lactate analysis, with a 5µM lactate and 2µM 
pyruvate solution. All samples were stored at -70oC until analysis with the 
COBAS bioanalyser as described in section 2.3.11. 
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3.3.8  Progesterone Measurements 
Progesterone levels in the spent medium were determined using the Abbott 
ARCHITECT i2000w automated Analyzer, which uses a chemiluminescent 
immunoassay and measures progesterone in nanomolar concentrations. 
Individual 3-µl aliquots of culture medium from the experimental and control 
incubation drops were collected using a 10µl pipette and diluted 1:100 with 
serum free medium 199. Assays were performed in the Clinical Chemistry 
Laboratory, Hammersmith Hospital with the help of Dr Mandy Donaldson. 
3.3.9  Statistical analysis 
Statistical analyses were performed using InStat 3.0a for Macintosh Graph 
Pad, San Diego, CA. Graphs were produced using GraphPad Prism Version 
5.0. The experiments were repeated 2-3 times to overcome the fact that cell 
culture experiments can produce variable results on different occasions 
However the statistics were calculated using one experiment in which the 
cells were plated in triplicate. Non parametric analysis was performed 
throughout as we were unable to calculate the normal distribution using three 
values.  
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3.4  Results 
3.4.1   Effects of FSH and androgens on glucose metabolism  
Addition of FSH 20ng/ml to KK1 cells transfected with the FSH receptor did 
not significantly increase either glucose uptake from the medium or lactate 
production. DHT 10nM alone as before did increase glucose metabolism 
significantly (<0.01, Kruskal-Wallis). But the addition of FSH did not augment 
the response to DHT (figure 3.3). 
 
Figure 3.3: Effect of FSH and androgen on glucose uptake and metabolism. Addition of 
FSH 20ng/ml to KK1 cells transfected with the FSH receptor did not significantly increase 
glucose uptake from the media or lactate production. DHT 10nM alone produced a 
significantly higher glucose uptake from the medium (p<0.01, KW) and lactate production 
(p<0.01, KW). FSH 20ng/ml did not augment the effect of DHT.  
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3.4.2  Effects of FSH and androgen on glucose metabolic 
pathways 
Akt was phosphorylated in response to FSH 20ng/ml (dose chosen after dose 
response experiments shown in figure 3.7 and 3.8). It was activated within 15 
minutes. Pre-incubation for 1 hour with the PI3K inhibitor, LY294002, 
appropriately inhibited this response (figure 3.4). Of interest is that 
phosphorylated Akt at time zero was also abolished by LY294002 which 
suggests that there is some constitutive Akt phosphorylation in the absence of 
FSH.  
 
 
 
     0  15  30  60  4h 24h              0   15  30  60  4h 24h      mins 
 
    Akt 
 
Figure 3.4:  Immunoblot: FSH 20ng/ml effect on PI3K. KK1 cells transfected with the FSH 
receptor. FSH produced a time dependent increase in phosphorylated Akt which was 
appropriately inhibited by PI3K inhibitor LY294002. 
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FSH 20ng/ml also activated the MAPK pathway in a time dependent manner 
(figure 3.5), as expected this response was not affected by PI3K inhibitor 
LY294002 (figure 3.6). 
 
 
 FSH 20ng/ml 
   0         5         15        30      60           mins 
 
Figure 3.5: Immunoblot, FSH 20ng/ml effect on MAPK. KK1 cells transfected with the FSH 
receptor demonstrated a time dependent increase in ERK phosphorylation in response to 
FSH 20ng/ml. 
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Figure 3.6: Immunoblot, FSH effect on MAPK unaffected by LY294002. KK1 cells 
transfected with the FSH receptor demonstrated a time dependent activation of 
phosphorylated ERK in response to FSH 20ng/ml, which as expected was unaffected by the 
presence of an inhibitor of the PI3K pathway LY294002 
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Two doses of FSH were compared, although there may be a slightly greater 
amount of Akt phosphorylation (figure 3.7) and a greater amount of ERK 
phosphorylation (figure 3.8) at FSH 20ng/ml compared to FSH 2ng/ml this is 
not very clear from our immunoblots. 
 
 
 
Figure 3.7: Immunoblot; Effect of different FSH concentrations on PI3K. In KK1 cells 
transfected with the FSH receptor, two FSH concentrations were compared; 2ng/ml and 
20ng/ml. It is not clear if FSH 20ng/ml produced a greater amount of Akt phosphorylation 
compared to FSH 2ng/ml.!!
 
 
 
 
Figure 3.8: Immunoblot; Effect of different FSH concentrations on MAPK. In KK1 cells 
transfected with the FSH receptor, FSH 2ng/ml produced no detectable effect. FSH 20ng/ml 
stimulated phosphorylation of ERK. 
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Unlike the results from Chapter 2, which showed insulin and androgen 
together had a synergistic effect on PI3K activation and Akt phosphorylation, 
the action of FSH 20ng/ml on both Akt and ERK phosphorylation was 
unaffected by DHT (10nM) pre-incubation for 48 hours (figure 3.9, 
experiments performed by Pavidra Sivanandarajah, BSc student, under 
supervision). 
 
a.  
 
b.  
 
Figure 3.9: Immunoblot; FSH induced signalling in response to androgen pre-incubation. (a) 
Akt was phosphorylated in response to FSH 20ng/ml in a time dependent manner. It was up-
regulated by 5 minutes and continues to be stimulated at 60 minutes. This is not affected by 
DHT (10nM) pre-incubation for 48h. (b) ERK was maximally stimulated by 15 minutes.   
 
Progesterone concentration in the medium measured in nmol/L was 
undetectable in the presence or absence of FSH 20ng/ml +/- DHT 10nM pre-
incubation (results not shown). 
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3.5  Discussion 
FSH did not increase glucose metabolism significantly in these experiments, 
but nevertheless did increase phosphorylated Akt in a time and dose 
dependent manner. This may be due to a failure of KK1 cell transfection 
however this seems unlikely given Akt was phosphorylated in response to 
FSH. It may be to do with FSH receptor transfection density, this was not 
visualised using immunocytochemistry. Or there may be a minimal effect on 
glucose metabolism that has not been picked up using the COBAS 
bioanalyser. Different doses of FSH were used in glucose metabolism but no 
significant differences were seen (data not shown). Interestingly, and in 
contrast to the effect of insulin action, pre-incubation with DHT had no 
significant effect on FSH stimulated PI3K or MAPK phosphorylation or 
glucose metabolism.  
Previous studies have investigated lactate accumulation but not glucose 
uptake of granulosa cells in the rat (95) and in humans (94). Unlike the results 
of our study, androgen was shown to enhance FSH stimulated lactate 
production after 48h of incubation in rat granulosa cells (95). Androgen and 
FSH had a synergistic effect on lactate accumulation, but androgen had no 
effect alone. However, the doses used in our study were physiological, while 
the doses used in the rat study were 5 fold higher (100ng/ml) for FSH and 10 
fold higher (100nM) for DHT.  
Harlow et al. used primary human granulosa cells exposed to either FSH 
30ng/ml alone or FSH 30ng/ml and testosterone 0.1µM, to assess lactate 
accumulation and therefore a measure of glycolysis.  FSH significantly 
increased glucose metabolism of human granulosa cells prior to the LH surge. 
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The effects of androgen did not give clear results. Testosterone 0.1 µM was 
only shown to have a synergistic effect with FSH on glucose metabolism of 
granulosa cells from one out of three subjects prior to LH surge, but no 
response was seen in granulosa cells from post the LH surge (94). 
In certain experiments a constitutive activation of Akt phosphorylation is 
present. This could be because KK1 cells were created using Simian Virus 40 
(SV40) T-antigen transgene and it has been reported that this T-antigen can 
bind to IRS1 and thus activate Akt (206, 207). 
We have demonstrated FSH 20ng/ml induces MAPK phosphorylation, as 
judged by an increase in phosphorylated ERK within 5 minutes, and peak at 
15 minutes. This is supported by other data showing FSH stimulates 
phosphorylation of MAPK in rat granulosa cells, with peak activity between 
10-20 minutes after FSH addition before decreasing  
(140). One of the limitations of our study includes the fact that we cannot 
correlate this MAPK phosphorylation with progesterone production.  
Multiple attempts were made to measure progesterone production in KK1 
cells. Previous reports of progesterone production results were obtained using 
cells of passage 8 which were unavailable to us (189). Our experiments using 
KK1 cells of passage 10 or higher showed undetectable or very low 
progesterone levels in response to FSH 20ng/ml, insulin 100ng/ml and DHT 
10nM. This suggests a de-differentiation of KK1 cells with respect to 
steroidogenesis at this passage level. Although it may also be due to the fact 
that the Abbott analyser, which is used clinically in the biochemistry 
department of Hammersmith hospital, measures progesterone concentrations 
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in the blood in nanomolar concentrations, which was not sensitive enough to 
detect the amounts produced by the KK1 cells. 
Prior to receiving the FSH receptor transfected cells some initial experiments 
were done using forskolin (data not shown). Forskolin activates cAMP and 
therefore acts to mimic the action of LH and FSH on the PKA pathway. 
Phosphorylated Akt and ERK are activated by both insulin 100ng/ml and 
forskolin 10µM in a time dependent manner. It appears that the addition of 
insulin and forskolin together produces an augmented response in 
phosphorylated Akt expression. Phosphorylated FOXO 03/01, a downstream 
marker of PI3K pathway is activated in a similar pattern to AKT 
phosphorylation but after a short time delay. Forskolin did not however 
activate glucose uptake or metabolism. 
The main disadvantage of working with the KK1 cell line was the likelihood of 
changing phenotype over time as the passage number grows. As always with 
cell line work it is important to appreciate that we are unsure how closely 
these KK1 cells represent primary mouse granulosa cells. But they provide a 
good model on which to experiment. 
Overall transfected KK1 cells are not ideal for studying the effect of FSH on 
glucose metabolism, there is a poor response compared to primary cells, but 
there is an effect of FSH on signalling, albeit unaffected by androgen. These 
experiments could be repeated using primary human granulosa cells from 
women without PCOS (control patients), as in Chapter 2 to confirm whether or 
not an effect is present. 
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Chapter 4 
Defining insulin signalling pathways in primary granulosa-lutein cells in 
women with polycystic ovary syndrome 
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4.1  Introduction 
4.1.1  Insulin resistance, mechanisms and complications 
Insulin resistance is an inability of a known quantity of exogenous or 
endogenous insulin to increase glucose uptake and utilisation as much as it 
does in the normal population. The main consequences are a reduced ability 
of insulin to suppress hepatic gluconeogenesis and stimulate peripheral 
glucose uptake. It would be expected that circulating glucose levels would rise 
in this state of insulin resistance, however provided " cell function of the 
pancreas is adequate, insulin secretion increases to overcome this insulin 
resistance and glucose levels are normalized. Compensatory high insulin 
levels are therefore the hallmark of insulin resistance.  Insulin resistance plays 
a major role in the development of type 2 diabetes, but it is important to note 
that other factors such as defective insulin secretion play an equally important 
role. 
In the UK 4.26% of the population have diagnosed diabetes (Quality and 
Outcomes Framework 2010) and an estimated further 3.1 % of men and 1.5% 
of women have undiagnosed diabetes (Health Survey for England 2003). It is 
estimated that by 2020 there will be 250 million people affected by type 2 
diabetes mellitus worldwide (222). 
Type 2 diabetes has many complications including cardiovascular disease 
such as stroke and myocardial infarction and also microvascular disease such 
as retinopathy, nephropathy and neuropathy. Women with PCOS have 
reduced insulin sensitivity (11) and a 3-4 times greater risk of developing type 
2 Diabetes (119, 120). Insulin resistance and subsequent hyperinsulinaemia 
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are found in 50-70% of PCOS women (6). Interestingly insulin resistance is 
most prevalent in women with PCOS who have both androgen excess and 
anovulation. Whereas weight matched women with ovulatory cycles, who are 
equally hyperandrogenaemic have normal insulin sensitivity and serum insulin 
concentrations (figure 1.10). 
Insulin resistance has been implicated in the mechanism of anovulation seen 
in PCOS patients. Therapies that lower insulin levels such as insulin 
sensitising drugs and weight loss significantly improve menstrual cyclicity, 
fertility, and hyperandrogenism, in both lean and obese patients, which 
suggests insulin resistance plays an important role in the aetiology of 
anovulation in PCOS (122) (123). 
Mechanism of insulin resistance in PCOS 
The activation of the PI3K signalling pathway by insulin stimulates the 
metabolic functions of insulin, such as glucose uptake and glycogen 
synthesis. However there is a divergence of the insulin signalling pathway 
following activation of the insulin receptor. The insulin receptor once activated 
can activate the MAPK signalling pathway, which stimulates certain mitogenic 
actions of insulin such as cell metabolism, growth, differentiation and 
steroidogenesis (figure 1.8). Insulin resistance in PCOS appears to be 
selective affecting metabolic but not mitogenic activity of insulin (71, 72). In 
insulin resistant states when pancreatic " cells are continuing to compensate, 
insulin levels rise overcoming insulin resistance and maintaining glucose 
levels. However the hyperinsulinaemia can lead to an overstimulation of 
mitogenic actions. This selective insulin resistance may explain how insulin 
acting through the insulin receptor can stimulate the overproduction of 
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androgen from thecal cells in women with PCOS, despite resistance to the 
effect of insulin on glucose metabolism (15, 73). MAPK activity is not reduced 
in type 2 diabetes, and it has been suggested that this may provide a 
mechanism for some of the detrimental effects of chronic high insulin levels 
on cell growth in vessels (104, 105).  
The exact mechanism of reduced insulin sensitivity in PCOS is unknown as 
explained in section 1.8.5 of Chapter 1. Potential areas of disturbance in the 
insulin signalling pathway are highlighted in Table 1, adapted from Diamanti-
Kandarakis et al. (124).  
Abnormalities of the insulin receptor itself are rare causes of PCOS and much 
evidence points to a post-receptor defect in insulin signalling pathways (3, 7, 
127).  It is likely that the signalling defect in insulin resistance seen in PCOS is 
located proximally in the pathway involving serine phosphorylation of the 
insulin receptor (IR) and/or insulin receptor substrates 1and 2 (IRS1/2) (3, 
127).  
Another feature of insulin target tissues in women with PCOS is that 
expression of the insulin-dependent glucose transporter GLUT4 is abnormally 
low. This has been shown in adipocytes from subjects with PCOS (67) as well 
as in skeletal muscle from type 2 diabetics (68). 
The mechanism of insulin resistance in the ovary also appears to involve a 
post receptor abnormality leading to a selective signalling defect. The effect of 
insulin on glucose metabolism in granulosa-lutein cells from women with 
anovulatory PCOS is attenuated while the steroidogenic response to insulin is 
preserved (71) (figure 1.11).  
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4.2  Aim 
The overall aim of this project is to investigate the mechanism of insulin 
resistance in polycystic ovary syndrome 
 
The specific aims were 
In granulosa lutein cells from women with normal ovaries (control), those with 
endogenous androgen excess i.e women with polycystic ovary syndrome who 
continue to ovulate (ovPCO) and those who have irregular or anovulation 
(anov PCO) 
1. to characterise the time and dose dependent effects of insulin action in 
glucose uptake and lactate accumulation in granulosa lutein cells in 
culture.  
2. to assess insulin action on progesterone production  
3. to assess insulin action on key phospho-proteins in the PI3K and 
MAPK signalling pathways 
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4.3  Materials and Methods 
4.3.1  Patients 
Granulosa cells were obtained, with informed, written consent, at the time of 
egg collection for IVF at Hammersmith Hospital from 31 women: 12 with 
normal ovaries, 8 with ovulatory PCOS (ov PCO) and 11 with anovulatory 
PCOS (anov PCO). These granulosa cells are isolated from the fluid that is 
collected from eggs in the ovary for IVF and are usually thrown away.  Ethical 
approval for this project was sought from the Hammersmith Research Ethics 
Committee (REC) and obtained in Feb 2009 (reference number: 
08/H0707/152) 
Polycystic ovaries were defined using ultrasonography, by the presence of 
two or more of the following; 10 or more follicles 2-10mm in diameter, 
increased stromal density or volume, enlarged ovarian volume. Patients with 
polycystic ovaries and a history of irregular menstruation or amenorrhoea 
were classified as anov PCO. Those with a cycle length of between 21 and 35 
days (but with no more than a 4 day variation between cycles) were classified 
as ov PCO. Clinical hyperandrogenism was defined as the presence of acne, 
hirsutism (Ferriman-Galway score &8) or alopecia. All 11 anov PCO patients 
and 6 of 8 ov PCO patients satisfied the Rotterdam criteria for diagnosis of 
PCOS (8). 
The indications for IVF were as follows. In the normal ovary group, male 
infertility (n=7), tubal disease (n=2), unexplained (n=3). In the anov PCO 
group, anovulation resistant to ovulation induction (n=11), in addition there 
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was tubal disease in 1 case and male infertility in 4 cases. In the ov PCO 
group male infertility (n=6), unexplained (n=2). 
4.3.2  Blood samples and follicular fluid aspiration 
Peripheral venous blood for LH, FSH and oestradiol (E2) were taken between 
Day 3-6 of a pre-treatment assessment cycle from women with regular cycles, 
and at random in women with anov PCO who had oligo or amenorrhoea.  
Insulin resistance was calculated from fasting plasma glucose and fasting 
serum insulin levels taken on the morning of the IVF procedure, by means of 
the Homeostatic Model Assessment (HOMA) algorithm (223). For this 
purpose, a mean average of two fasting glucose samples, obtained with a 30 
minute collection interval, was used. Type 2 diabetes is associated with 
peripheral insulin resistance, elevated hepatic glucose production and 
inappropriate insulin secretion. The HOMA model is most useful for large 
scale population studies, but is fairly good as a description of individual insulin 
resistance as we have used here.   
Testosterone (after extraction) and sex hormone binding globulin (SHBG) 
were also taken on the morning of the procedure and measured by 
immunoassay as previously described (48, 224) (Table 3). 
Pituitary-gonadal suppression was achieved using GnRH analogue buserelin 
[(Suprecur, Sanofi-Aventis) 0.5ml sc daily for 1-3 weeks until gonadotrophin 
production is down-regulated]. Following this, superovulation of patients was 
achieved using recombinant FSH (Gonal-F, Serono). The anovulatory PCOS 
patients received the lowest doses of recombinant FSH, followed by the 
ovulatory PCOS patients in order to avoid ovarian hyperstimulation syndrome. 
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PCOS patients are at higher risk of developing this complication with IVF 
(table 3). Ultrasonography and serum E2 levels were used to monitor the 
patient’s response to FSH. When three or more follicles reached a diameter of 
17mm and E2 levels reached 3000pmol/L, human chorionic gonadotrophin 
(hCG) 10000IU (Ovitrelle 250mcg. Serono) was administered. 32-36h after 
hCG administration, transvaginal follicle aspiration was performed. Oocytes 
were recovered and the follicular fluid aspirations from the left and right side 
were pooled and collected in sterile centrifuge tubes (TPP). 
4.3.3 Human granulosa lutein cell collection, preparation and 
culture 
 
Figure 4.1: Flow diagram showing experimental protocol for human primary granulosa-lutein 
cell separation from red blood cells (RBCs), and preparation for experimentation. See text for 
description of percoll gradient preparation. 
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All procedures were carried out under sterile conditions in a fume hood using 
aseptic tissue culture techniques. To enable removal of serum and reduce 
follicular fluid volume, samples were centrifuged at 200g for 5 minutes using a 
Centra CL3 (Thermo IEC) centrifuge. After discarding the clear follicular fluid 
supernatant, the pellets were then transferred into one 50mL centrifuge tube. 
If the volume of flush was too large, the pellets were centrifuged again and the 
process above repeated. The supernatant was then discarded and the cell 
solution volume was made up to 8mL with PBS.  
In order to separate off any remaining red blood cells (RBCs) the follicular 
fluid mixture was gently layered over a percoll gradient. An autoclaved glass 
pipette was filled with cells and pipetted into 15mL centrifuge tubes containing 
8mL pre-prepared shaken Percoll solution (8.9mL of Percoll [GE Healthcare], 
1mL 10xM199, 100mL NaHCO3 7.5%, 10mL M199 [all from Invitrogen]). The 
45% Percoll solution was filtered before use and shaken to produce bubbles, 
which provided a gentle surface for the cells to land on. The tubes were then 
centrifuged at 400g for 20-30min to isolate the granulosa-lutein cells; red 
blood cells separated off and sank to the bottom of the tube. If the cell mixture 
was seen to be particularly bloody a greater number of test tubes of percoll 
gradients were used.  
Granulosa lutein cells were then aspirated from the Percoll/PBS interface with 
an autoclaved glass pipette and washed twice, using 10% serum 
supplemented M199. Cell number and viability were determined using a 
Trypan Blue exclusion test (Sigma). The experimental protocol is summarised 
in figure 4.1.  
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For the glucose, lactate and progesterone assays, 20 x 104 cells were plated 
into 96 well plates, and supplemented with 200µl fetal bovine serum 
supplemented medium 199. Each experimental condition was repeated in five 
replicates. Cells were placed centrally and surrounding wells filled with sterile 
PBS to avoid evaporation. After 24h incubation at 37°C in 5% CO2, serum 
containing medium was removed and the cells washed with PBS. They were 
then incubated for a further 24h with 200µL serum free Medium 199 with or 
without varying doses (1,10,100ng/ml) of Insulin (Sigma).  
For the protein expression results, 50 x 104 cells were added to 24 well plates 
and each well was supplemented with 1mL serum supplemented media. After 
24h incubation at 37°C in 5% CO2, the medium was removed and cells 
washed with PBS. They were then incubated for a further 24h with 1mL serum 
free Medium 199.  The cells were the incubated with or without varying doses 
(10,100ng/ml) of Insulin (Sigma) for 5,10 or 15 minutes. There were only 
sufficient cells for one well per treatment. 
Cells were then harvested in RIPA buffer, with aprotinin (MP Biochemicals, 
Cambridge, UK), protease inhibitors and sodium orthovanadate (Sigma). The 
samples were then centrifuged at 12000xg for 5 minutes at 4°C and 
supernatant collected. Laemmli sample suffer was added, and 20 µl loaded on 
a Bis-Tris NuPAGE pre cast polyacrylamide gel (Invitrogen). 5µl of a pre 
stained standard ladder was also loaded (Invitrogen) (figure 4.2).  
4.3.4  Western Blotting 
Gels were run using a wet-blotting system, X cell Surelock Mini-Cell system. 
The gels were then transferred using a semi-dry transfer system. 
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Polyvinylidene fluoride (PVDF) membrane (Thermo Scientific, p/a Perbio 
Science UK, Northumberland, UK), was cut to the size of the gel and soaked 
in ethanol or methanol for membrane activation. The transfer sandwich was 
then assembled in the following way: transfer sponge, followed by two sheets 
of Whatman chromatography paper, the PVDF membrane, the gel, a further 
two sheets of Whatman paper and finally another transfer sponge. The whole 
sandwich of layers was soaked in a dish filled with transfer buffer and a roller 
was rolled over the sandwich to remove trapped air. The apparatus was 
closed into the transfer machine and proteins were then transferred for 3.5h at 
200mA.          
4.3.5  Immunoblot analysis 
The membrane was blocked with 5% skimmed milk and 1% 100mM sodium 
orthovanadate in 10% diluted 10x TBST buffer solution (Tris Buffered Saline 
with Tween) (blocking solution) for 15min at room temperature. Primary 
antibodies (appendix 1) were diluted in blocking solution and incubated with 
membranes overnight at 4°C. Blots were washed and incubated with near 
infrared (NIR) fluorophore labelled secondary antibodies were then used at a 
dilution of 1:10000 for 1 hour, prior to visualisation using the Odyssey infrared 
imaging system (LI-COR Biosciences).  
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Figure 4.2: Flow diagram illustrating western blot protocol 
4.3.6  Quantification of protein concentrations 
ImageJ (Image processing and analysis in Java), was downloaded from the 
following website http://rsbweb.nih.gov/ij and was used to analyse the 
immunoblots. ImageJ and its Java source code are freely available and in the 
public domain. No license is required. It was developed at the Research 
Services Branch (RSB) of the National Institute of Mental Health (NIMH), part 
of the National Institutes of Health (NIH).  
Each western jpeg file was dragged onto the ImageJ icon. The image was first 
converted to grayscale. The background was then subtracted. The next step 
involved selection of the measurements required, area, mean gray value, and 
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integrated density. Followed by selection of pixels as the unit of length 
required. 
The colours on the image were then inverted, with the dark areas becoming 
light, and the light areas dark. As outlined above, this has the benefit of 
making the measured values for bands increase with increasing protein 
expression. Freehand selection was then chosen to draw a line around the 
boundary of the first band, using judgment about where the edges of the band 
are, and what is background noise. The enclosed area selected was then 
measured. The integrated density was calculated from the multiplication of the 
area by the mean gray value for each band. This was then repeated for each 
phosphorylation band and each control (GAPDH or total protein) and the 
results copied into an excel spreadsheet. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is one of the key 
enzymes involved in glycolysis. It catalyzes the reversible oxidative 
phosphorylation of glyceraldehydes-3-phosphate. GAPDH is constitutively 
and stably expressed in almost all tissues at high level. It is a well-established 
“housekeeping” protein and is widely used as a loading control for protein 
normalization in western blotting (225). Insulin can stimulate GAPDH mRNA 
expression but this occurs over hours not minutes (226). 
The integrated density of the phosphorylated protein band was then divided 
by the integrated density of the GAPDH or total protein band, to correct for 
any loading differences or cell/protein concentration differences between wells 
of the experiments.   
Chapter 4 
 147 
It was then necessary to investigate whether the amount of phosphorylated 
protein was affected by the treatments administered i.e. insulin 10ng/ml or 
100ng/ml. This was done by dividing the newly calculated loading protein 
concentration corrected integrated densities of the phosphorylated protein 
bands by the amount of phosphorylated protein seen in the control wells, 
unexposed to treatment for the same time points. Protocol summarised in 
figure 4.3. 
 
Figure 4.3: Flow chart detailing the protocol used to quantify amount of protein 
phosphorylation using image J software. (Integrated density=ID) 
 
4.3.7  Measurement of lactate production and glucose uptake 
This has previously been described in Chapter 2, section 2.3.11. Individual 3-
µl aliquots of culture medium from the experimental and control incubation 
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drops were collected using a 10µl pipette and diluted 1:200 for the glucose 
assay and 1:400 for the lactate assay, with a mixture of 5µM lactate and 2µM 
pyruvate solution. All samples were stored at -70oC until analysis with the 
COBAS bioanalyser. 
4.3.8  Progesterone measurements 
Progesterone levels in the spent medium were determined using the Abbott 
ARCHITECT i2000w automated Analyzer, which uses a chemiluminescent 
immunoassay. Individual 3-µl aliquots of culture medium from the 
experimental and control incubation drops were collected using a 10µl pipette 
and diluted 1:100 with serum free medium 199. Assays were performed in the 
Clinical Chemistry Laboratory, Hammersmith Hospital with the help of Clinical 
Biochemist Dr Mandy Donaldson. 
4.3.9  Statistical analysis 
Experiments to measure lactate, glucose and progesterone were done in five 
replicates. As there was considerable variability in basal values between 
subjects, the basal results of each patient prior to treatment was subtracted 
from results from each patient at 48h. The results of all the patients within a 
particular group (normal, ov PCO and anov PCO) were then combined and 
expressed graphically as mean +/- SEM. Statistical analysis was performed 
using Instat (Version 3 for Macintosh) and Prism software packages 
(Graphpad software, San Diego, CA, USA). 
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 Normal 
(n=12) 
0v PCO 
(n=8) 
Anov PCO 
(n=11) 
One way 
Anova  
(p value) 
Normal vs 
anov PCO 
(p value) 
Normal vs 
ov PCO 
(p value) 
Anov PCO 
vs ov PCO 
(p value) 
Age (years) 33.6 (1.6) 32.8 (1.1) 28.7 (1.6) 0.06    
BMI (kg/m2 22.6 (1.1) 24.2 (1.2) 25.5 (1.2) 0.19    
LH (IU/L) 4.6 (0.4) 4.8 (0.7) 11 (1.7) 0.0002 <0.001 >0.05 <0.01 
FSH (IU/L) 6.8 (0.5) 4.7 (0.6) 5.2 (0.5) 0.02 >0.05 <0.05 >0.05 
Fasting Insulin (mU/L) 7.6 (0.84) 5.7 (1.2) 13 (2)  0.0042 <0.05 >0.05 <0.01 
Fasting glucose (average,mmol/L) 4.7(0.1) 4.5 (0.1) 4.4 (0.1) 0.2    
HOMA-IR 1 (0.1) 0.74 (0.2) 1.6 (0.2) 0.0049 <0.05 >0.05 <0.01 
Testosterone (nmol/L) 2.2(0.2) 2.8 (0.2) 3.5 (0.5) 0.0475 <0.05 >0.05 >0.05 
SHBG (nmol/L) 111.6 (9.2) 125.9 (17.4) 90.8 (15.3) 0.2308    
Oestradiol pmol/L 188.4 (14) 185 (11.6) 203 (17.6) 0.69    
FSH dose (IU) 2406 (239.6) 1542 (144.5) 1235 (75) <0.0001 <0.001 <0.01 >0.05 
Ovarian volume (left side, ml) 5.5 (0.3) 12.4(1.2) 11.5 (1.2) <0.0001 <0.001 <0.001 >0.05 
Ovarian volume (right side, ml) 6.3 (0.4) 10.8 (0.7) 12.1 (0.9) <0.0001 <0.001 <0.001 >0.05 
Follicle count (left) 4.8(0.6) 13.2 (1.2) 18.4 (2.4) <0.0001 <0.001 <0.01 >0.05 
Follicle count (right) 4.7 (0.5) 12.9 (0.9) 18.4 (1.9) <0.0001 <0.001 <0.001 <0.05 
Table 3: Clinical and biochemical data [mean (SEM)] in normals, ov PCO and anov PCO patients. One way anova was used to perform statistical analysis 
between the groups.
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4.4  Results  
4.4.1  Patients recruited to the study 
In total 66 patients were recruited.  Of these, 10 were excluded because after 
processing and counting the cells there were insufficient numbers to plate in 
the wells. 4 developed fungal infections and were discarded. 11 patient 
samples were used in preliminary studies to achieve optimum plating density, 
washing technique, insulin and FSH treatment doses. Granulosa lutein (GL) 
cells from 2 controls were used in experiments to test GL response to insulin 
alone and insulin and androgen in combination (Chapter 2). 8 other patients 
were recruited but did not have complete data sets of information and as a 
result were unable to be included in the final analysis.  
In total 12 controls, 8 ovulatory PCO patients and 11 anovulatory PCO 
patients were used in the study (Appendix 5). 
4.4.2  Clinical and biochemical data of the patient subgroups 
The clinical and biochemical data of the control, ovulatory PCOS and 
anovulatory PCOS patients recruited are summarised in Table 3 [arithmetic 
mean (SEM)].  
The anovulatory PCOS group had a higher BMI [25.5 (1.2)] than both the 
control group [22.6 (1.1)] and ovulatory PCOS group [24.2 (1.2)], but this was 
not significant. 
There were significantly higher levels of fasting insulin and HOMA-IR in the 
anovulatory PCO group than both the control and ovulatory PCOS group. Of 
note the ovulatory PCOS group were the most insulin sensitive with a HOMA-
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IR 0.74 (0.2), control cells were the next most sensitive with a HOMA-IR of 1 
(0.1), and the anovulatory PCOS group were least insulin sensitive with a 
HOMA IR of 1.6 (0.2). Type 2 diabetes is associated with peripheral insulin 
resistance, elevated hepatic glucose production and inappropriate insulin 
secretion. The HOMA model is most useful for large scale population studies, 
but is fairly good as a description of individual insulin resistance as we have 
used here.   
Testosterone levels were highest in the anovulatory PCOS group [3.5nmol/L 
(0.5)], followed by the ovulatory PCOS group [2.8nmol/L (0.2)] and lowest in 
the control group [2.2nmol/L (0.2)]. 
Sex hormone binding globulin  (SHBG) levels were found to be lowest in the 
anovulatory PCOS group [90.8nmol/L (15.3)] and highest in the control group 
[111.6nmol/L (9.1)] although this was not significantly different.  
All 3 groups had oestradiol levels within the normal range [203pmol/L (17.3)] 
in the anovulatory group, [188.4pmol/L (14)] in the controls and [185pmol/L 
(11.6)] in the ovulatory PCOS group. There were no differences between the 
groups. As expected there were many more follicles in the anovulatory and 
ovulatory PCOS patients then in the control patients. Both the anovulatory 
PCOS group [1235IU (75)] and ovulatory PCOS group [1542 IU (144.5)] 
received significantly less FSH than the controls [2406IU (239.6)] during IVF 
for the reasons stated in section 4.3.2. 
4.4.2  Glucose uptake, lactate and progesterone production 
The data were analysed in different ways in order to find the best 
presentation. Although the same numbers of cells (20,000) were plated in 
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each well, over serial washing steps some cells were lost which may account 
for the differences in baseline glucose, lactate and progesterone values. 
In order to address the variability of baseline glucose, lactate and 
progesterone values, we used the difference in glucose and lactate 
measurements in each well between time zero (the time when the cells were 
switched to serum free media) and 48h.  
The response to insulin was most clear when changes in glucose uptake and 
lactate production and progesterone production were expressed as a 
percentage change from baseline (i.e no treatment). 
Figures 4.4-4.6 
Figures 4.4A, 4.5A, 4.6A shows the variable lactate production from (T0-
T48h) and figure 4.4B, 4.5B and 4.6B, the variable glucose uptake, of 
individual anovulatory PCOS patients, control patients and ovulatory PCOS 
patients, in response to insulin 1-100ng/ml.  
Each patient’s response is plotted in a separate colour. Beside each patient in 
figure 4.4A, 4.5A and 4.6A, data for BMI, HOMA IR, HOMA-S (measure of 
insulin sensitivity) and fasting insulin levels are listed to see if any correlation 
could be made between individual responses and their insulin sensitivity 
levels. No clear patterns were seen. 
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Figure 4.4: Control patients (n=12). (A) Lactate production of each patient from 0-48h (mmol/L), 
in response to no treatment or 1,10,100ng/ml insulin. Body mass index (BMI), insulin resistance 
(HOMA-IR), insulin sensitivity (HOMA-S) and fasting insulin (FI) of each patient have been listed 
by each patient. (B) Glucose uptake from the media of each individual patient from 0-48h 
(mmol/L), in response to 0,1,10,100ng/ml insulin. 
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Figure 4.5:  Ovulatory PCOS patients (n=8). (A) Lactate production of each patient from 0-48h 
(mmol/L), in response to no treatment or 1,10,100ng/ml insulin. Body mass index (BMI), insulin 
resistance (HOMA-IR), insulin sensitivity (HOMA-S) and fasting insulin (FI) of each patient have 
been listed by each patient. (B) Glucose uptake from the media of each individual patient from 0-
48h (mmol/L), in response to 0,1,10,100ng/ml insulin. 
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Figure 4.6: Anovulatory PCOS patients (n=11). (A) Lactate production of each patient from 0-
48h (mmol/L), in response to no treatment or 1,10,100ng/ml insulin. Body mass index (BMI), 
insulin resistance (HOMA-IR), insulin sensitivity (HOMA-S) and fasting insulin (FI) of each patient 
have been listed by each patient. (B) Glucose uptake from the media of each individual patient 
from 0-48h (mmol/L), in response to 0, 1,10,100ng/ml insulin. 
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Percentage change from baseline for glucose uptake, lactate production 
and progesterone formation (figure 4.7) 
The response to insulin was most clear when changes in glucose uptake and 
lactate production and progesterone production were expressed as a 
percentage change from baseline (i.e no treatment).  
The control group showed significantly higher lactate production than the 
anovulatory PCOS group (p=0.0235, Mann Whitney testing) in response to 
10ng/ml insulin and an almost significantly higher response to 100ng/ml 
insulin  (p=0.0694, Mann Whitney testing). The ovulatory PCOS group 
showed significantly higher glucose uptake than either the control or 
anovulatory PCOS group (p=0.0229, Kruskal Wallis testing) in response to 
100ng/ml insulin.   
Insulin stimulated progesterone production in a dose related manner in all 
three groups. No significant differences were seen between the groups. 
The actual baseline values of glucose, lactate and progesterone are 
expressed as histograms in figure 4.8. 
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Figure 4.7: Percentage change: Glucose uptake, lactate production and progesterone 
production of granulosa lutein cells cultured in serum free culture for 48h. Calculated as difference 
of levels of glucose, lactate or progesterone in the wells from 0-48h, and expressed as percentage 
change from baseline. (A) Glucose uptake (Mean and SEM) in response to 1,10,100ng/ml insulin. 
(B) Lactate production (Mean and SEM) in response to 1,10,100ng/ml insulin. (C) Progesterone 
production (Mean and SEM) in response to 10,100ng/ml insulin. 
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Figure 4.8: Histograms: Glucose uptake, lactate production and progesterone production of 
granulosa lutein cells cultured in serum free culture for 48h. Calculated as difference of levels of 
glucose, lactate or progesterone in the wells from 0-48h (A) Glucose uptake (Mean and SEM) in 
response to no treatment, 10ng/ml and 100ng/ml insulin. (B) Lactate production (Mean and SEM) 
in response to no treatment, 10ng/ml and 100ng/ml insulin. (C) Progesterone production (Mean 
and SEM) in response to no treatment, 10ng/ml and100ng/ml insulin. 
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4.4.3  Immunoblot quantification 
Ser 473 phosphorylation of Akt  
In 3 anovulatory PCO patients (SRo,LB,CN) 1 ovulatory PCO patient (LW) 
and 2 controls (LT and CD), it was very difficult assess total Akt levels using 
immunoblot analysis as the Akt immunostaining although present was too 
weak. For this reason data from these patients were not included in the final 
analysis of immunoblot results when Akt was used as the loading control.  
Figure 4.8 illustrates the variability of total Akt staining. 
The GAPDH antibody however produced a strong response all the subjects 
and it was therefore possible to make a good assessment of protein loading in 
all subjects, thus no one was excluded. 
Examples of blots from each subgroup of patients are illustrated in figure 4.9. 
The immunoblots illustrate the time dependent phosphorylation of Akt, ERK 
and GSK 3! phosphorylation to insulin 10,100ng/ml in all three groups of 
patients. Total Akt, ERK and GAPDH are also shown. 
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Control (ZD) 
 
Ovulatory (EH) 
  
Anovulatory (SF) 
 
Figure 4.9: Examples of immunoblots from one patient in each group, control, ovulatory 
PCOS and anovulatory PCOS patients. Showing blots for phosphorylated Akt, 
phosphorylated ERK, total Akt, total ERK and GAPDH in response to insulin 10,100ng/ml and 
no treatment. 
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Dot plots and line graphs 
The dot blots show each individual subjects response to insulin 10/100ng/ml 
at 5, 10 and 15 minutes, with a median line through the group of dots.  
The line graphs show a mean and SEM for each patient group at 5, 10 and 15 
minutes exposure to insulin 10/100ng/ml. 
Akt phosphorylation using GAPDH as loading control (figure 4.10 dot 
plot and 4.11 line graph) 
In response to 10ng/ml insulin, no significant changes were seen in any of the 
groups (using non parametric, kruskal-wallis testing, p=0.49). 
In response to 100ng/ml insulin, no significant differences were seen between 
the groups (using non parametric, kruskal-wallis testing, p=0.24). 
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Figure 4.10:  Western blot quantification of ser 473 phosphoryation of Akt using GAPDH as 
a loading control. Dot graph; Akt phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of GAPDH expression (used as a loading control).  Each 
dot on the graph represents the fold change in expression for each individual patient, after 
5,10 or 15 minutes exposure to insulin, from baseline Akt phosphorylation in the presence of 
no treatment for each patient. Median values shown by horizontal line 
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Figure 4.11:  Western blot quantification of serine 473 phosphorylation of Akt using 
GAPDH as a loading control, line graph, line graph; Akt phosphorylation in response to insulin 
(0,10,100ng/ml) was quantified and expressed as a ratio of GAPDH expression (used as a 
loading control).  Each dot on the graph represents the average fold change in expression for 
all the patients in that group, after 5,10 or 15 minutes exposure to insulin, from baseline Akt 
phosphorylation in the presence of no treatment for each patient group. Mean and SEM 
shown.  
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Akt phosphorylation, using total Akt as a loading control (figure 4.12 dot 
plot and 4.13 line graph) 
In response to 10ng/ml insulin, no significant changes were seen in any of the 
groups (non parametric anova, kruskal-wallis p=0.44). 
In response to 100ng/ml insulin, no significant changes between any of the 
groups. It did not make a difference whether analysis of Akt phosphorylation 
was done using total Akt or GAPDH as a loading control, both produced 
similar results (non parametric anova, kruskal-wallis, p=0.72) 
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Figure 4.12:  Western blot quantification of serine 473 phosphorylation of Akt using Akt as 
a loading control, dot plot. Akt phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of Akt expression (used as a loading control).  Each dot 
on the graph represents the fold change in expression for each individual patient, after 5,10 or 
15 minutes exposure to insulin, from baseline Akt phosphorylation in the presence of no 
treatment for each patient. Median values shown by horizontal line 
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Figure 4.13: Western blot quantification of serine 473 phosphorylation of Akt using Akt as 
a loading control, line graph. Akt phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of Akt expression (used as a loading control).  Each dot 
on the graph represents the average fold change in expression for all the patients in that 
group, after 5,10 or 15 minutes exposure to insulin, from baseline Akt phosphorylation in the 
presence of no treatment for each patient group. Mean and SEM. 
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Serine 9 phosphorylation of GSK! phosphorylation, using GAPDH as a 
loading control (figure 4.14 dot plot and 4.15 line graph) 
No serine 9 or 21 phosphorylation was seen in 2 anovulatory PCO patients 
(CN, LB) and in 1 ovulatory PCO patient (LW). Therefore these patients were 
unable to be included in this analysis. The lower GSK 3! (ser 9) band was 
used for quantification, as it was clearer and easier to measure. 
In response to 10ng/ml insulin, using Kruskal-Wallis testing no significant 
changes were seen between the groups in GSK 3! serine 9 phosphorylation 
(p=0.12)  
In response to 100ng/ml insulin, no significant changes seen between any of 
the groups at any time points, using non parametric anova, kruskal-wallis 
testing, p=0.51.  
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Figure 4.14:   Western blot quantification of serine 9 phosphorylation of GSK3! using 
GAPDH as a loading control, dot plot. GSK 3! phosphorylation (P-GSK 3!) in response to 
insulin (0,10,100ng/ml) was quantified and expressed as a ratio of GAPDH expression (used 
as a loading control).  Each dot on the graph represents the fold change in expression for 
each individual patient, after 5,10 or 15 minutes exposure to insulin, from baseline GSK 3! 
phosphorylation in the presence of no treatment for each patient. Median values shown by 
horizontal line 
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Figure 4.15:  Western blot quantification of serine 9 phosphorylation of GSK3! using 
GAPDH as a loading control, line graph. GSK 3! phosphorylation (P-GSK 3!) in response to 
insulin (0,10,100ng/ml) was quantified and expressed as a ratio of GAPDH expression (used 
as a loading control).  Each dot on the graph represents the average fold change in 
expression for all the patients in that group, after 5,10 or 15 minutes exposure to insulin, from 
baseline GSK 3! phosphorylation in the presence of no treatment for each patient group. 
Mean and SEM. 
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Phosphorylation of ERK 1/2 p44/42. The p42 band (Erk 2) was used for 
quantification, as this appeared clearer on all the membranes. 
In 2 anovulatory PCO patients (LB,CN) 1 ovulatory PCO patient (LW) and 2 
controls (LT and AK), it was very difficult assess ERK levels using immunoblot 
analysis as the ERK immunostaining although present was very weak. For 
this reason this patients were not included in the final immunoblot results 
when ERK was used as a loading control.  The GAPDH antibody however 
picked up protein levels in all the subjects and it was therefore possible to 
make a good assessment of protein loading in all subjects, thus no one was 
excluded.  
Measurement of ERK phosphorylation using GAPDH as a loading 
control (figure 4.16 dot plot, figure 4.17 line graph) 
In response to 10ng/ml insulin, no significant changes were seen between any 
of the groups. 
In response to 100ng/ml insulin, there was a statistically significant difference 
between the groups at both 10 minutes (p=0.0088) and 15 minutes (p=0.03). 
Statistics done using non parametric testing, Kruskal-Wallis, as not all data 
was normally distributed. 
Specifically there was a significantly higher phosphorylation of ERK in the 
control group compared to the ov PCO group at both 10 minutes (p=<0.01) 
and 15 minutes (p=<0.05).  
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Figure 4.16: Western blot quantification of p42 phosphorylation of ERK using GAPDH as a 
loading control, dot plot. ERK phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of GAPDH expression (used as a loading control).  Each 
dot on the graph represents the fold change in expression for each individual patient, after 
5,10 or 15 minutes exposure to insulin, from baseline ERK phosphorylation in the presence of 
no treatment for each patient. Median values shown by horizontal line 
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Figure 4.17: Western blot quantification of p42 phosphorylation of ERK using GAPDH as a 
loading control, line graph. ERK phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of GAPDH expression (used as a loading control).  Each 
dot on the graph represents the average fold change in expression for all the patients in that 
group, after 5,10 or 15 minutes exposure to insulin, from baseline ERK phosphorylation in the 
presence of no treatment for each patient group. Mean and SEM. 
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Using ERK p44/22 as a loading control (figure 4.18 dot plot, figure 4.19 
line graph) 
Similar results are seen when using ERK as a loading control to those seen 
with GAPDH as a loading control. In response to 10ng/ml insulin, no 
significant changes seen between any of the groups. 
In response to 100ng/ml insulin, there was a significantly higher 
phosphorylation of ERK in the ov PCOS group compared to controls at 10 
minutes (p=0.028). No other significant changes were seen. Statistics done 
using kruskal-wallis, non parametric testing. 
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Figure 4.18: Western blot quantification of p42 phosphorylation of ERK using ERK a 
loading control, dot plot. ERK phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of ERK expression (used as a loading control).  Each dot 
on the graph represents the fold change in expression for each individual patient, after 5,10 or 
15 minutes exposure to insulin, from baseline ERK phosphorylation in the presence of no 
treatment for each patient. Median values shown by horizontal line 
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Figure 4.19:  Western blot quantification of p42 phosphorylation of ERK using ERK a 
loading control, line graph. ERK phosphorylation in response to insulin (0,10,100ng/ml) was 
quantified and expressed as a ratio of ERK expression (used as a loading control).  Each dot 
on the graph represents the average fold change in expression for all the patients in that 
group, after 5,10 or 15 minutes exposure to insulin, from baseline ERK phosphorylation in the 
presence of no treatment for each patient group. Mean and SEM. 
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4.4.4  Summary of results 
There is evidence for insulin dependent changes in glucose metabolism and 
progesterone production in granulosa-lutein cells. Women with anovulatory 
PCOS have impaired glucose metabolism with reduced glucose uptake and 
lactate production with preserved insulin stimulated progesterone formation, 
as previously shown by Rice et al (71).  
There is evidence for insulin-mediated activation of PI3K and MAPK signalling 
pathways. No differences were seen between the groups in PI3K signalling 
but there was a reduction of ERK phosphorylation in the ovulatory PCOS 
group compared to controls.  
No impairment of the insulin stimulated PI3K was seen between the women 
with PCOS and without PCOS, using 2 signalling proteins, serine 473 
phosphorylation of Akt and serine 9 phosphorylation of GSK 3! 
phosphorylation. No phosphorylation of FOXO 01/03 was seen in any of the 
groups of patients (data not shown). 
No obvious pattern in PI3K signalling or glucose and lactate metabolism can 
be seen when looking directly at the insulin sensitivity of individuals. 
 
 
 
 
 
 
Chapter 4 
 177 
4.5  Discussion 
We confirmed the selective resistance to insulin in glucose metabolism in GL 
cells in women with anovulatory PCOS, with preservation of gonadotrophin-
stimulated glucose uptake and metabolism seen by Rice et al. (71).  
It was hypothesized that when comparing PI3K signalling in GL cells from 
women with anovulatory PCOS who are the most insulin resistant group and 
had significantly higher testosterone levels, than controls, that there would be 
a significant difference in Akt phosphorylation between the groups. This was 
not shown to be the case. No significant differences were seen in Akt or GSK 
3! phosphorylation between the groups. This remained the case whether 
GAPDH or total Akt protein was used as a loading control. There was 
however a time dependent response in Akt and GSK3! phosphorylation to 
insulin at both doses in all groups. The Akt and GSK3! phosphorylation ratios 
of each patient were also analysed alongside their individual HOMA IR levels 
and no obvious correlations were seen (data not shown). 
The absence of any obvious impairment in the insulin-stimulated PI3K 
signalling pathway in response to insulin in women with anovulatory PCOS is 
unexpected. We did however see significant impairment in MAPK signalling 
between women with ov PCO and control patients, the significance of this 
finding with respect to impaired glucose metabolism in granulosa cells 
remains to be determined. Again this remained the case whether GAPDH or 
total ERK was used as a loading control. All three patient groups made similar 
amounts of progesterone and there were no significant differences seen. 
The reduction in expression of p42-44 ERK in women with ovulatory PCOS 
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compared to controls is interesting. There is some data to suggest a role for 
p38 MAPK in glucose metabolism in cardiac myocytes, 3T3-L1 adipocytes, 
and skeletal muscle. 
In vivo differentiation of cardiac myocytes involves, up-regulation of GLUT4 
and down regulation of GLUT1 (227-229). Studies in primary cardiac 
myocytes have shown that in culture, primary adult cardiomyocytes de-
differentiate into a fetal program of GLUT gene expression, up-regulating 
GLUT1 and down-regulating GLUT4. Treatment with IGF-1 restored 
expression of GLUT4 protein and mRNA, and this was mediated by the p38 
MAPK axis. Use of a p38 inhibitor SB203580, completely abolished the 
overexpression of GLUT4 induced by 500ng/ml IGF-1. Transient transfection 
experiments in neonatal cardiac myocytes confirmed p38 MAPK can activate 
the GLUT4 promoter. Transient transfection of the ERK1/2 mutant DN3MEK1 
did not significantly alter GLUT4 promoter activity, whereas p38 MEK6DD 
elicited good stimulation of GLUT4 promoter activity, which was entirely 
blocked by SB203580 (230). 
Another study this time in 3T3-L1 adipocytes showed that sodium arsenite (a 
protein modifying agent) stimulates glucose uptake in 3T3-L1 adipocytes 
(231-233). Using western blotting this was shown to be mostly via 
translocation of GLUT4 and GLUT1 to the cell surface. Arsenite in this study 
did not activate other signalling steps normally activated in response to insulin 
such as IR tyrosine kinase, IRS-1 and IRS-2 tyrosine phosphorylation, Akt 
phosphorylation or PKC-!, suggesting that the target of arsenite is 
downsteam of PI3K or in a separate pathway.  Both arsenite and insulin 
induced glucose uptake were partially inhibited by p38 MAPK inhibitor 
Chapter 4 
 179 
SB203508 (233). 
Work in the L6 muscle cell line has shown that insulin stimulated GLUT4 
translocation precedes the stimulation of glucose uptake in time, suggesting 
that GLUT4 may undergo an activation step following it’s insertion into the 
plasma membrane (234). Using p38 MAPK inhibitors SB203580 and a 
dominant negative p38 MAPK mutant, it has been shown that insulin 
stimulated glucose uptake is attenuated without altering GLUT4 translocation, 
suggesting insulin may activate GLUT4 via a p38 MAPK pathway (235, 236).  
The studies above have been done looking at the effect of p38 MAPK in 
glucose metabolism and our study looked at the effect of p42/44 ERK.  Little 
conclusive evidence has been found for an effect of p42/44 ERK on glucose 
metabolism. MAPK is capable of phosphorylating an impressive array of 
target proteins in vitro, many of which have a regulatory role and are known to 
be phosphorylated in response to insulin. For example, GSK-3 ! and " are 
phosphorylated and inactivated by two protein kinases ribosomal protein S6, 
the 90kDa S6 (also known as 90rsk or MAPKAP-K1) (79) and 70KDa S6 
which lie downstream of MAPK (80, 81). But this only gives us circumstantial 
evidence in favour of a role for MAPK in insulin action. Studies ablating MAPK 
activity using truly specific inhibitors or mRNA targeting, have been hampered 
by the presence of multiple related MAPK isoforms (82). It would be useful to 
investigate the expression of p38 MAPK in our system. Interestingly p42/44 
MAPK signalling in primary human thecal cells from women with PCOS has 
been shown to be by down-regulated, and this was associated with an 
increase in androgen production (237). 
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It is possible that there may be defects in pathways other than PI3K and 
MAPK that we have not investigated for, such as the PKC, AMPK or FOXO 
pathways. AMPK is an intracellular energy sensor that plays a central role in 
glucose and lipid metabolism. AMPK activates when cellular energy is 
depleted and accelerates ATP generating catabolic pathways such as 
oxidation of fatty acid and glucose (238-240), and at the same time reduces 
ATP consuming anabolic pathways such as fatty acid synthesis (241, 242). 
Activators of AMPK enhance glucose uptake in 3T3-L1 adipocytes. Using 
GFP labelled GLUT4 and live confocal imaging, it has been shown that AMPK 
activator 5-aminoimidadole-4-carboxamide-1-!-D-ribofuranoside (AICAR), 
accelerates GLUT4 translocation within 4 minutes. GLUT4 translocation is not 
affected by wortmannin (PI3K inhibitor), but wortmannin did inhibit AICAR and 
insulin induced glucose uptake.  SB-203580 an inhibitor of p38 MAPK also did 
not inhibit GLUT4 translocation but did prevent the enhancement of glucose 
uptake induced by AMPK and insulin. It is possible that the increase in 
glucose uptake seen with AMPK activators may be via a p38 MAPK 
dependent mechanism (243).   
So far, 12 PKC isoforms have been cloned in mammals, consisting of PKC 
three subgroups: classical or conventional PKCs (!, "I, "II and #), novel PKCs 
(PKC", $, % and &), and atypical PKC (PKC#, $). There is evidence to indicate 
that atypical PKCs (aPKCs) are involved in the regulation of glucose 
metabolism and play a crucial role in pathogenesis in type 2 diabetes (244).  
Atypical PKCs are thought to have a role in induction of insulin mediated 
GLUT4 translocation to the plasma membrane. There are 2 distinct pathways 
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that are thought to be involved in glucose transport, PI3K and the Cbl-TC10 
pathway, aPKCs function as a downstream target of both (245).  
The second pathway Cbl-TC10, involves insulin binding to the insulin receptor 
and activating protein Casitas B lineage Lymphoma (Cbl). Which is recruited 
to the insulin receptor via interaction with adapter proteins CAP and APS. On 
phosphorylation the Cbl-CAP complex dissociates from the insulin receptor 
and moves to the caveolin rich membrane fraction. The complex then binds a 
protein flotillin and this ternary complex is recruited to lipid rafts in the plasma 
membrane (246, 247). TC10 a member of the Rho family is constitutively 
localized to plasma membrane lipid raft domains. Activated Cbl recruits 
CRKII-C3G complex here to lipid rafts, where C3G specifically activates 
TC10. TC10 then activates aPKCs through a Par 6-3 interaction (245, 248) 
(figure 4.20). 
 
Figure 4.20: Atypical protein kinase in insulin sensitive cells, from Liu et al.  (244) 
 
polypeptide chain, cPKCs contain an NH2-terminal regulatory
domain and a COOH-terminal catalytic domain. They encom-
pass 4 conserved motif (C1–C4) and 5 variable motif (V1–V5).
The conserved motif 1 (C1) contains a tandem repeat of a
cysteine-rich sequence involved in DAG-/PMA-binding and
membrane binding [1]. As aPKCs contain only one set of the
cysteine-rich sequence, they can not bind DAG or PMA and are
not allosteric regulated by DAG or PMA [2]. APKCs are not
allosteric regulated by Ca2+, either, because of devoiding of the
C2 motif, Ca2+ binding site [1]. Fig. 1 shows the structure of
PKC.
APKCs are ubiquitously expressed and evolutionarily
conserved in many different species. PKCζ is expressed in
almost all cells which implies that PKCζ plays a distinct and
important role in general cellular functions [3]. PKCλ is
expressed in a wide variety of cells and tissues, including P19
and NIH 3T3 cells, as well as brain, kidney, testis, and ovary [4].
PKCι is expressed predominantly in the lung and brain, but also
expressed at lower levels in other tissues such as the pancreatic
islets [5]. As the important kinases in signal transduction
pathway, aPKCs are involved in wide biological functions, such
as cell proliferation [6], cell migration and development [7], cell
apoptosis [8], cell polarity maintenance [9], and cytoskeleton
regulation [10]. In addition, there is a considerable evidence to
indicate that aPKCs are involved in the regulation of glucose
Fig. 1. The structure of PKCs.
Fig. 2. (a) APKCs in insulin-sensitive cells; (b) APKCs in islet cells.
2072 X.-J. Liu et al. / Cellular Signalling 18 (2006) 2071–2076
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One study done in adipocytes correlates well with our work and supports the 
idea of a defect in the atypical PKC pathway. The action of androgen on pre-
adipocytes from healthy women treated with testosterone or anti-androgens 
for 48h was investigated. Maximal insulin stimulated glucose uptake (insulin 
10nM) was impaired in the cells treated with testosterone 10nmol/L and 
100nmol/L. This defect was attenuated by co-incubation with anti-androgens. 
However testosterone treatment did not alter phosphorylation of insulin 
receptor substrate-1, Akt or MAPK. It did however impair atypical protein 
kinase C (PKC) isoform ! phosphorylation (188). PKC as described above is 
activated by PI3K and PDK, and has been shown to be important in glucose 
metabolism (204). 
However some studies in adipocytes have shown defects in the PI3K 
pathway. A study done in adipocytes from women with polycystic ovary 
syndrome demonstrated reduced insulin stimulated glucose uptake in 
adipocytes from women with PCOS compared to controls. The PCOS 
adipocytes showed higher tyrosine phosphorylation and lower serine 
phosphorylation of GSK 3", indicating a higher GSK3" activity and therefore 
reducing glycogen synthase activity. The GSK 3" overactivity was confirmed 
using a radioactive GSK 3" activity assay (249). 
Akt also phosphorylates and inactivates members of the forkhead 
transcription factor family (FOXO) by causing its nuclear exclusion and 
inactivation (89). FOXO transcription factors play an important role in 
modulating metabolic functions. Given relatively high expression of FOXO1 in 
insulin-responsive tissues and the impact of insulin signalling on Akt-mediated 
phosphorylation of FOXO, this transcription factor is highly poised to regulate 
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energy metabolism. When insulin and nutrient levels are low, FOXO1 
promotes expression of gluconeogenesis enzymes. In insulin resistance, 
negative signalling to FOXO1 is compromised (250). However in our study we 
failed to find any evidence of FOXO1 or FOXO3 phosphorylation (data not 
shown). FOXO 01, FOXO 03 and FOXO 04 have all been seen previously in 
human mural luteinized granulosa cells using western blotting (251). Due to 
time and sample limitations we did not run blots for total FOXO1. 
Another suggestion is that the signalling defect in the PI3K pathway involves a 
protein in the signalling pathway that is more proximal to Akt, such as IRS1 or 
the insulin receptor itself. 
Primary differentiated rat skeletal muscle myotubes were subjected to 30min 
insulin 100nM and showed serine phosphorylation of IRS-1 636/639 and Akt 473 
were increased. When these cells were subjected to 16h pre-exposure to 
testosterone (20ng/ml), they showed a significant increase in insulin induced 
serine phosphorylation of IRS-1636/639 (p=0.042), insulin induced m-Tor-ser2448 
and insulin induced S6K-Thr389 were increased, compared to cells not pre-
exposed to testosterone (252). Higher dose of testosterone 200ng/ml showed 
a non significant rise in insulin induced serine phosphorylation of IRS-1636/639 
(p=0.2). 
Another protein of interest is IRS-1 ser312 phosphorylation. Cultures of skeletal 
muscle in obese women with PCOS have been studied. Basal and insulin 
stimulated GLUT1 abundance were significantly increased. IRS-1 protein 
abundance was significantly increased in PCOS resulting in significantly 
decreased PI3K activity when normalised for IRS-1. Phosphorylation of IRS-1 
ser312 (equivalent to Ser307 in rat) was significantly increased in PCOS, but 
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despite these defects the cultured myotubules showed normal insulin 
responsiveness. No differences in IR tyrosine phosphorylation were seen 
between women with PCO and controls. In contrast to skin fibroblasts the 
defects in skeletal muscle seen in vivo resolve in culture consistent with the 
major role of the in vivo environment in insulin resistance. However the 
defects in insulin signalling persist (127). Serine phosphorylation of IRS1 
inhibits its tyrosine phosphorylation and therefore its ability to recruit PI3K 
(62). 
IR serine phosphorylation is another area of possible differences. Isolated 
skin fibroblasts of about 50% of women with PCOS who had insulin resistance 
documented by euglycaemic clamp studies, have constitutively active serine 
phosphorylation of the insulin receptor that inhibits insulin-stimulated tyrosine 
phosphorylation (130). 
This was also shown in a study using primary human granulosa cells from 
women with insulin resistant PCOS (IR-PCOS) and non insulin resistant 
PCOS (NIR-PCOS), measured by continuous infusion of glucose model 
assessment test (CIGMA), as well as controls. Cells cultured in vitro with 
insulin and/or LH showed that insulin stimulated lactate production in the NIR-
PCOS and control group but not in the IR-PCOS group. This was associated 
with a down regulation of insulin receptor (assessed using western blotting) in 
the IR-PCOS group (253). 
Conclusions 
The selective resistance to insulin in glucose metabolism in GL cells in 
women with anovulatory PCOS was confirmed. The absence of any obvious 
Chapter 4 
 185 
impairment in the insulin-stimulated PI3K signalling pathway in response to 
insulin in women with anovulatory PCOS is unexpected. We did however see 
impairment in MAPK signalling and the significance of this finding with respect 
to impaired glucose metabolism in granulosa cells remains to be determined. 
It may be possible that granulosa cells are behaving in a similar way to brain 
and red blood cells, where insulin action is far less important in glucose 
metabolism than in tissues such as the liver and skeletal muscle. There is 
evidence that gonadotrophins are involved in glucose metabolism in 
granulosa cells (70, 71) (Chapter 5), and may well be the primary regulator of 
glucose metabolism in these cells. 
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5.1  Introduction 
FSH has been shown to have important effects on glucose metabolism. FSH 
significantly increased oocyte maturation and produced a 2-3 fold increase in 
glucose uptake and lactate production by cumulus oocyte complexes in which 
the enclosed oocyte completed maturation (70). In this study, the PI3-kinase 
inhibitor LY294002 inhibited FSH stimulated glucose uptake, and GLUT4 
glucose transporter was found in granulosa cells suggesting that FSH 
increased glucose uptake by PI3-kinase-mediated translocation of GLUT4 to 
the granulosa cell membrane (70). 
Gonadotrophins are thought to be involved in energy metabolism during 
follicle development. Hillier et al. showed granulosa cells respond to 
gonadotrophins by increasing lactate production (95).  
Rice et al. used granulosa-lutein cells from women with anovulatory PCOS, 
ovulatory PCOS, and a control group of women and looked into the effects of 
insulin (1-1000ng/ml) and LH (1-5ng/ml) on carbohydrate metabolism and 
progesterone production. Cells from the anovulatory PCOS subjects were 
significantly less responsive to insulin in lactate production than those from 
both of the other two groups. The addition of LH however resulted in a dose-
dependent increase in glucose uptake, which was similar in each of the 
groups as well as dose-dependently, stimulated lactate and progesterone 
production in each group (figure 1.12). Therefore in contrast to the response 
to insulin, there was no significant difference in response to LH between the 
groups. LH stimulated progesterone production in all three groups with a peak 
response of two to three times that of the basal value. Progesterone 
production by the anovulatory PCOS cells was significantly greater than from 
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the control (P=0.046, ANOVA) and ovulatory PCOS (P=0.03, ANOVA) cells 
(71). 
Several studies have shown an effect of FSH on steroidogenesis in human 
primary granulosa lutein cells taken from normal women undergoing IVF (190-
193). However this is the first study in primary human granulosa lutein cells to 
look at gonadotrophin effects on downstream signalling pathways involved in 
glucose metabolism. Previous work in luteinized GL cells has looked at the 
effect of LH but not of FSH.  
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5.2  Aim 
The purpose of this project is to assess the effect of FSH on human primary 
granulosa lutein cells [that are harvested at the time of egg collection for in 
vitro fertilization (IVF)] on glucose metabolism and downstream signalling 
pathways involved in glucose metabolism.  
 
Specific aims were: 
 
1. to assess FSH action on glucose metabolism 
2. to assess FSH action on progesterone production  
3. to assess FSH action on PI3K and MAPK signalling pathways 
 
in granulosa lutein cells from women with normal ovaries and those 
with endogenous androgen excess i.e women with polycystic ovary 
syndrome.  
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5.3  Materials and Methods 
Details of the materials and methods used in the chapter are given in Chapter 
4. In brief, patient groups are described in section 4.3.1 and blood samples 
and follicular fluid aspirations are described in section 4.3.2. Human 
granulosa lutein cell collection, preparation and culture are described in 
section 4.3.3.  
For the glucose, lactate and progesterone assays, 20 x 104 cells were plated 
into 96 well plates, and supplemented with 200µl serum supplemented 
medium 199. Each experimental condition was repeated in five replicates. 
Cells were placed centrally and surrounding wells filled with sterile PBS to 
avoid evaporation. After 24h incubation at 37°C in 5% CO2 serum containing 
medium was removed and the cells washed with PBS. They were then 
incubated for a further 48h with 200µL serum free Medium 199 with or without 
FSH 20ng/ml (dissolved in PBS +0.1% bovine serum albumin, National 
Hormone and Pituitary Program, California, USA). FSH 20ng/ml was chosen 
as it is a physiological dose. 
For the protein expression results, 50 x 104 cells were added to 24 well plates 
and each well was supplemented with 1mL serum supplemented media. After 
24h incubation at 37°C in 5% CO2, the medium was removed and cells 
washed with PBS. They were then incubated for a further 24h with 1mL serum 
free Medium 199.  The cells were the incubated with or without FSH 20ng/ml 
(dissolved in PBS +0.1% bovine serum albumin, appendix 3) for 5,10 or 15 
minutes. Cells were then harvested in RIPA buffer, with aprotinin (MP 
Biochemicals, Cambridge, UK), protease inhibitors and sodium orthovanadate 
Chapter 5 
 191 
(Sigma). The samples were then centrifuged at 12000x g for 5 minutes at 4°C 
and supernatant collected. Laemmli sample suffer was added, and 20 µl 
loaded on a Bis-Tris NuPAGE pre cast polyacrylamide gel (Invitrogen). 5µl of 
a pre stained standard ladder was also loaded (Invitrogen) (figure 4.2). 
Western blotting technique is described in section 4.3.4 and immunoblot 
analysis described in section 4.3.5. Protein concentration quantification is 
described in 4.3.5. Glucose, lactate and progesterone measurement are 
described in section 4.3.6 and 4.3.7. Finally statistical analysis is described in 
section 4.3.8. 
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5.4  Results 
5.4.1 Glucose uptake, lactate and progesterone production 
in response to FSH 20ng/ml 
As previously described in section 4.4.2, in order to address the variability of 
baseline glucose and lactate and progesterone values, we used the difference 
in glucose and lactate measurements in each well between time zero (the 
time when the cells were switched to serum free media) and 48h. The 
response to FSH 20ng/ml was expressed as a percentage change from 
baseline (figure 5.1).  
Effects of FSH on glucose metabolism 
FSH 20ng/ml induced glucose uptake from the media and lactate production 
in all 3 groups of patients, controls, ovulatory PCOS and anovulatory PCOS. 
The FSH induced rise in lactate production was statistically significant in both 
the anovulatory PCOS (p=0.0004, Mann Whitney) and ovulatory PCOS 
groups (p=0.023), but not in the control group (p=0.45). 
The effect of FSH on glucose uptake was similar to that of lactate.  Compared 
to no treatment, FSH 20ng/ml produced a significant rise in glucose uptake in 
both the anovulatory PCOS (p=0.01, Mann Whitney) and ovulatory PCOS 
groups (p=0.02), but not in the control group (p=0.3).  
Compared to no treatment, FSH 20ng/ml produced a significant rise in 
progesterone production in all three groups, anovulatory PCOS (p<0.0001, 
Mann Whitney), ovulatory PCOS (p<0.0001, Mann Whitney), and controls 
(p<0.0001, Mann Whitney).  
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Comparison of the FSH response between the three groups was made using 
non parametric ANOVA (Kruskal-Wallis). There was a significant difference in 
lactate production between the 3 groups (p=<0.0001). There was a 
significantly higher lactate production from the anov PCO group compared to 
both the controls, and ov PCO group. There was also a significant difference 
in glucose uptake between the 3 groups (p=0.02). There was also a 
significantly higher glucose uptake from the anov PCO group compared to the 
controls.  
FSH 20ng/ml induced a highly significant (3-4 fold) increase in progesterone 
production in GL cells in all three groups of subjects (p<0.0001 in each group; 
Mann Whitney). However, there was no significant difference in progesterone 
production between the three groups (figure 5.1).   
The absolute values for glucose uptake, lactate and progesterone production 
are depicted as histograms in figure 5.2. 
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Figure 5.1: Glucose uptake, lactate production and progesterone production of primary granulosa 
lutein cells cultured in serum free culture for 48h. Calculated as difference of levels of glucose, 
lactate or progesterone in the wells from 0-48h, and expressed as percentage change from 
baseline. (A) Glucose uptake (Mean and SEM) in response to 20ng/ml FSH (B) Lactate 
production (Mean and SEM) in response to 20ng/ml FSH (C) Progesterone production (Mean and 
SEM) in response to 20ng/ml FSH. 
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Figure 5.2: Histograms, Glucose uptake, lactate and progesterone production of primary 
granulosa lutein cells cultured for 48h in response to FSH 20ng/ml. (A) Glucose uptake (absolute 
values before and after treatment) in response to 20ng/ml FSH (B) Lactate production (absolute 
values before and after treatment) in response to 20ng/ml FSH (C) Progesterone production 
(absolute values before and after treatment) in response to 20ng/ml FSH. 
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5.4.2  FSH signalling in primary granulosa lutein cells 
Examples of blots from each subgroup of patients are illustrated in figure 5.3. 
The immunoblots illustrate the time dependent phosphorylation of Akt, ERK 
and GSK 3! phosphorylation in response to FSH 20ng/ml in all three groups 
of patients. Total Akt, total ERK and GAPDH are also shown. 
FSH 20ng/ml produced very little PI3K activation as seen in figure 5.1. Akt 
phosphorylation was unaffected by the addition of FSH. There was also no 
GSK3! phosphorylation in response to FSH 20ng/ml in any of the groups. It 
was therefore not possible to quantify the low amount of Akt or GSK3! 
phosphorylation in response to FSH 20ng/ml.  
ERK phosphorylation was however detectable in response to FSH 20ng/ml. 
This is seen clearly in the control and anovulatory PCOS patient examples 
below. There was as expected variation from subject to subject; so for 
example little evidence of ERK phosphorylation is seen in the particular 
ovulatory PCOS subject shown here.  
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Control (ZD) 
 
Ovulatory PCO (EH) 
 
Anovulatory PCO (SF) 
 
 
Figure 5.3: Examples of immunoblots from one patient in each group, control, ovulatory 
PCOS and anovulatory PCOS patients. Shown are blots for phosphorylated Akt, 
phosphorylated ERK, total Akt, total ERK and GAPDH in response to FSH 20ng/ml and no 
treatment 
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5.4.3   Quantification of phospho-proteins 
As in Chapter 4, when measuring phosphorylation of ERK 1/2 p44/42, the p42 
band (ERK 2) was used for quantification, as this appeared clearer on all the 
membranes.  
ERK phosphorylation was quantified using GAPDH as a loading control (dot 
plot shown in figure 5.4, and line graph in figure 5.5). The dot plots show each 
individual subjects response to FSH 20ng/mL at 5, 10 and 15 minutes. The 
line graphs show a mean and SEM for each patient group at 5, 10 and 15 
minutes exposure to FSH. 
In response to 20ng/ml FSH, no significant changes were seen between any 
of the groups at any time point. Statistics were done using the Kruskal-Wallis 
test, as not all data were normally distributed. 
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Figure 5.4: Western blot quantification of p42 phosphorylation of ERK using GAPDH a 
loading control, dot plot. ERK phosphorylation in response to FSH 20ng/ml was quantified 
and expressed as a ratio of GAPDH expression (used as a loading control).  Each dot on the 
graph represents the fold change in expression for each individual patient, after 5,10 or 15 
minutes exposure to FSH 20ng/ml, from baseline ERK phosphorylation in the presence of no 
treatment for each patient. Median values shown by horizontal line 
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Figure 5.5:  Western blot quantification of p42 ERK phosphorylation using GAPDH as a 
loading control, line graph. ERK phosphorylation in response to FSH 20ng/ml was quantified 
and expressed as a ratio of GAPDH expression (used as a loading control).  Each dot on the 
graph represents the average fold change in expression for all patients in that group, after 
5,10 or 15 minutes exposure to FSH 20ng/ml, from baseline ERK phosphorylation in the 
presence of no treatment for each patient group. Mean and SEM shown.  
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5.5  Discussion 
FSH 20ng/ml stimulated significant glucose uptake and lactate production in 
both the anov PCO and ov PCO groups although not in GL cells from the 
control subjects with normal ovaries. The variant responses are not easy to 
explain but could be related to the difference in the number of FSH receptors 
(FSHR) expressed in the GL cells of anov PCO patients compared to controls. 
The response to FSH in patients undergoing IVF has been shown to be 
positively correlated to the expression level of FSHR in granulosa-lutein cells 
(figure 5.6). Compared with patients with no ovarian factor of infertility, the 
FSHR expression level is significantly higher in patients with PCOS (254-256). 
This may also explain why there was a significantly greater lactate production 
and glucose uptake in the anovulatory PCO patients in response to FSH 
20ng/ml compared to the control subjects.  
 
Figure 5.6: Variable FSHR expression in IVF patients. Mean and SD of expression levels 
(relative to !-actin, using qPCR) of FSHR, in patients with different infertility diagnoses. NOF 
= no ovarian factor; PR = poor responders; EM-A = endometriosis with "10 oocytes retrieved; 
EM-B = endometriosis with >10 oocytes retrieved; PCOS = polycystic ovary syndrome. For 
each bar graph, the results of comparisons between groups are reported as follows: a = 
significantly different from NOF; b = significantly different from poor responders; c = 
significantly different from endometriosis-A; d = significantly different from endometriosis-B; e 
= significantly different from PCOS. From Gonzalez-Fernandez et al. 2011(256) 
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One explanation for the higher FSHR levels seen in PCOS GL cells is 
hyperandrogenism. Using quantitative RT-PCR, AR gene expression has 
been reported in GL cells from human stimulated preovulatory follicles. A 
higher expression of AR was seen in smaller follicles than larger follicles in 
PCOS (255). Increased AR expression in GL cells of testosterone-treated 
monkeys from the pre-antral to the large antral follicle stage has also been 
shown; and primate ovary AR gene expression is most abundant in granulosa 
cells of healthy growing follicles, where its expression is up-regulated by 
testosterone. These data support the view that androgens stimulate AR 
expression (257). Both AR and FSHR expression were strongly and positively 
correlated in small follicles from PCOS patients and controls and in large 
follicles from PCOS patients (255). Weil et al. (258) also reported a highly 
significant positive correlation between FSHR and AR mRNA levels in GL 
cells from testosterone-treated or control primate follicles. Androgen treatment 
significantly increased FSHR mRNAs in GL cells (by !50–100%, depending 
on follicle size) (258).  
The greater number of FSH receptors in patients with PCOS also explains the 
requirement of lower doses of exogenous recombinant FSH during IVF in 
order to prevent ovarian hyperstimulation (Table 3).  
The differences between the groups in the response of glucose and lactate to 
FSH is in surprising contrast to the changes induced by insulin in GL cells 
(see chapter 4). Furthermore, in our study unlike the effect of insulin, FSH 
20ng/ml did not show any measurable levels of Akt and GSK 3! 
phosphorylation. FSH 20ng/ml did however show measureable increases in 
p42/44ERK phosphorylation, which may suggest an involvement of the MAPK 
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pathway in glucose metabolism or may simply reflect changes in the 
pathways involved in FSH-induced progesterone production. Another 
possibility is that an alternative signalling pathway such as AMPK or atypical 
PKC is involved in FSH induced glucose metabolism but this has not yet been 
investigated in our system. 
ERK was phosphorylated in a time dependent manner for all three groups of 
subjects however there were no significant differences seen between the 
groups. Alongside this result, FSH 20ng/ml produced a significant rise in 
progesterone production compared to no treatment in all three groups.  
In conclusion, in primary human granulosa lutein cells FSH 20ng/ml has an 
effect on MAPK signalling but little effect on PI3K signalling. Compared to no 
treatment addition of FSH 20ng/ml produced significant glucose metabolism in 
ovPCO and anovPCO subjects, but not in controls.  This is the first study to 
investigate the effect of FSH on glucose metabolism in primary human 
granulosa cells. We conclude that, as in the mouse ovary, FSH can induce 
glucose uptake and lactate accumulation but without clear evidence of 
activation of the PI3-kinase pathway. 
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KK1 cells were useful for looking into the action of insulin and androgen as 
well as the positive interactive effect of insulin and androgen. This could be 
said to be a quirk of cell line work, however the fact that it was possible to 
repeat these experiments in primary human granulosa lutein cells from two 
control patients, suggests otherwise. Rather than the expected inhibition, of 
insulin-stimulated glucose uptake and lactate production, this augmentation 
by androgens is a surprising result.  
The results suggest that the insulin resistance observed in granulosa cells 
from women with PCOS, cannot be explained by direct exposure to androgen. 
Perhaps other circulating factors in vivo such as fatty acids or adipokines 
produced by fat cells such as tumour necrosis factor ! (TNF-!), leptin and 
adiponectin are contributing to insulin resistance in granulosa cells.  
Future studies could employ techniques such as microarray analyses to 
identify which genes are up regulated by androgen therapy in KK1 cells. One 
anomaly noted was that glucose uptake and lactate production, were only 
detectable after 24h of exposure to substrates such as insulin, but 
phosphorylation of Akt and ERK and also movement of GLUT4 were seen 
within minutes. It is possible that the amount of glucose uptake was simply too 
small to be detected any earlier by the COBAS bio-analyser, and if time had 
permitted an alternative method to measure glucose uptake such as uptake of 
radio-labelled glucose from the medium would have been a more sensitive 
method of monitoring small amounts of glucose taken up rapidly by KK1 cells. 
The KK1 cells were less useful for looking into the action of FSH although this 
was not our primary objective, and they were also not useful in investigating 
the action of hormones on steroidogenesis. This could be because the Abbott 
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analyser, which is used clinically in the biochemistry department of 
Hammersmith hospital to measure progesterone concentrations in the blood 
in nanomolar concentrations, was not sensitive enough to detect the amounts 
produced by the KK1 cells. It may also be explained by inadequate 
transfection of KK1 cells with the FSH receptor. It is also possible that 
phenotypic drift of the cell line over repeated passages may have had an 
effect. It would be useful to look for gene expression of FSH sensitive genes, 
or immunocytochemistry for the FSH receptor.  
The results of the human primary granulosa lutein cell experiments confirmed 
selective impairment of glucose metabolism in cells from anovulatory PCOS. 
It was hypothesized that when comparing PI3K signalling in GL cells from 
women with anovulatory PCOS, who are the most insulin resistant group and 
had significantly higher testosterone levels, than controls, that there would be 
a significant difference in Akt phosphorylation between the groups. This was 
not shown to be the case. No significant differences were seen in Akt or GSK 
3! phosphorylation between the groups. However there was a reduction of 
p42/44ERK phosphorylation in the ovulatory PCOS group compared to 
controls. The role of MAPK in insulin stimulated glucose metabolism is 
unclear and the significance of this finding with respect to impaired glucose 
metabolism in granulosa cells remains to be determined. There is some 
evidence to link p38 MAPK to insulin stimulated glucose metabolism, but not 
much evidence to support a role for p42/44 MAPK.  
Given that insulin resistance in PCOS appears to be selective, affecting the 
metabolic but not mitogenic activity of insulin it is surprising that defects in 
p42/44 MAPK signalling was found in the PCOS patients. This study is the 
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first to suggest that there may be a difference in MAPK signalling between 
women with and without PCOS. It would be useful to use specific p42/44 ERK 
inhibitors to see if this has an effect on glucose metabolism. If no changes 
were seen using this inhibitor then it may be more likely that an alternative 
pathway that we have not yet investigated may be involved.  
The remaining lysates could be used for immunoblotting for phosphorylated 
AMPK, phosphorylated PKC and phosphorylated p38 MAPK. We could also 
use phosphoprotein microarrays to see if any other important proteins in the 
insulin signalling pathway are phosphorylated. Alternatively, it may be that the 
western blot techniques used were not sensitive enough to pick up small 
changes in the PI3K pathway.  
This is also the first study to investigate the effect of FSH on glucose 
metabolism in primary human granulosa cells. As in the mouse ovary, FSH 
can induce glucose uptake and lactate accumulation but without clear 
evidence of activation of the PI3-kinase pathway. FSH 20ng/ml did however 
induce measureable increases in p42/44ERK phosphorylation and significant 
amounts of progesterone production in all three groups, which may suggest 
an involvement of the MAPK pathway in glucose metabolism or may simply 
reflect changes in the pathways involved in FSH-induced progesterone 
production. Another possibility is that an alternative signalling pathway such 
as AMPK or atypical PKC is involved in FSH induced glucose metabolism but 
this has not yet been investigated in our system.  
It would be useful to test more doses of FSH in our experiments with primary 
human granulosa cells, and confirm our findings. It would also be useful to 
check the mRNA levels of FSH receptor like Gonzalez-Fernandez et al. (256) 
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or use immunocytochemistry to check for the presence and density of FSH 
receptors in anovulatory PCOS, ovulatory PCOS and control primary human 
granulosa cells. If we confirm that the FSH receptor levels are higher in our 
anovulatory PCOS patients, we could hypothesize that the amount of MAPK 
phosphorylation in PCOS women is actually reduced considering the quantity 
of FSH receptors is greater. 
It is hoped the greater the knowledge of the specific pathways involved in the 
dysfunction of granulosa cell glucose metabolism, the greater chance of 
ultimately developing specific therapeutic agents to improve the ovarian 
dysfunction seen in PCOS, particularly in anovulatory PCOS, the most insulin 
resistant group. 
This thesis has shown us that selective insulin resistance is present in 
granulosa cells but the changes in glucose uptake are small and not reflected 
in obvious changes in activation of the PI3K pathway. From a clinical and 
scientific point of view, our findings are significant because there are very 
dynamic changes in oocyte metabolism, particularly in the maturing follicle 
and even small changes in insulin-mediated glucose metabolism may have an 
impact on oocyte function and fertility. 
It may also be possible that insulin action is far less important than 
gonadotrophins in granulosa cell glucose metabolism. We have provided 
evidence that gonadotrophins are involved in glucose metabolism in 
granulosa cells, and may well be the primary regulator of glucose metabolism 
in these cells. The pathways stimulated by FSH stimulated have also been 
explored and did not reflect any obvious changes in activation of the PI3K 
pathway.  
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So where does this research take us? Further study of FSH and LH regulation 
of glucose metabolism in the human ovary should be investigated in detail in 
the normal ovary. Comparisons can then be made between gonadotrophin 
action on glucose metabolism in the normal and PCOS ovary.   
Insulin resistance in other target tissues such as adipose and skeletal muscle 
may be even more important areas for research in PCOS. Insulin action on 
glucose metabolism and signalling pathways in adipose tissue biopsies from 
women with and without PCOS could be investigated. 
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Appendix 1: Table of commonly used antibodies 
 
Antibody Source Use  Dilution Blocker 
Rabbit anti-phospho-
Akt (ser 473) 
monoclonal 
Cell Signalling Technology 
4060 New England 
Biolabs, Hertfordshire, UK 
WB 1:1000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Akt Cell Signalling Technology 
9272 New England 
Biolabs, Hertfordshire, UK 
WB 1:1000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
p42-44 MAPK Cell Signalling Technology 
9102 New England 
Biolabs, Hertfordshire, UK 
WB 1:1000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Rabbit anti-phospho-
p42-44 (Thr 202/Tyr 
204) MAPK polyclonal 
Cell Signalling Technology 
4370 New England 
Biolabs, Hertfordshire, UK  
WB 1:1000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Rabbit, phospho-GSK-
3!/"(ser21/9)  
Cell Signalling Technology 
9331 New England 
Biolabs, Hertfordshire, UK 
WB 1:1000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Alexa 488 conjugated 
Goat anti- Rabbit IgG 
Invitrogen Molecular 
Probes 
IF 1:500 10% FCS/ PBS 
Mouse anti-GAPDH Millipore MAB374, 
California, USA 
WB 1:5000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Goat anti rabbit Red 
680nmn  
Invitrogen A21109  WB 1:10000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Goat Anti Mouse: 
Green 800nm  
 
Lichor 926-32210 
 
WB 1:10000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Rabbit anti-Androgen 
receptor 
Fitzgerald:  
20-RAR012, Acton, MA, 
USA 
ICC 1:50 Goat serum 
Rabbit IgG Sigma Aldrich I8140 ICC 1:50 Goat serum 
Rabbit polyclonal 
IgG,GLUT4 (H-61) 
Santa Cruz Biotechnology 
(sc 7938) 
ICC m, 
r, h 
1:200 Goat serum 
Rabbit phospho-FOXO 
(01/03a) 
Cell Signalling Technology, 
9464 
 
WB 1:1000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Alexa 568 conjugated 
Goat anti- Mouse IgG 
Invitrogen Molecular 
Probes 
IF 1:500 10% FCS/ PBS 
Peroxidase conjugated 
Goat anti-mouse IgG 
Sigma Aldrich WB 1:10000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
Peroxidase conjugated 
Goat anti-rabbit IgG 
Sigma Aldrich WB 1:10000 5% non fat 
milk/TBS 0.15% 
TWEEN 20 
 
Western blotting(WB), Immunoprecipitation (IP), Immunofluorescence (IF), 
Immunocyctochemistry (ICC)
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Appendix 2: Table of commonly used solutions 
 
Laemmli lysis buffer 
20%   Glycerol 
2%   SDS 
0.1M  Tris pH 6.8 
10%   ß-Mercaptoethanol 
7M   Urea 
10x Running Buffer 
121g    Tris base 
578g   Glycine 
40g   SDS 
 
Water to 4 litres 
 
Laemmli Loading Buffer  
20%   Glycerol 
2%   SDS 
0.1M  Tris pH 6.8 
10%   ß-Mercaptoethanol 
7M         Urea 
0.004%              bromophenol blue  
 
RIPA/SDS 
1%   Nonidet P-40 
1%   Triton X-100 
1%   Sodium deoxycholate 
0.1%   SDS 
150mM  NaCl 
10mM   Tris pH 8.0 
2nM   NaF 
RIPA/SDS was stored at 4°C and 10!l per ml of 
protease inhibitor mix and Aprotinin was added before 
use 
Transfer Buffer 
25mM   Tris base 
0.2M   Glycine 
20%  Methanol 
0.05%  SDS 
Protease inhibitor mix 
20mg/ml      phenyl methyl sulfonyl fluoride (PMSF) 
 
20mg/ml      1-10 phenanthroline 
20mg/ml      Benxamine 
 
Dissolved in ethanol and stored at -20°C 
Polyacrylamide 12% gel  
10.15 ml           Deionised water 
20 ml                30% Acrylamide / 
                         Bis solution 
(Biorad) 
 
18.75 ml          1M Tris (pH 8.8) 
0.5 ml              10 % SDS     
0.5 ml              10 % APS 
30 µl                TEMED 
Polyacrylamide stacking gel 
6.8 ml     Deionised water 
1.7 m      30% Acrylamide / 
               Bis solution (Biorad) 
 
1.25 ml   1 M Tris (pH 6.5) 
0.1 ml     10 % SDS     
0.1 ml     10 % APS 
10 µl       TEMED 
Polyacrylamide 8% gel  
16.95 ml           Deionised water 
13.4 ml             30% Acrylamide / 
                         Bis solution 
(Biorad) 
18.75 ml           1M Tris (pH 8.8) 
0.5 ml               10 % SDS     
0.5 ml               10 % APS 
30 µl                 TEMED    
2xTY + AGAR 
Same as 2xTY but with 15g of Bacto-agar add per litre. 
2xTY 
16g   Tryptone 
10g   Bacto-yeast extract 
5g   NaCl 
 
Water to 1L 
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Appendix 3:  Stimulants and inhibitors used for cell treatment in protein expression 
assays 
 
Stimulants and inhibitors Supplier Stock concentration 
Insulin 
Sigma, Dorset, UK 
10mg/ml in acidified 
H2O 
Dihydrotestosterone  
Sigma, Dorset, UK 
5mg/ml in 100% 
ethanol 
FSH (recombinant peptide 
hormone) 
National hormone and pituitary 
program, California, USA 
1IU/µL, 100ng/µL 
in PBS 0.1% BSA 
mixture 
Wortmannin 
Sigma, Dorset, UK 
0.1mg/ml in 10% 
ethanol 
Flutamide 
Sigma, Dorset, UK 
50mg/ml in 100% 
ethanol 
LY 294002 
Sigma, Dorset, UK 5mg/ml in DMSO 
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Appendix 4: Programmes used for running the COBAS BIO Autoanalyser 
 
Parameter Glucose Lactate (1) Lactate (2) 
Alpha Code 11 11 11 
Units 4 4 4 
Calculation Factor 0 0 0 
Standard 1 concentration (µM) 25 5 20 
Standard 2 concentration (µM) 30 10 40 
Standard 3 concentration (µM) 35 15 60 
Limit 40 20 70 
Temperature (
o 
C) 25 25 25 
Type of analysis 6 6 6 
Wavelength 340.2 340.2 340.2 
Sample Volume (µl) 70 40 40 
Dilutent volume (µl) 25 25 25 
Reagent Volume (µl) 200 200 200 
Incubation time (sec) 120 300 300 
Start regent volume (µl) 40 20 20 
Time of first reading (sec) 0.5 0.5 0.5 
Time interval (sec) 30 30 30 
Number of readings 5 30 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 215 
Appendix 5: Summary of total patients recruited. 
 
Complete data: Western/glucose uptake/lactate depletion and progesterone 
production: 
 
Control (12)  ov PCO (8)   anovPCO (10) 
 
SJ   KB    CK 
AK   SRa    FC 
LT   CC    SP 
CD   OC    LB 
JC   NL    KP 
RM   LW    KB 
SC              EH    VJ 
RB   SA               CT   
F-WD                   SRo 
ZD       CN 
LB       SF 
AC 
    
 
Incomplete data sets:  
 
• Progesterone missing in Clinical Biochemistry (4) 
 
• No FSH data, No 1ng/ml Insulin data (4) 
 
• Insufficient cells, unable to analyse (8) 
 
• No glucose or lactate data insufficient cells (2) 
 
• Infection cells thrown away (4) 
 
• Patients used in preliminary studies plating cells/technique/doses/manual 
mistakes (11)  
 
• Controls used for insulin vs insulin and androgen expt (2)   
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A   androstenedione 
Ab   antibody 
AICAR   5-aminoimidadole-4-carboxamide-1-!-D-ribofuranoside  
Anov   anovulatory 
aPKC   atypical protein kinase C 
AMPK   5’ adenosine monophosphate-activated protein kinase  
APS   ammonium persulfate 
APS   adaptor protein binds to Cbl 
ADP   adenosine diphosphate 
ARKO   androgen receptor knock out 
ATP   adenosine triphosphate 
AKT/PKB  protein kinase B 
AR   androgen receptor 
mAR   membrane bound androgen receptor 
BSA   bovine serum albumin 
cAMP   cyclic AMP 
camp-GEF  cyclic AMP-guanine nucleotide exchange factor  
CAP   adaptor protein binds to Cbl 
Cbl   casitas B lineage lymphoma 
CDC42  cell division cycle-42  
CRE   cyclic AMP response elements 
DAB   diaminobenzidine 
Abbreviations 
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DNA   deoxyribonucleic acid 
DHEA   dehydroepiandrosterone 
DHEAS  dehydroepiandrosterone sulphate  
DHT   dihydrotestosterone  
DMSO   dimethylsulfoxide 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
ER   oestrogen receptor 
ERK   extracellular signal-regulated kinase (ERK) 
FBS   foetal bovine serum  
FOXO-1/FKHR forkhead transcription factor 
FSH   follicle stimulating hormone 
FSH-R   follicle stimulating hormone receptor 
G3PDH/GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GDP   guanosine diphosphate 
GRB2-SOS  growth factor receptor bound protein 2- son of sevenless 
protein  
GTP   guanosine triphosphate 
GC   granulosa cell 
GL   granulosa lutein 
GLUT   glucose transporter  
GSK3   glycogen synthase kinase 3   
h   hour 
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HA   haemagglutinin 
HeLa   immortalized cervical cancer cell line 
HOMA-IR homeostatic model assessment, method used to quantify 
insulin resistance 
HOMA-S homeostatic model assessment, method used to quantify 
insulin sensitivity 
3 ! HSD  3 ! hydroxysteroid dehydrogenase 
17!HSD  17! hydroxysteroid dehydrogenase 
ID   integrated density 
IGF1   insulin like growth factor 1 
IGFBP1  IGF binding protein 1 
IGFR   insulin growth factor receptor 
IgG   immunoglobulin 
IR   insulin receptor 
IRS   insulin receptor substrate  
IVF   in vitro fertilisation 
JNK   c-Jun NH2-terminal kinase  
KW   kruskal-wallis 
LDH   lactate dehydrogenase 
LDL   low density lipoprotein 
LH   luteinising hormone 
LY   LY294002, PI3K inhibitor 
LY294002  LY294002, PI3K inhibitor 
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LnCaP   androgen-sensitive human prostate adenocarcinoma cells 
M   molarity 
mA   milli ampere 
MAPK  (ERK)  mitogen-activated protein kinase 
MEK   MAP kinase kinase  
mg   milligram   
min (s)   minute (s) 
ml   millilitre 
MNAR   modulator of genomic activity of the oestrogen receptor 
mTOR   the mammalian target of rapamycin  
NAD+/NADH  nicotinamide adenine dinucleotide 
NADP   nicotinamide adenine dinucleotide phosphate 
NaF   sodium fluoride 
NaOH   sodium hydroxide 
NaCl   sodium Chloride 
NATP   nicotinamide adenine dinucleotide phosphate 
ng   nanogram 
NIH   national institutes of health 
NIMH   national institute of mental health 
nM   nanomolar 
OHSS   ovarian hyperstimulation Syndrome 
Ov   ovulatory 
Abbreviations 
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PAK   p21-Activated Kinase  
PAR 3 and 6  partitioning defective 3 and 6 proteins 
PCOS   polycystic ovary syndrome 
PBS   phosphate buffered saline  
PI3K   phosphoinositide 3 kinase 
PIP2   phosphadtidylinositol 4,5 bisphosphate   
PIP3   phosphadtidylinositol 3,4,5 trisphosphate  
PKA   protein kinase A 
PKC   protein kinase C 
PMSF   phenyl methyl sulfonyl fluoride  
PTP   protein tyrosine phosphatase 
PTP1B   protein tyrosine phosphatase 1B 
PVDF   polyvinylidene Fluoride 
P450 scc  P450 side chain cleavage 
Raf   MAP kinase kinase kinase  
RBC   red blood cell 
RICTOR  rapamycin insensitive companion of mTOR  
RSB   research services branch 
RTK   receptor tyrosine kinase 
Sec (s)   second (s) 
SEM   standard error of the mean 
SgK   serum and glucocorticoid inducible kinase  
Abbreviations 
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SHBG   sex hormone binding globulin 
SDS   sodium dodecyl sulfate 
SHC   mammalian adaptor protein 
StAR   steroidogenic acute regulatory protein 
T   testosterone 
TC10   small signalling g protein 
TCA   tricarboxylic acid cycle 
T-BSA   testosterone conjugated to bovine serum albumin 
TEMED  tetramethylethylenediamine 
TBS-T   tris-Buffered Saline and Tween 20 
TNF-!   tumour necrosis factor !  
V   volt 
µg   microgram 
µl   microlitre 
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